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Virus-like particles (VLPs) are multi-subunit protein assemblies that self-
assemble into homogenous particles with periodic structure, making them ideal 
candidates for applications in biomedicine. This dissertation will discuss both the 
chemical and genetic modification of Qb and PP7 VLPs for the design of vaccine 
platforms and drug delivery vehicles. Both the Qb and PP7 VLPs are comprised of 180 
copies of their respective coat protein (CP) monomers, which assemble to form 
icosahedral capsids of T = 3 geometry that are 28 and 30 nm in diameter, respectively. 
Herein, genetic engineering of the Qb coat protein to introduce peptide and protein 
domains is described. First, these modifications were encoded as C-terminal extensions 
of the CP, and co-expression with unmodified subunits produced hybrid particles 
displaying the peptide or protein domains. These particles were successfully applied in 
both vaccination studies as well as the targeted delivery of prodrug-converting enzymes 
encapsulated within the VLP. To broaden the scope of targeting applications, the 
chemical conjugation of small molecules to the surface of Qb VLPs was also used to 
direct cellular uptake and trafficking. The clearance of VLP delivery vehicles from 
circulation is an important factor governing their efficacy; to this effect, a survey of 
different polymer modifications and their effects on the immunological response to the 
Qb VLP was undertaken. Lastly, PP7 VLPs were modified by genetically encoding 
extensions of a peptide implicated in mitigating phagocytic clearance to further explore 
strategies for prolonging circulation. All of the work presented here builds upon previous 
studies employing VLPs for drug delivery and vaccine development, while building upon 
 xix 
the knowledge of chemical and genetic modifications that can be used to develop these 
materials. This work is poised to bring together the power of chemical and genetic 
modification in the development of nanoparticle platforms with novel properties that are 













All work herein is adapted to varying degrees from manuscripts that are in preparation 
and/or manuscripts that have been submitted for publication. Chapters 2 and 3 detail 
experiments conducted in collaboration with several workers at Cleveland Clinic and 
Emory University – their contributions are presented here to give a full account of the 
work accomplished, and due credit is given to all those listed in the Acknowledgments.  
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Chapter 1: Introduction to virus-like particles as biomedical platforms 
 
1.1. Virus-like particle platforms 
 The development of systems for targeted drug delivery and vaccine design that 
combine efficacy concurrently with high margins of safety remains an elusive goal in 
biomedicine,1 but advances within the past two decades have produced numerous 
nanoscale platforms that have been explored as candidates. Inorganic nanoparticles,2 
polymer assemblies,3 dendrimers,4 and liposomes5 have all received attention as potential 
platforms for biomedical applications, but each have their own associated set of 
disadvantages. Inorganic materials are readily prepared but have raised concerns over 
their long-term accumulation in various tissues and associated toxicity.6,7 Polymeric 
materials offer tunable stability but often at the cost of biocompatibility, while liposomes 
are often more biocompatible but are prone to rapid clearance.8 Additionally, all of these 
platforms suffer from batch-to-batch variability in size distribution and structural 
composition.9 In contrast, proteinaceous virus-like particles (VLPs) offer a more robust 
set of materials that allow for the union of chemistry and molecular biology in the 
generation of multifunctional platforms. 
VLPs are structurally well-defined materials that are typically rod-like or 
icosahedral in shape with diameters ranging from 10-200 nm.10 They are comprised of 
one or more repeating protein subunits derived from bacteriophages,11–14 plant 
viruses,15,16 or mammalian viruses,17,18 that spontaneously assemble into particles which 
can be produced and isolated from recombinant expression systems in high yields. These 
particles are noninfectious, as they lack the native viral genome; however, VLPs do 
 2 
nonspecifically encapsidate nucleic acids from the host cell.10 In addition to their ease of 
production and homogeneity, VLPs are also remarkably stable structures, tolerant of a 
wide range of temperature,19,20 pH,19 and solvent compositions,21 which allows for a 
broad scope of chemical modifications in the design of novel vaccines and delivery 
platforms. The inherent nature of VLPs as protein-based materials also permits 
modifications to be introduced at the genetic level prior to expression and assembly. 
Changes at the genetic level can vary from single point mutations22,23 to incorporation of 
peptides24 or protein domains25 as extensions of the coat protein sequence, depending on 
the intended application.  
The unique features of VLPs places them at the interface of chemistry, biology, 
and materials science, whereby combined techniques from each of these disciplines has 
the ability to generate novel platforms for medicine and biotechnology. The subsequent 
sections will discuss specific examples of nine different icosahedral, non-enveloped 
VLPs (CCMV, CPMV, HBcAg, AAV, P22, AP205, MS2, PP7, Qb) (Figure 1; Table 1) 
that have been chemically or genetically engineered as vaccine carriers or targeted 
delivery vehicles. Modifications discussed will focus on the design principles of the 
resulting materials and their applications in vaccine development or drug delivery.  
1.1.1. Cowpea chlorotic mottle virus 
 Cowpea chlorotic mottle virus (CCMV) is a positive-sense single-stranded RNA 
plant virus classified in the Bromoviridae family, but it is structurally similar to the 
bacteriophages in the Leviviridae family.26 While it can be produced in high yields (1-2 
mg/g) from infected plants, it can also be produced recombinantly in both bacteria and 
yeast.27 The viral capsid is composed of 90 homodimers of the coat protein, which  
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Figure 1. Three-dimensional structures of the virus-like particles discussed. Images were 







Table 1. Relevant structural information of virus-like particles discussed. Viral geometry, 






assemble into a 28 nm icosahedral particle possessing T=3 symmetry.29 Reversible 
assembly of CCMV particles can be accomplished by tuning the ionic strength and pH of 
the solution, making them promising candidates for stimuli-responsive delivery.30 
The Kormelink group engineered fusions of peptides from influenza A virus and 
foot-and-mouth disease virus as a proof-of-concept for epitope display.16 Interestingly, 
insertion of the peptides into any loops on the CCMV coat protein surface abrogated 
particle assembly, but N- and C- terminal extensions were well-tolerated. Despite the 
incorporation of disease-associated peptides, no testing of the vaccine platforms was 
reported. Testing of the immune response was reported in a study by Pincus and 
colleagues, where a peptide mimitope of the group B streptococcal capsular 
polysaccharide was chemically conjugated to CCMV using a heterobifunctional 
maleimide cross-linker and shown to generate a Th1 response in mice.31 The Th1 
response bias was attributed to the encapsidated RNA within the CCMV particles, 
although this was not explored experimentally.  
CCMV has also been explored for use as a drug delivery agent. Shin and 
colleagues developed a platform for applications in photothermal therapy by genetically 
encoding a tumor-homing peptide at the N-terminus of the coat protein.32 After 
expression and purification, these particles were reversibly assembled in the presence of a 
near-infrared dye and directed against MCF-7 cancer cells. A separate study 
demonstrated covalent modification of CCMV with folic acid and doxorubicin via EDC 




1.1.2 Cowpea mosaic virus 
 Unlike CCMV, cowpea mosaic virus (CPMV) is a member of the Secoviridae 
family and is formed from 60 copies of an asymmetric subunit comprised of a small (S) 
and large (L) domain.34 The virions can be isolated in high yields (1 mg/g) from infected 
black-eyed pea plants (Vigna unguiculata) as approximately 30 nm particles with pseudo 
T=3 symmetry.35,36 Interestingly, native CPMV particles have been shown to enter 
mammalian endothelial cells through interactions with surface vimentin,37 but these 
VLPs can be directed against other cell types through chemical or genetic modification. 
 Hovlid and colleagues demonstrated selective targeting of cancer cells expressing 
aVb5 integrins with CPMV that was chemically modified with a derivative of the cyclic 
arginine-glycine-aspartate (RGD) peptide Cilengitide using copper(I)-catalyzed azide-
alkyne cycloaddition (CuAAC) chemistry.38 In this same report, display of RGD peptide 
sequences through genetic insertion into loops on the particle surface was also 
accomplished to impart similar targeting function.38 Steinmetz and coworkers 
demonstrated the capability of CPMV to serve as a drug delivery vehicle by covalently 
conjugating doxorubicin to the surface carboxylates for improved therapeutic efficacy 
relative to the free drug at similar concentrations.39 The potential of CPMV as an agent 
for immunotherapy was assessed in a recent report by Fiering and coworkers where in 
situ vaccination of unmodified particles that were devoid of nucleic acid induced 
systemic anti-tumor immunity in metastatic breast, colon, and ovarian carcinoma 
models.40 The broad efficacy of the CPMV platform in this context was linked to specific 
activation of neutrophils in the tumor microenvironment which mediate downstream anti-
tumor immune responses.   
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1.1.3. Hepatitis B virus 
 The core antigen protein from hepatitis B virus (HBcAg) can be expressed in both 
bacterial and cell-free expression systems to yield two populations of T=3 and T=4 
icosahedral particles comprised of 180 and 240 protein subunits, respectively.17,41,42 
These particles have been designed for both antigenic display as well as delivery of 
functional cargoes to cells. HBcAg has been shown to be incredibly stable towards the 
incorporation of extensions into the c/e1 loop region, ranging from large domains25 to 
entire proteins.43 Full-length green fluorescent protein (238 amino acids) was expressed 
in this manner as a model insert, and absorbance measurements revealed that ~ 50% of 
the displayed proteins were properly folded.43 Khanna and colleagues expanded upon this 
technology by incorporating envelope domain III from dengue virus (104 amino acids) 
onto the HBcAg surface that was capable of generating cross-reactive antibody responses 
in mice.25  
 Modification of HBcAg VLPs for applications in therapeutic delivery has also 
been extensively explored. Particles designed for the selective encapsidation of plasmid 
DNA have been shown to be stable, yet their ability to deliver the DNA for expression in 
cells remains untested.44 Strable and colleagues were the first to demonstrate successful 
incorporation of the unnatural amino acids azidohomoalanine and homopropargylglycine 
into the HBcAg capsid protein by expression in a methionine auxotroph strain of E. 
coli.45 This allowed for the chemoselective conjugation of proteins and imaging agents to 
the capsid via CuAAC with near-perfect spatial control, although capsid stability was 
compromised by the formation of more than 120 triazole linkages on the capsid surface.45  
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1.1.4. Adeno-associated virus 
 Adeno-associated virus (AAV) is a small, non-enveloped virus of the 
Parvoviridae family that naturally encapsulates a single-stranded DNA genome and has 
received the lion’s share of attention in the field of gene therapy. Engineered variants of 
AAV serotype 2 have been the most widely used vehicles for gene delivery applications, 
yet there has been relatively limited clinical success.46–48 Delivery and expression of the 
cystic fibrosis transmembrane conductance regulator (CFTR) gene has been 
demonstrated in patients, but there was no clear therapeutic efficacy.48 Several trials for 
the treatment of hemophilia B have also been conducted with varying levels of success. 
Kay and colleagues reported on an early trial of factor IX replacement using AAV that 
was halted due to cytotoxic T-cell responses against transduced hepatocytes in patients,47 
but Davidoff and coworkers later showed stable expression in patients over 6 months 
following treatment with a different AAV variant.49 The lone example of an AAV-based 
therapeutic reaching market approval is GlyberaÒ, which received approval for the 
treatment of lipoprotein lipase deficiency in the European Union in 2012, but it is being 
withdrawn due to the expensive price point and lack of demand.50 
 Neutralizing antibodies to AAV generated from previous asymptomatic exposures 
to adenovirus are the main challenge to therapeutic applications as they limit AAV 
transduction into certain tissues and hinder readministration of the vector.46 Nakagawa 
and colleagues labeled AAV with varying degrees of polymer modifications and found 
that with higher levels of polymer loading, the antibody response against AAV was 
significantly diminished.51 Directed evolution of the AAV capsid has also been employed 
to generate vectors capable of avoiding recognition by the neutralizing antibodies present 
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in a large portion of the population. Several studies have reported on the development of 
AAV variants capable of avoiding neutralization by AAV-specific antibodies both in 
vitro52 and in vivo.53 AAV variants prepared in this manner required 20-fold higher 
concentration of human antibodies for neutralization in vitro and could achieve 
significantly higher rates of transduction in mice that had been passively immunized with 
human antibodies. 
1.1.5. P22 
 The bacteriophage P22 is a double-stranded DNA virus in the Podoviridae family 
that assembles from 420 identical copies of a coat protein subunit with the aid of ~ 300 
scaffolding proteins.54 P22 VLPs have the unique ability to undergo large morphological 
changes, with four distinct forms observed.54,55 The procapsid is assembled as a 58 nm 
shell containing the scaffolding proteins; treatment of the procapsid with the chaotrope 
guanidinium chloride denatures the scaffolding protein and yields empty particles. Mild 
heating (65°C) of either the procapsid or empty particle induces a transition into an 
expanded from, measuring 64 nm in diameter. Further heating (75°C) leads to the 
formation of 10 nm pores at the fivefold symmetry axis, which is classified as the 
“wiffle-ball” formation. 
 Douglas and coworkers have shown that encapsulating protein antigens inside of 
P22-based VLPs promotes an antigen-specific CD8+ T-cell response upon 
immunization.56,57 Encapsulation of the conserved nucleoprotein from influenza resulted 
in a vaccine formulation that provided multi-strain protection against 100 times the lethal 
dose of the virus in a T-cell dependent manner.56 Using the same VLP platform, Schwarz 
and colleagues were able to show that co-encapsidation of two different proteins from 
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respiratory syncytial virus (RSV) gave rise to robust CTL responses specific to both 
antigens that conferred protection against an RSV challenge.57 Douglas and colleagues 
have also worked extensively in the area of encapsulating active proteins within P22 
VLPs, demonstrating assembly of entire enzyme cascades for industrial applications58 as 
well as the confinement of therapeutic proteins, such as cytochrome P45059 and Cas9,60 
within the protein shell. 
1.1.6. AP205 
 The single-stranded RNA bacteriophage AP205 is distantly related to the other 
viruses of the Leviviridae family but shares no sequence similarity other than two 
cysteine residues which form stabilizing inter-subunit disulfide bonds.61 AP205 VLPs 
demonstrated variable tolerance to insertions at both the N- and C-termini when 
genetically fused with multiple disease-related antigens, with the largest fusion being a 
55 amino acid peptide derived from HIV epitopes.62 Additionally, Bachmann and 
colleagues combined genetic fusion with covalent attachment by encoding the 
SpyCatcher protein (~ 15 kDa) to the N-terminus of AP205 followed by covalent 
coupling to SpyTag-linked malaria antigens for VLP surface presentation.63,64 
1.1.7. MS2 
 The bacteriophage MS2 is a positive-sense single-stranded RNA virus that bears 
structural homology to the Qb bacteriophage. MS2 VLPs assemble from 180 identical 
protein subunits into a 28 nm capsid with T=3 geometry, and these particles bear pores at 
both the fivefold (1.7 nm) and threefold (1.4 nm) axes of symmetry. These particles have 
been investigated extensively for the development of both vaccines as well as targeted 
delivery platforms. 
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  MS2 VLPs are known to spontaneously assemble in the presence of nucleic 
acids, which allowed Peabody and colleagues to package RNA-modified derivatives of 
doxorubicin, cisplatin, 5-fluorouracil, and ricin toxin A-chain inside of MS2 and 
selectively target cancer cells using a displayed peptide ligand.65 All drug formulations 
tested with this platform resulted in selective cytotoxicity at sub-nanomolar drug 
concentrations. Building on the capacity of MS2 to encapsidate nucleic acids, this study 
further showed that delivery of an siRNA cocktail packaged within VLPs induced growth 
arrest and apoptosis of cancer cells.65 Hall and colleagues showed that display of 
autoinducing peptide 4 from Staphylococcus aureus on a surface-exposed loop in the 
MS2 coat protein allowed for the affinity selection of VLP vaccine candidates that 
provided protection in a mouse model of S. aureus-induced dermonecrosis.66 
 Francis and colleagues have developed MS2-antibody conjugates using a covalent 
oxidative coupling strategy67 that showed promising results in vitro but only moderate 
tumor uptake in a murine model of breast cancer.68 Francis and coworkers had previously 
employed a similar coupling strategy for the attachment of DNA aptamers to the surface 
of MS2 VLPs for cancer-specific targeting applications, as well.69 
1.1.8. PP7 
 PP7 is a single-stranded RNA phage that naturally infects Pseudomonas 
aeruginosa; these VLPs also bear structural as well as sequence homology with MS2 and 
Qb.70 PP7 capsids are comprised of 180 identical coat protein monomers that assemble 
into a 30 nm capsid bearing T=3 geometry and have been shown to be remarkably stable, 
in part due to the presence of inter-subunit disulfide bonds.12 These particles have also 
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received considerable attention in the development of platforms for both vaccines and 
drug delivery. 
Peabody and colleagues have engineered single-chain dimer variants of both MS2 
and PP7 that were stable towards insertion of defined or random peptide sequences in the 
AB-loop region;24,71 these platforms were employed in both rational vaccine design71,72 as 
well as the generation of libraries for epitope discovery.73 PP7 VLPs have also been 
investigated for the delivery of messenger RNA, with a proof-of-concept study showing 
the expression of fluorescent proteins in a target cell population.74 
1.1.9. Qb 
 Also a member of the Leviviridae family, bacteriophage Qb is a single-stranded 
RNA virus with a 4.2-kilobase genome encoding for three genes (Figure 2).75 The 
replicase and A2 protein are essential components for virulence, enabling replication of 
the viral genome and capsid maturation, respectively.76 The A1 coat protein is the major 
structural element of the virion and can be expressed as either a full-length or truncated 
version. While most of the viral shell is comprised of the truncated variant, Qb naturally 
incorporates 5-10 copies of the full-length coat protein.77,78 This extended form of the A1 
coat protein is produced through occasional read-through of an opal stop codon, and its 
incorporation into the capsid is vital for infectivity.  
 Qb VLPs can be produced by recombinant expression of the truncated coat 
protein in both yeast79 and bacteria,80 as well as cell-free expression systems,81 with high 
yields. The capsid assembles from 180 copies of the coat protein as a 28 nm icosahedral 
particle with T=3 symmetry.82 Pores formed at the threefold (1.3 nm) and fivefold (0.7 
nm) axes of symmetry allow for selective access of small molecules to the capsid interior, 
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and similar to other leviviruses, the coat protein forms tightly-associated noncovalent 
dimers.83 Qb VLPs are remarkably stable to changes in temperature, pH, and solvent 
composition, which has allowed for the engineering of platforms for numerous 
applications; this stability is largely attributed to the formation of inter-subunit disulfide 
bonds.22 
The coat protein contains four solvent-exposed lysine residues, providing a total  
Figure 2. Cartoon representation of the Qb genome.76 Differences in the capsid 
composition for the native virion and non-infectious VLP are highlighted. 
 
 
of 720 reactive amines per Qb particle.82 These residues have been addressed through N-
hydroxysuccinimide ester chemistry to install numerous bifunctional linkers for 
biorthogonal conjugation to small molecules, peptides, polymers, and imaging agents. 
Rhee and colleagues demonstrated attachment of a modified sialic acid moiety to Qb 
VLPs using CuAAC in order to target cells displaying CD22.84 Pokorski and colleagues 
detailed the attachment of an atom-transfer radical polymerization (ATRP) initiator 
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moiety to the surface of Qb VLPs followed by graft-from polymerizations to generate 
hybrid protein-polymer materials for use in drug delivery and imaging.85 
 The Qb coat protein has also been shown to be stable to the genetic insertion of 
peptide or protein domains at the C-terminus. Taking advantage of the natural read-
through process that produces the extended A1 coat protein, Pumpens and coworkers 
displayed foreign peptides on the surface of the assembled virion.86 Building upon this 
approach, Brown and colleagues developed a system for displaying large protein domains 
on the surface in higher numbers by employing a two-plasmid system.14 In this system, 
one plasmid harbors the gene for the truncated coat protein while the second harbors the 
coat protein plus a polypeptide extension at the C-terminus; co-expression in bacteria 
produces hybrid VLPs displaying these extensions on a greater number of subunits.  
 Functional therapeutic proteins can also be encapsulated within Qb VLPs for 
delivery. Fiedler and colleagues used the propensity for Qb to encapsidate endogenous 
cellular RNA to their advantage in designing a system to control the loadings of different 
proteins.87 In this system, the cargo protein was engineered with an arginine-rich (Rev) 
terminal tag, and a bifunctional RNA was transcribed bearing an aptamer against the Rev 
peptide in combination with a hairpin that interacts with the interior of the Qb capsid 
protein. Simultaneous expression of these factors in bacteria allows for the assembly of 
VLPs harboring the desired protein cargo.  
1.2. Immunology of virus-like particles 
As discussed in the preceding section, VLPs are structurally identical to the 
viruses from which they are derived, and it is their mimicry of viral structure that 
contributes to their interaction with both arms of the immune system. The specific 
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structural features contributing to the engagement of each component of innate and 
adaptive immunity will be discussed herein to provide an understanding of the 
immunogenicity of VLPs and to demonstrate their effectiveness as platforms for vaccine 
development. An understanding of the features that govern the interactions of VLPs with 
the immune system is also critical in guiding the design and implementation of VLPs as 
drug delivery platforms, which will be subsequently discussed in detail.   
The innate immune system is comprised of a number of different proteins and cell 
types that circulate throughout the body and serve as a first line of defense against 
invading microorganisms and viruses.88,89 As such, these molecules have evolved to be 
activated by structural features that are commonly associated with pathogenic 
organisms.90 Pentraxins,91 complement component 1q (C1q),92 and IgM93 are all 
multimeric proteins that perform critical roles in innate immunity by promoting the 
clearance of pathogens through activation of the complement cascade. These molecules 
are ideally suited for the recognition of highly repetitive structures, such as those of 
VLPs, due to their capacity for multivalent interactions. Although the affinity of the 
individual binding events may be low, the avidity of the interaction afforded by these 
multivalent structures may be quite high and promote strong binding.94    
Not surprisingly, it has been shown that viral particles both bind natural IgM 
antibodies and trigger complement activation in mice. Bachmann and coworkers have 
shown that natural IgM antibodies recognize Qβ VLPs, and these particles are transported 
to B-cell follicles in a complement-dependent fashion by non-cognate B-cells.95 These 
particles were subsequently transferred to follicular dendritic cells (FDCs) for prolonged 
retention and display, which is essential for B-cell activation and clonal selection within 
 15 
the germinal center.96 These observations were not recapitulated using the soluble Qβ 
coat protein, further supporting that the repetitive organization of the particle was 
necessitating activation of the complement system.95  
The complement system has also been found to play a key role in the immune 
response to AAV vectors.97 Binding of C3 proteins to the AAV capsid was shown to 
mediate uptake by macrophages, which promoted subsequent activation and expression 
of inflammatory cytokines.97 Additionally, the binding of C3 proteins to AAV was shown 
to be essential for initiating the humoral response, either by promoting cross-linking of B-
cell receptors (BCRs) with complement receptors on the B-cell surface or by an adjuvant 
effect to enhance the response to AAV.97 
Activation of the complement system plays a significant role in the initial 
response to VLPs and AAV vectors, both in terms of initial clearance of the particles 
from circulation as well as initiating mechanisms for adaptive immune responses. The 
repetitive organization of VLPs serves to engage interactions with native IgM antibodies 
and other components of the innate immune system, which in turn gives rise to robust 
adaptive B-cell responses – a key component for the development of effective vaccines. 
Initiation of a strong adaptive response can undermine applications where multiple 
administrations of the therapeutic are necessary, however, as has been observed 
previously with AAV. Despite these observations, numerous strategies have been 
developed that allow VLPs to avoid immune recognition and serve as effective delivery 
vehicles. 
Dendritic cells (DCs) and macrophages are the primary groups of antigen 
presenting cells (APCs) that serve to bridge the gap between the innate and adaptive 
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immune response. Macrophages are a diverse population of cells that perform various 
roles, from scavenging apoptotic cellular debris to regulating immune responses and 
antigen presentation.98 The numerous subsets of macrophages that perform these tasks 
have been reviewed in excellent detail elsewhere.99,100 Similarly, DCs are most well 
characterized as professional APCs that present processed antigens to lymphocytes for 
the initiation of adaptive immunity.101  
Due to their size and repetitive structure, most VLPs are efficiently recognized for 
uptake by both DCs and macrophages.10 As previously discussed, the binding of natural 
IgM antibodies and pentraxins to the VLP surface can result in the activation of the 
classical pathway in the complement cascade, facilitating uptake of the particles by 
interactions with both Fc and complement receptors on the APC surface.102 Upon uptake, 
VLPs traffic to the endolysosomal compartment, where they are degraded into peptides 
and loaded onto major histocompatibility complex class II (MHC-II) molecules for 
presentation to CD4+ T-cells (Figure 3). It should also be noted that cross-presentation of 
antigenic peptides on MHC class I (MHC-I) molecules occurs much more readily with 
particulate antigens than soluble proteins and can lead to the priming of CD8+ T-cell 
responses, as well.103   
Display of antigenic peptides on MHC-II is insufficient to fully activate helper T-
cells, however; APCs must also be activated and express co-stimulatory signals.104 Most 
VLPs and viral vectors package nucleic acid during assembly, either by design105 or 
through non-specific interactions,106 which serve as stimulatory Toll-like receptor (TLR) 
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ligands for APC activation once the particles are degraded in the endosome.107 VLPs 
containing ssRNA stimulate TLR7/8,108,109 while vectors or VLPs packaging CpG-rich  
Figure 3. Uptake and processing of virus-like particles by antigen-presenting cells. VLPs 
are internalized by APCs through opsonin-mediated or passive phagocytosis (1) and are 
either released into the cytosol (2a) or retained and degraded as the phagosome matures 
into the endosome (2b). VLPs gaining access to the cytosol undergo degradation and 
processing by the proteasome (3a) and peptide antigens are trafficked into the 
endoplasmic reticulum (4a), where they are loaded onto MHC-I complexes and shuttled 
to the cell surface for cross-presentation (5). Nucleic acid released from VLPs in the 
endosome stimulate TLR7/8 and phosphorylation of IRF7 in a MyD88-dependent manner 
(3bi), which translocates to the nucleus (4bi) and induces inflammatory cytokine gene 
expression. Protein antigens retained in the endosome are degraded and loaded onto 
MHC-II following acidification to the lysosome (3bii), and MHC-II trafficks to the cell 
surface to present antigens for cellular recognition (4bii).     
 
 
DNA activate TLR9.110 Activation of these pathways results in the expression of 
inflammatory gene networks and the production of cytokines, such as interleukin-1β (IL-
1b), interleukin-4, (IL-4), interleukin-6 (IL-6), transforming growth factor-b (TGF-b), 
and interleukin-12 (IL-12), which are key in initiating T-helper cell responses.104,111  
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In addition to priming signaling for innate immunity, the geometry and repetitive 
organization of VLPs are also the primary determinants of their interaction with and 
activation of B-cells.112 The host-pathogen response has evolved to promote cross-linking 
of the BCR by repetitively organized antigens, which is the key activation signal for B-
cells.113 VLPs can directly interact with B-cells by virtue of their size; particles that are 
20-200 nm in diameter efficiently drain into the lymphatic system and gain access to 
secondary lymphoid organs (Figure 3).114 As shown for Qβ VLPs, complement fixation 
also played a key role in trafficking antigen to B-cell follicles and prolonging display for 
interactions in the germinal center.95 Complement factors displayed on the VLP surface 
can also engage complement receptors on the cognate B-cell surface and provide further 
stimulation for activation.115  
 The B-cell response to VLPs is also influenced by TLR stimulation, both through 
TLR activation in DCs and direct TLR activation in B-cells that was independent of 
signaling from T-helper cells.116,117 Delivery of ssRNA or CpG packaged inside of VLPs 
was found to significantly improve the IgG antibody response compared to the delivery 
of soluble TLR ligands mixed with VLPs.118 Bachmann and colleagues further elucidated 
the role of direct TLR stimulation in B-cells by showing that activation of TLR9 was 
sufficient to induce isotype class switching to IgG2a in a T-bet-dependent manner that 
was irrespective of signaling in other cell types.116 While VLPs are capable of stimulating 
B-cell activation and high titers of IgG antibodies even in the absence of TLR signaling, 
the quality of the immune response can be greatly influenced by TLR stimulation. An 
increase in the formation of antigen-specific germinal centers has been shown following  
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Figure 4. Key steps in the generation of humoral and cellular immune responses. (A) 
VLPs encounter antigen presenting cells in the periphery, where uptake is mediated by 
either passive phagocytosis or opsoninization by complement and other multivalent 
molecules involved in innate immune responses. Particles are degraded in the proteasome 
or endolysosome and peptide antigens are loaded onto MHC Class I (cross-presentation) 
or MHC-Class II for display on the mature APC surface and stimulation of T-cell 
activation. Maturation of APCs results in the secretion of cytokines that influence the 
differentiation of naïve lymphocytes into numerous classes of effector cells. Presentation 
of antigens on MHC-II promotes recognition by naïve CD4+ T-cells, which can undergo 
differentiation into TH1, TH2, TH17, or Treg lineages dependent upon the co-stimulatory 
signals received from the APC. In the absence of other signals, TGF-b favors the 
generation of Treg cells; however, the production of TGF-b in combination with IL-6 
during early responses induces TH17 differentiation. APCs can later produce cytokines 
favoring TH1 (IL-12, IFN-g) or TH2 (IL-4) responses. Cross-presentation of antigens on 
MHC-I combined with production of IL-12 and IL-18 promotes proliferation of CD8+ T-
cells; activated CD4+ helper cells also aid in stimulating this proliferation by producing 
IL-2. (B) Due to their size, VLPs can traffic to the lymph nodes and gain direct access to 
resident B-cells. Cross-linking of cognate BCRs by the repetitive structure of the particle, 
in combination with co-stimulatory signals from activated CD4+ T-cells (IL-4, IL-5, IL-
6), promote activation of the B-cells and differentiation into antibody-producing plasma 
cells. A subset of these activated cells undergoes further differentiation into memory cells 









immunizations with antigens linked to TLR ligands, which directly governs the affinity 
and isotype switching of IgG antibodies produced.118 
As VLPs are efficiently taken up and processed by DCs, they can also serve to 
stimulate robust CD4+ and CD8+ T-cell responses.119,120 After uptake, DCs migrate to the 
lymph nodes and can present antigenic peptides loaded on MHC-II to CD4+ T-cells 
(Figure 4); however, DCs can also cross-present antigens on MHC-I molecules for the 
activation of CD8+ T-cells.103 While CD4+ T-cells feed back into promoting robust 
antibody responses by providing co-stimulatory signals to B-cells, the activation of 
cytotoxic CD8+ T-cells promotes cellular immunity against cells displaying cognate 
antigens. 
Priming cytotoxic T-lymphocyte (CTL) responses is a promising approach for 
vaccination against certain diseases, but it can also pose major limitations to certain 
therapeutic applications involving VLPs. Douglas and coworkers have shown that 
encapsulating protein antigens inside of P22-based VLPs promotes an antigen-specific 
CD8+ T-cell response upon immunization.56,57 On the other hand, CD8+ T-cell responses 
have been identified as a significant hindrance to adenoviral gene delivery.121 CTL 
responses have been found against both the AAV capsid and the transgene product,122 
which has been shown to compromise cells transduced by the vector and expressing the 
delivered gene product. Kay and colleagues reported on a clinical trial employing AAV 
for hemophilia B treatment that was halted due to CTL-mediated response against AAV-
transduced hepatocytes,47 but attempts to replicate the phenomenon in animal models for 
further study have proven unsuccessful.123,124  
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 It is clear that the structural organization and composition of VLPs that are 
beneficial in the design of VLP-based vaccines can also hinder the development of VLP 
platforms for applications in targeted delivery. Thus, while native IgM antibodies and the 
complement system function as early effectors in stimulating adaptive memory 
responses, these systems can promote rapid clearance of VLPs from circulation and 
undermine their use as delivery agents. Uptake by APCs also serves to remove VLPs 
from circulation, but more importantly, begins to initiate adaptive B- and T-cell 
responses, which are ideal for effective vaccines but are detrimental for the long-term 
administration of VLPs for other applications.  
 Adaptive immune responses are the primary hindrance to repeat administrations 
of VLPs for delivery applications, as circulating antibody repertoires from previous 
exposures or treatments can function to neutralize VLPs.  In the case of AAV, both B- 
and T-cell responses have been implicated in hindering clinical applications. Neutralizing 
antibody responses from previous exposures to AAV limit the capabilities for effective 
delivery and transduction of a gene product into target cells, while T-cell responses are 
more problematic, as they serve to eliminate transduced cells that are displaying peptides 
from either the protein cargo or the virus itself. In contrast, relatively little focus has been 
placed on studying the effects of adaptive immune responses on the clearance of other 
VLP platforms. A single study by Young and colleagues investigated the biodistribution 
and clearance of CCMV in both naïve and immunized mice, finding the distribution and 
trafficking of particles to be similar in both cases.125  
Thus, while VLPs are now a generally accepted platform for immune activation, 
their general suitability for use as platforms for the directed delivery of therapeutics 
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remains an open question. Many of the same chemistries and design principles used for 
the generation of VLP-based vaccines can be employed for the development of delivery 
vehicles. For the remainder of this thesis, I will discuss the use of VLPs for both of these 
applications, with a focus on the key chemical and genetic modifications that can be 
leveraged for the development of both classes of functional nanoparticles.  
1.3. Summary 
 In the preceding sections, I have described several examples of the chemical and 
genetic modifications of different virus-like particles and the applications of these 
platforms for vaccine development and drug delivery. These examples indicate that VLP 
systems hold considerable promise in biomedicine, but there are several inherent 
limitations to the current approaches. The immunogenicity of VLPs represents a 
substantial hindrance for applications in drug delivery, and the continuing development 
of new tools and methodologies to modify VLPs is critical. The following chapters of this 
thesis will discuss the chemical and genetic engineering of Qb and PP7 VLPs for targeted 
delivery and shielding from the immune system, with a small focus on leveraging native 
VLP immunogenicity for vaccine development. Chapter 2 will describe the construction 
of hybrid Qb VLPs displaying genetically encoded peptide extensions for applications as 
vaccines. Chapter 3 will detail the construction and application of hybrid Qb VLPs 
displaying Fc-binding domains for antibody-directed targeting. In contrast to genetic 
strategies, Chapter 4 will discuss the chemical modification of Qb VLPs with small 
molecules to alter trafficking and cellular uptake. Chapter 5 will detail the development 
of hybrid protein-polymer Qb VLPs and an evaluation of their abilities to abrogate 
immune recognition, while Chapter 6 will detail the genetic modification of PP7 VLPs 
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with peptide extensions to mitigate uptake by immune cells. This body of work provides 
insights, tools, and techniques that will lead to the continued development of VLPs as 
platforms in biomedicine. The technologies developed here build towards the ultimate 
goal of engineering modular virus-like particle platforms that can be tailored for 
implementation as both vaccines as well as drug delivery vehicles.   
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Chapter 2: Design of Qb VLPs displaying peptide epitopes for vaccination 
 
2.1. Abstract 
The complement system is emerging as a new target for treating many diseases. 
For example, eculizumab, a humanized monoclonal antibody against complement 
component 5 (C5), has been approved for paroxysmal nocturnal hemoglobinuria (PNH) 
in which patient erythrocytes are lysed by complement. In this study, we developed 
vaccines to elicit autologous anti-C5 antibody production in mice for complement 
inhibition. Immunization of mice with a conservative C5 xenoprotein raised high titers of 
IgGs against the xenogenous C5, but these antibodies did not reduce C5 activity in the 
blood. In contrast, an autologous mouse C5 vaccine containing multiple predicted 
epitopes together with a tolerance-breaking peptide was found to induce anti-C5 
autoantibody production in vivo, resulting in decreased hemolytic activity in the blood. 
We further validated a peptide epitope within this C5 vaccine and created recombinant 
virus-like particles displaying this epitope fused with the tolerance-breaking peptide. 
Immunizing mice with these novel nanoparticles elicited strong humoral responses 
against recombinant mouse C5, reduced hemolytic activity, and protected the mice from 
complement-mediated intravascular hemolysis in a model of PNH. This proof-of-concept 
study demonstrated that autologous C5-based vaccines could be an effective alternative 
or supplement for treating complement-mediated diseases such as PNH. 
2.2. Introduction 
Therapeutic vaccination has recently emerged as a potential strategy for the 
treatment of numerous autoimmune disorders.1–3 In contrast to viral or bacterial infections, 
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it is inherently difficult to treat autoimmune disorders using vaccination strategies due to 
the evolution of immunological tolerance against self-antigens.4 Virus-like particles 
(VLPs) have provided a particularly useful vaccine platform in this respect. While VLPs 
resemble viruses in most ways relevant to the generation of an immune response (repetitive 
structure, lymphatic trafficking, B-cell recognition, T-cell stimulation, packaged bacterial 
RNA),5,6 they are non-infectious and can act as self-adjuvants capable of breaking immune 
tolerance.7–9  
The bacteriophage Qβ is a highly effective and easily-modified VLP platform for 
these purposes.10,11 It has been reported that the direct attachment of antigens to the surface 
of Qβ VLPs using chemical cross-linkers is effective in eliciting strong immune responses 
against self-antigens for vaccine development. Bachmann and colleagues have worked 
extensively in this area, designing Qb-based vaccines against several cytokines that have 
been implicated in autoimmune disorders, with several candidates advancing to clinical 
trials.12–14 Conjugation of full-length IL-1b to Qb VLPs generated vaccines that were well-
tolerated and gave rise to neutralizing antibody responses which correlated with improved 
glucose tolerance in both pre-clinical1 and clinical trials.2 Interleukin-17 (IL-17) has been 
implicated in the pathology of rheumatoid arthritis15 and multiple sclerosis,16 and chemical 
conjugation of recombinant IL-17 to Qb VLPs produced vaccines that ameliorated disease 
progression in murine models of both collagen-induced arthritis and experimental 
autoimmune encephalomyelitis.3,17 Immunization of mice deficient in apolipoprotein E 
with full-length IL-1a conjugated to Qb VLPs was shown to be effective at reducing 
inflammation and plaque progression, suggesting that vaccination may be an effective 
treatment for atherosclerosis.18  
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Despite the promising results of these studies, the display of full-length proteins on 
the VLP surface still presents challenges in construct design, safety, and efficacy. The 
ligation of two large biomolecules is relatively inefficient using all but the most robust 
conjugation strategies, and the systemic delivery of cytokines and other bioactive proteins 
is often associated with acute off-target toxicity.19 Furthermore, delivery of full-length 
protein conjugates may not present antigens in a context capable of overcoming 
immunological tolerance. The technology developed by Brown and Fiedler for the genetic 
incorporation and display of peptide antigens on the Qb VLP surface11 could provide useful 
strategies for overcoming these hurdles but has remained relatively unexplored. 
Introduction of antigenic peptides at the genetic level overcomes the limitations of 
challenging conjugations, while also eliminating toxicity concerns associated with delivery 
of the full-length protein. Introducing minimized domains and peptides could also allow 
for presentation in a more unnatural context on the VLP surface, favoring the development 
of a specific immune response. The work presented in this chapter will detail the 
application of this technology in developing vaccines to treat complement-mediated 
hemolytic disorders. 
The complement system is an important part of the innate immune system, 
consisting of multiple proteins present at varying levels in the blood.20 When complement 
is activated through any of three general pathways (by antibody-antigen complexes through 
the classical pathway, by certain carbohydrates through the lectin pathway, or 
spontaneously through the alternative pathway), C3 is activated to form C5 convertase and 
cleaves C5 into C5b and C5a. When C5 is activated in this way, membrane attack 
complexes (MACs) consisting of C5b-9 are assembled and form pores through the cell 
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membrane, resulting in lysis or damage of the target cell. At the same time, the small 
fragment C5a is released into the fluid phase and binds to its receptor (C5aR) on nearby 
immune cells to promote inflammatory reactions. Activated complement cannot 
distinguish self from foreign cells, but self-cells express cell surface complement 
inhibitors, including CD55 and CD59, which confer protection from complement-mediated 
attack.20 Aberrant complement activation is integrally involved in many diseases, and many 
complement components are currently being tested as new targets for drug development.21 
C5 is a promising example because its concentration in blood is relatively low (~100 
µg/mL for C5 versus ~1500 µg/mL for C3), and C5 inhibition should theoretically inhibit 
both the formation of MACs, which damage tissue cells, and suppress the release of C5a, 
a potent inflammation initiator that is involved in many pathological conditions.  
Indeed, eculizumab, a humanized anti-human C5 monoclonal antibody (mAb) has 
been successfully employed to treat complement-mediated diseases including paroxysmal 
nocturnal hemoglobinuria (PNH)22 and atypical hemolytic uremic syndrome (aHUS).23 In 
most patients with PNH, inactivation of the gene for phosphatidylinositol glycan A in the 
glycosyl phosphatidylinositol (GPI) pathway in hematopoietic stem cells results in red 
blood cells (RBCs) lacking the GPI-anchored cell surface complement inhibitors CD55 
and CD59, rendering these cells highly susceptible to complement-mediated lysis.24 
Eculizumab binds to C5 and inhibits the formation of MACs, thereby preventing 
complement-mediated hemolysis in PNH. Although highly effective, eculizumab is the 
most expensive drug on the market with an annual cost of more than $400,000/patient, and 
in most of the patients, life-long drug administration is required.25,26 Clearly, the 
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development of an effective and affordable C5-targeting therapy for treating PNH is a 
worthwhile goal.  
We describe here our first exploration of the idea that eliciting a moderate immune 
response against the C5 protein may represent a cost-effective treatment of diseases such 
as PNH caused by excess complement activity. To explore the feasibility of eliciting anti-
C5 antibody production from the host immune system to prevent complement-mediated 
hemolysis, we combined the identification of C5 epitopes using previously reported data 
and computational prediction with a modular strategy of VLP functionalization to produce 
candidate immunogens. These vaccine candidates were able to elicit anti-C5 
autoantibodies and protect mice in a model of intravascular hemolysis. Our data suggest 
that autologous C5 vaccines could be developed as an alternative or supplement to 
eculizumab for treating complement-mediated diseases such as PNH. 
2.3. Materials and Methods 
Mice and complement reagents 
C57BL/6 WT mice were purchased from the Jackson Laboratory and maintained 
in the animal facility of Cleveland Clinic. All animal care and experimental procedures 
were approved by the Institutional Animal Care and Use Committee of Cleveland Clinic. 
Purified human C5 protein and pooled human C5-depleted serum were purchased from 
Complement Technology Inc. (Tylor, TX). 
Mouse C5 vaccine design 
The mouse C5 protein sequence was analyzed using OptimumAntigen DesignTM 
software (Genscript, NJ) which utilizes an advanced antigen design algorithm based on 
several protein databases. The identified epitopes were compared with the published C5 
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protein crystal structure27 to check for surface exposure. These steps provided twelve 
potential immunogenic epitopes that are likely present on the surface of the native mouse 
protein. An artificial gene was designed coding for a polypeptide comprised of these twelve 
potential epitopes interspersed in three places with a copy of the nonnatural pan-DR epitope 
(PADRE) sequence (a linear peptide that improves humoral responses against antigens and 
helps break immune tolerance28,29) and capped at the C-terminus with a 6XHis tag.  
Mouse C5 vaccine expression and purification 
The artificial gene (obtained from Genscript, NJ) was cloned into the PET-21b 
expression vector and transformed into E. coli strain BL21. Expression of the desired 
protein, intended to be a recombinant mouse C5 vaccine, was induced using the Overnight 
Express™ Autoinduction System (EMD Millipore, MA) following manufacturer-provided 
protocols. The protein formed inclusion bodies and was isolated using the B-PER® 
Bacterial Protein Extraction Reagent (Thermo Fisher, IL), denatured in 8 M urea, and 
refolded by dialysis against PBS containing gradually reduced concentrations of urea. The 
refolded recombinant C5 was then affinity-purified using HisPur™ Cobalt Resin (Thermo 
Fisher, IL) following our previously published and manufacturer-provided protocols. The 
purity of the resultant protein was checked by SDS-PAGE and then purified again using a 
C8 reversed-phase HPLC (Beckman, CA). The single major protein peak was collected for 
sequential experiments.  
Mouse immunizations  
C57BL/6 WT mice (8-12 weeks old) were used in all in vivo experiments. The 
amounts administered per mouse were as follows: human C5, 25 µg; recombinant mouse 
C5, 100 µg; VLP-based C5, 200 µg. For immunization, vaccines were emulsified with 
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complete Freund’s adjuvant (CFA) (Difco Laboratories, MI), then administered 
subcutaneously. For human C5 and recombinant mouse C5 vaccine studies, mice 
immunized with CFA alone were included as controls; for VLP-based C5 vaccine studies, 
mice immunized with the same amount of wild-type VLPs (lacking the C5 epitope) were 
used as controls. The immunized mice were boosted 2 weeks after the initial immunization 
with the same amount of antigens in incomplete Freund’s adjuvant (IFA) (Difco 
Laboratories, MI) once or twice after every other week.   
Serum anti-C5 antibody titer measurements by ELISA 
One week after the last boost, serum was collected from the tail vein and the anti-
C5 IgG titers were measured by ELISA. Briefly, the ELISA plate was coated with 5 µg/mL 
purified full-length human C5 or recombinant mouse C5. After blocking, diluted serum 
samples were added to the plate and incubated for 2h. After washing, HRP-anti-mouse IgG 
was added as a detection antibody. The absorbance was read at 450 nm using a microtiter 
plate reader (Molecular Devices, CA).  
Ex vivo mouse complement-mediated hemolysis assay 
Antibody-sensitized sheep erythrocytes (EshA) were used in the ex vivo mouse 
complement-mediated hemolysis assay following previously published protocol with 
modifications.30 In brief, 15 µL mouse serum and 5 µL human C5 depleted serum were 
added to GVB+2 (5 mM Barbital, 145 mM NaCl, 0.5 mM MgCl2, 0.15 mM CaCl2 and 0.1% 
Gelatin, pH 7.4) in a total volume of 90 µL, then 10 µL of EshA (~ 5x106) suspended in 
GVB+2 were added to each sample and incubated in 37℃ for 5mins. For negative control, 
5 mM EDTA was added to the GVB+2 to inhibit the complement activation. After 
incubation, samples were centrifuged, and the absorbance of the supernatant was measured 
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at 414 nm using a microtiter plate reader. To calculate the percentage of hemolysis rate, 
the following equation was used: Hemolysis rate (%) = [(A-B)/(C-B)] x100%. A= OD414 
reading of sample in GVB+2, B= OD414 reading of sample in GVB+2 with 5mM EDTA, C= 
OD414 reading of maximum hemolysis induced by H2O. 
In vivo complement-mediated intravascular hemolysis and hemoglobinuria 
Complement-induced intravascular hemolysis was induced followed by published 
protocols with modifications.31 In brief, each mouse was injected with 200 µL human C5-
depleted serum intraperitoneally, and 1 hour later, blood was collected through retro-orbital 
bleeding (to minimize bleeding-related hemolysis). Sera were diluted at a 1:10 ratio in PBS 
in a total volume of 100 µL and hemolysis was quantitated by OD reading at 414 nm. At 
the same time of blood collection, the mouse abdomen was gently pressed to collect urine, 
which was diluted at a ratio of 1:10 before hemoglobin levels were measured by OD 
reading at 414 nm. 
Epitope mapping of the recombinant mouse C5 vaccine 
A library of 15-mer oligopeptides overlapping each other by 6 amino acids, 
spanning the entire sequence of the recombinant mouse C5 vaccine, was custom-
synthesized (GenScript, NJ) and used to map the dominant epitope(s) by ELISA. In brief, 
each peptide (20 µg/mL) was used to coat a plate at 4°C overnight. After blocking with 1% 
BSA in PBS for two hours, the plate was incubated (room temperature, 2 h) with 1:500 
diluted sera collected from the recombinant C5 vaccine-immunized mice. After washing, 
the plate was incubated with HRP-labeled anti-mouse IgG at RT for 1 h, followed by color 
development by adding the HRP substrate TMB and OD450 reading using a microplate 
reader (Molecular Devices, CA). 
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Mouse C5 protein structure modeling and peptides epitope localization 
 A structural homology model of mouse C5 was generated using the Phyre2 protein 
recognition server following an established protocol.32 The X-ray crystal structure of 
human C5 protein was used as the template (PDB access code: 3cu7).27 Sequence identity 
and homology between human and mouse C5 proteins is 89% respectively. A normal 
modeling mode was used. Major steps of modeling include gathering homologous 
sequences, fold library scanning, loop modeling, and side-chain placement. The PyMOL 
visualization program (Schrödinger, LLC, MA) was used to display all the structural 
models in this work. 
Construction of plasmids for VLP-C5 vaccine     
The previously described pCDF-CP plasmid33 has a multiple cloning site 
(containing NdeI and XhoI restriction sequences) immediately downstream of the viral 
coat protein (CP) gene. The DNA sequence for the mC5 cleavage domain and the PADRE 
peptide, codon optimized for E. coli expression, were inserted at this site to generate 
plasmids pCDF-CP-mC5 and pCDF-CP-PADRE, respectively. The pCDF-CP-PADRE 
vector was further elaborated with the codon-optimized DNA for the identified C5 epitope 
(ASYKPSKEESTSGS, designated P2) or a scrambled variant (SPAGSEETSKSYSK, 
designated scrP2) downstream of the PADRE sequence, resulting in the plasmids pCDF-
CP-PADRE-P2 or pCDF-CP-PADRE-scrP2.   
VLP-C5 vaccine production and characterization 
The VLP-C5 vaccines were produced and characterized following previously 
published protocols.33 In brief, electrocompetent ClearColi BL21(DE3) E. coli cells 
(Lucigen) were co-transformed with both pCDF-CP-mC5/pCDF-CP-PADRE-P2 and 
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pET28-CP to produce VLP-C5 particles. The control VLP particles were produced using 
only cells transformed with pET28-CP. Cells were plated on selective SOB agar. After 24 
h, isolated colonies were selected into autoclaved SOB media (1% NaCl; 25 mL) 
containing appropriate antibiotics and grown overnight at 37°C. Cultures were diluted into 
autoclaved selective SOB media (1% NaCl; 500 mL) the following day. Cultures were 
grown at 37°C until the cultures reached mid-log phase (O.D.600 ~ 0.9), at which time 
protein expression was induced by the addition of IPTG to a final concentration of 1 mM. 
Cultures were maintained at 30°C for 16 h, after which cells were pelleted by centrifugation 
at 6,000 rpm for 10 min. Cells were lysed with a probe sonicator (10 min total, 5 s intervals) 
in an ice bath. Cell debris was removed by centrifugation at 14,000 rpm for 10 min, and 
supernatant collected. VLPs were precipitated by the addition of 30% (NH4)2SO4 (w/v) at 
4°C for 2 h, and samples were pelleted at 14,000 rpm for 10 min. The pellet was dissolved 
in 1x TBS and extracted with n-BuOH:CHCl3 (1:1, v/v) to remove lipids and aggregates. 
The samples were centrifuged at 3,500 rpm for 10 min, and the aqueous phase was 
collected and subsequently loaded onto 10-40% sucrose density gradients. VLPs purified 
on gradients by centrifugation at 28,000 rpm for 4 h, and VLP bands were isolated via 
syringe. Particles pelleted by centrifugation at 68,000 rpm for 2 h, and subsequent pellets 
dissolved in 0.1M phosphate buffer and characterized.  
The resulting VLPs were characterized by FPLC size-exclusion chromatography 
(Superose 6, monitored by absorbance at 280 nm), dynamic light scattering (Wyatt 
Dynapro plate reader), and microfluidic gel electrophoresis (Agilent 2100 Bioanalyzer 
with Series II Protein 80 chips). The average number of CP and CP-C5 subunits per 
particle was determined by integrating the electropherogram peaks in the instrument 
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software. Levels of endotoxin contamination were found to be less than 0.1 EU/mL using 
Pierce LAL Chromogenic Endotoxin Quantitation Kit (Thermo Fisher, IL). 
2.4. Results and Discussion 
2.4.1. Epitope discovery and vaccine design 
Because 1) autoantigens are generally immune tolerized, 2) previous studies 
suggest that conservative antigens from different species could elicit the production of 
antibodies that cross-react with the autoantigens,34–38 and 3) mouse and human C5 protein 
share >80% homology,39 we initially immunized mice with purified human C5 protein, 
hoping that the developed polyclonal antibodies could cross-react with mouse C5, therefore 
inhibiting mouse C5 activity in vivo. Indeed, mice immunized with human C5 protein 
developed high titers of antibodies against human C5 (Figure 1A); however, sera from  
Figure 1. Immunization of mice with purified human C5 (hC5) generating anti-hC5 
IgG’s that do not reduce mouse C5 (mC5) activity. WT C57BL/6 mice were immunized 
with purified hC5 in CFA or CFA alone (control) and boosted 2 weeks later. One week 
after the boost, serum samples were collected. (A) Serum samples were tested for anti-
hC5 IgG antibody titers using a hC5 ELISA, showing high titers of anti-hC5 antibodies 
developed in the hC5 immunized (IM) mice (detectable at a 1:32 000 dilution), but not 
control mice (not detectable even at a 1:500 dilution). (B) C5 activity in the serum 
samples were assessed by a modified EshA hemolysis assay, and no significant difference 




these immunized mice had similar potency as sera from control mice in lysing sensitized 
sheep erythrocytes ex vivo (Figure 1B). These results demonstrated that immunizing mice 
with human C5 did not develop cross-reacting antibodies to reduce mouse C5 activity in 
vivo. 
We next sought to minimize a domain from the mouse C5 protein for recombinant 
display on the Qb VLP platform with the goal of reducing or blocking C5 activity as in 
patients receiving eculizumab A large domain (60 amino acids) of the mC5 protein 
containing the cleavage site was encoded as a C-terminal extension of the viral coat protein; 
flanking regions of the cleavage site were included in the construct design to ensure the 
cleavage site maintained the context of its native structure in order to generate effective 
neutralizing antibody responses. These particles were prepared according to a well-
established method33 in which a mixture of truncated and extended capsid proteins are co-
expressed in E. coli and self-assemble into a hybrid particle. Notably, only 15 copies of the 
extension were displayed per capsid in this case. The resultant VLP-mC5 vaccine was 
characterized using dynamic light scattering, size-exclusion chromatography, and gel 
electrophoresis, showing intact particles of the expected size (~ 30 nm) and composition. 
Mice immunized with these particles developed robust IgG titers against the Qb capsid 
(Figure 2A) but failed to develop a response against the C5 protein (Figure 2B). 
Furthermore, sera from immunized mice possessed similar activity as sera from control 
mice in lysing sheep erythrocytes (Figure 2C).  
After failing to generate a cross-reactive immune response with the first generation 
VLP vaccine, we next planned to immunize the mice with an autologous mouse C5 mosaic 
protein to systematically identify immunodominant epitopes. Analysis of the mouse C5 
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protein sequence identified 12 potential immunogenic epitopes that are likely to be on the 
surface of the protein (important so that the generated antibodies can have access to them  
Figure 2. Immunizing mice with VLPs displaying the mouse C5 (mC5) cleavage site 
domain did not generate anti-mC5 antibody responses. WT C57BL/6 mice were 
immunized with VLP-mC5 in CFA or wild-type VLP in CFA (control) and boosted 2 
weeks later. One week after the boost, serum samples were collected. (A) Serum samples 
were tested for anti-mC5 and anti-Qb IgG antibody titers by ELISA, showing high titers 
of anti-Qb antibodies developed in both cohorts (detectable at a 1:32 000 dilution), but no 
detectable anti-mC5 antibodies. (B) C5 levels in the serum samples from both cohorts as 
measured by anti-mC5 ELISA. (C) C5 activity in the serum samples were assessed by a 
modified hemolysis assay using C5-depleted human serum, and no significant difference 
was found between the VLP-mC5 immunized mice and the control mice. n = 5 in each 
group   
 
under native conditions; Table 1). We designed an artificial gene coding for all of these 
identified epitopes in a linear sequence together with three copies of a previously published 
tolerance-breaking peptide, PADRE (Figure 3A).28,29 This polypeptide was expressed in 
E. coli, isolated from inclusion bodies, denatured, refolded, affinity purified via a 6XHis 
tag (Figure 3B), and finally purified by reversed-phase HPLC (Figure 3C).  
Mice that were immunized and boosted with the purified C5 multi-epitope 
polypeptide showed high IgG antibody titers against full-length recombinant mouse C5 
protein by ELISA (Figure 4A). Therefore, this C5 vaccine was able to break immune 
tolerance and develop a significant immune response to the autologous C5 epitopes.  
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Figure 3. Design, expression, and purification of the recombinant mouse C5 vaccine. (A) 
Amino acid sequence of the recombinant C5 vaccine, consisting of 12 computer-identified 
mouse C5 surface epitopes (non-highlighted amino acids), three copies of the PADRE 
peptide (highlighted in yellow), and a 6XHis-tag (highlighted in green). (B) Reversed-
phase HPLC to further purify the recombinant C5P after affinity chromatography. (C) 
SDS-PAGE analysis of the purified recombinant C5 vaccine. M = markers; lys = whole E. 
coli lysate; ID = inclusion bodies; C51 = 60 µg of purified recombinant C5 vaccine; C52 = 
20 µg of purified recombinant C5 vaccine.  
 
 
Table 1. Computer-predicted immunogenic C5 protein surface epitopes. 
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Figure 4. Recombinant mouse C5 vaccine reducing mouse C5 (mC5) levels and activity 
in the blood and significantly reducing hemolysis in these mice in a model of PNH. (A) 
After the last immunization of the recombinant mouse C5 vaccine or CFA alone, serum 
samples were collected and tested for their anti-mC5 vaccine IgG titers by ELISA (n = 4 
in each group). (B) Mouse C5 activity in these samples was compared using the modified 
EshA-based hemolytic assay (n = 12 in each group). (C) The recombinant C5 vaccine-
immunized mice and control mice were intravenously injected with 200 µL of C5-
deficient human serum per mouse and then, 1 h later, were bled retro-orbitally using a 
heparinized capillary tube, and in vivo intravascular hemolysis was assessed by 
measuring the OD414 of the plasma samples (n = 4 in each group). IM, immunized. 
 
Furthermore, the mice receiving the C5-based polypeptide vaccine showed less 
complement-mediated hemolytic activity than the control mice (Figure 4B,C). This 
suggests that the recombinant autologous C5 vaccine is effective in eliciting functional 
anti-C5 autoantibodies that have the intended outcome of inhibiting C5 activity.  
 To identify which of the 12 C5 peptide sequences were most effective in inducing 
the above immune response, we designed a library of overlapping 15-mer oligopeptides 
spanning the entire sequence of the recombinant C5 vaccine (Table 2). Using these 
individual peptides as ELISA probes, we assessed the IgG composition of the serum from 
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the C5 vaccine-immunized mice and found that the sera contained high titers of IgG against 
the peptide ACKPEASYKPSKEES, suggesting that this sequence contains a dominant 
surface epitope within the vaccine that elicited strong humoral responses.  
The C5 peptide P2 (ASYKPSKEESTSGS) is predicted by the computer algorithms 
to be an immunogenic epitope exposed on the C5 protein surface and it contains the peptide 
sequence identified in the above-described epitope mapping experiments. To verify that 
this peptide is indeed on C5 protein surface for our future VLP-C5 vaccine development, 
we constructed a mouse C5 three-dimensional homology model based on the published 
human C5 crystal structure27 using the Phyre2 protein recognition program following 
published protocols.32 Mouse C5 protein shares 89% homology with the human C5 
sequence, providing a model with high confidence (100%) and sequence coverage (98%). 
Visualization of the location of the P2 peptide in the mouse C5 structure model showed it 
to be exposed on the solvent-exposed surface (Figure 5, in red), further supporting the 
hypothesis that it represents a suitable epitope for development of VLP-C5 vaccines. 
A recombinant VLP bearing a linear peptide composed of the putative dominant 
C5 surface epitope P2 and the PADRE peptide (separated by a short spacer) was expressed 
as a C-terminal extension of the VLP coat protein (Figure 6A). These particles were 
produced by a well-established method33 in which a mixture of truncated and extended 
capsid proteins are co-expressed in E. coli and self-assemble into a hybrid particle in which 
an average of 50 copies of the extension were incorporated per capsid. The resultant VLP-
C5 vaccine was characterized using dynamic light scattering, size-exclusion 
chromatography, and gel electrophoresis (Figure 6B-D), showing intact particles of the 
expected size (~ 30 nm) and composition. 
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2.4.2. Evaluation of protection in PNH disease model 
WT mice were immunized with either the VLP-C5 vaccine or the same amount of 
control VLP lacking the extended capsid component. Using the same analyses as described  
Figure 5. Verification of the P2 peptide on the surface of mouse C5 protein by homology 
modeling. A three-dimensional model of mouse C5 was constructed based on the published 
human C5 X-ray crystal structure. Mouse C5 protein shares 89% sequence homology with 
human C5 protein. The P2 epitope (red) was found to be exposed on mouse C5 surface 
based on this model. (A) Ribbon representation of the mouse C5 structure model. Amino 
(N) and carboxy (C) terminus of the protein are also labeled. (B) Surface representation of 
the mouse C5 structure model. 
 
above, we found that mice receiving the control VLP produced no detectable recombinant 
mouse C5-reactive IgG (Figure 7A), whereas the VLP-C5 vaccine immunized mice 
developed high titers of IgG antibodies against intact recombinant mouse C5. Mice 
immunized with VLPs displaying the scrambled P2 peptide also failed to generate cross-
reactive antibodies (Figure 8). Most importantly, the complement-mediated hemolytic 
activity of these VLP-C5 vaccine-immunized mice was also significantly reduced (Figure 
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7B), indicating that this VLP-based vaccine is effective in eliciting C5-reactive 
autoantibody production and reducing C5 activity.   
Figure 6. Expression and characterization of hybrid Qβ VLPs. (A) Schematic 
representation of plasmids used for particle expression. PADRE sequence highlighted in 
gold; C5 P2 peptide highlighted in blue. CP: coat protein. (B) Denaturing electrophoretic 
analysis of VLPs displaying the P2 peptide. Bands for the wild-type CP and the CP-P2 
fusion are indicated. Particle composition calculated using densitometry. (C) FPLC 
elution profile for Qβ-P2 VLPs showing particles are intact and greater than 95% pure. 
(D) Dynamic light scattering histogram of Qβ-P2 VLPs showing particles are 
monodisperse in size with a hydrodynamic radius of 16.9 nm. 
 
To test whether the C5 vaccine approach is effective in protecting mice from 
complement-mediated intravascular hemolysis, as found in patients with PNH, we 
modified a previously established complement-mediated intravascular hemolytic anemia 
model.31 In brief, we introduced 200 µL of C5-depleted human serum into each of the VLP-
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C5 vaccine-immunized mice and control mice by i.p. injection. After one hour, each mouse 
was bled retro-orbitally to collect sera to measure intravascular hemolysis, and urine was 
also collected to measure hemoglobinuria. We found that injection of C5-depleted human 
serum-induced much less severe hemolysis and hemoglobinuria in the VLP-C5 vaccine-
immunized mice compared to the control mice (Figure 9). This suggests that mouse C5 
can replace human C5 to form functional MAC and that the VLP-C5 vaccine is effective 
in protecting mice from complement-mediated cell damage in vivo. 
 
Figure 7. VLP-C5 vaccine eliciting high titers of anti-C5 autoantibodies and significantly 
decreasing mouse C5 hemolytic activity. WT mice were immunized subcutaneously with 
the VLP-C5 vaccine or empty VLP as controls and boosted once or twice after every 
other week. IgG titers of the anti-recombinant mouse C5 in the sera were measured 
before the immunization and after the last boost. (A) Before immunization, anti-C5 
antibodies were not detectable in both groups of mice. After the last boost, anti-mouse C5 
IgGs were highly detectable in sera from VLP-C5 vaccine immunized mice but not in 
sera from the control mice. (B). In the modified ex vivo hemolysis assays, sera from the 
same VLP-C5 vaccine immunized mice and control mice were incubated with antibody-
sensitized sheep RBCs (EshA) to quantitate mouse C5 activity. Sera from C5 KO mice 
were used as negative controls. n = 13 in each group. 
 
2.4.3. Discussion 
Aberrant activity of the complement system is emerging as a target for treating 
certain inflammatory and autoimmune diseases.40 While excess complement activity can  
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Figure 8. Scrambled peptide display fails to elicit cross-reactive antibody responses in 
mice. WT mice were immunized subcutaneously with the VLP-scrambled peptide vaccine 
and boosted once every other week. IgG response of anti-C5 and anti-Qb antibodies in the 
sera were measured after the final boost by ELISA (n = 4). 
 
have many potential causes, a choke point of the system is the C5 protein, responsible for 
the penultimate step in the induction of hemolytic function. Most of the complement-
targeted reagents that have been approved or under development are mAbs;41 others are 
based on aptamers,42 peptides,43,44 and small molecules.45 Given the life-long complement 
inhibition required in most of these patients, all currently available complement inhibition 
therapies suffer from limited half-life, high costs, and compliance issues. This is especially 
true in the case of the anti-C5 antibody eculizumab, which many PNH patients have to 
receive by i.v. infusion every two weeks for life, at a current price of almost a half million 
dollars a year per patient.22,46 Interest in C5 as a target has recently expanded to other  
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Figure 9. VLP-C5 vaccine immunization protecting mice from complement-mediated 
hemolysis and hemoglobinuria in a model of PNH. (A) VLP-C5 vaccine immunized mice 
and empty VLP-immunized control mice were injected with 200 µL of human C5- depleted 
serum intraperitoneally. One hour later, blood was collected through the venous sinus of 
the eye, and the resultant sera were diluted at a ratio of 1:10 using PBS before OD values 
were measured at 414 nm. n = 8 in each group. (B) Urea samples were collected from the 
VLP-C5 vaccine immunized mice and empty VLP-immunized control mice, and 
hemoglobinuria were measured by reading OD414 after 1:10 dilution with PBS. n = 5 in 
each group. 
 
diseases, with eculizumab in late-stage clinical trials for conditions such as myasthenia 
gravis47 and cold agglutinin disease48 that involve excessive complement activation. 
We show here proof-of-concept examples of C5 vaccine-based approaches for the 
production of autologous C5-reactive antibodies to reduce C5 activity for the treatment of 
complement-mediated diseases, mimicking the effect of eculizumab. Vaccination with a 
homologous C5 from a different species (human) did not confer anti- mouse C5 function 
in mouse, although it did elicit a strong antibody response against the immunized human 
C5. This stands in contrast to many examples of the use of conservative xeno-antigens in 
antitumor vaccines, in which immunization elicited T- and/or B-cell responses that cross-
react with their mouse counterparts on tumor cells.35–38 In our case, we suggest that the 
overlapping epitopes between mouse and human C5 (which are more than 80% 
 56 
homologous) are well-tolerated in mice and that all the antibodies produced were likely 
against the epitopes that are unique in the human C5.  
 We further explored the display of a large protein domain from the mouse C5 
protein on Qb VLPs as a potential vaccine. These particles also failed to elicit cross-
reactive C5 antibodies in immunized mice, although all mice responded to the viral coat 
protein. In this case, we hypothesize that the truncated domain maintained the native 
conformation of the C5 cleavage site and was unable to stimulate a robust immune response 
and overcome tolerance against the self-antigen.  
Instead, we were able to break tolerance in mice using a linear polypeptide 
composed of computer-predicted strong immunogenic epitopes along with the PADRE 
sequence. We identified a potential dominant C5 peptide within these 12 computer-
predicted immunogenic peptides by epitope mapping using an overlapping peptide library 
and constructed a mouse C5 structure model to ensure that this identified C5 peptide is 
exposed on the mouse C5 protein surface. We then developed VLP nanoparticles that 
display this dominant C5 surface peptide together with the PADRE sequence as a new 
autologous C5 vaccine. The VLP-based C5 vaccine proved to be especially effective at 
eliciting autologous anti-C5 antibody production, inhibiting C5 activity, and protecting the 
vaccinated mice from intravascular hemolysis and hemoglobinuria in a model that mimics 
PNH. Our results suggest that autologous C5 vaccines may hold potential as a supplement 
and/or alternative for eculizumab for treating complement-mediated diseases. Of course, 
whether the human counterparts of the identified mouse C5 epitopes work in humans needs 
to be confirmed in assays such as in vitro immunization using human peripheral blood 
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mononuclear cells49 followed by human C5 blocking experiments and, eventually, in 
human clinical studies.  
Although numerous studies have extensively explored the development of Qb 
vaccines for the display of self-antigens, these have all focused on the chemical conjugation 
of full-length proteins to the particle surface.2,12,13,18 Peptide display through genetic 
extension has been explored using both PP7 and MS2 VLPs; however, these studies have 
focused on insertions into the AB loop on the VLP surface and remained limited to targets 
in infectious disease.50–53 The work presented in this chapter represents the first study to 
explore the rational design and assembly of hybrid Qb VLPs displaying genetically-
encoded peptide epitopes as terminal extensions for the development of vaccines against 
self-antigens. 
Vaccination against C5 to have the immune system produce its own anti-C5 
antibodies could represent a cost- and compliance-effective alternative to antibody 
infusion, with therapeutic effects prolonged by booster immunizations. Indeed, one 
publication has appeared testing the potential of a vaccination approach against 
complement in treating/preventing diseases.54 In that work, a peptide of undisclosed 
sequence was designed to mimic one or more mouse C5a epitopes, and immunization of 
this peptide conjugated to carrier protein KLH elicited anti-C5a autoantibodies and 
protected the vaccinated mice from chronic neuroinflammation and neuropathologic 
alterations in a model of Alzheimer’s disease.54 This work supports the concept of 
complement-targeted vaccination for treating complement-mediated diseases, but it also 
significantly differs from the work presented here. The vaccine tested in the prior report 
was specific to C5a, which is a complement activation product released from activated C5, 
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and therefore does not have an effect on C5b-9 (MAC) formation. In contrast, the C5 
vaccines developed here do not target C5a, but are specific for the C5b part of C5, which 
is the essential component to initiate the assembly of the MAC to lyse RBCs and to damage 
other tissues in pathological conditions. 
 Another important difference in these approaches is the relative concentrations of 
the target. The C5a protein exists in blood at very low levels (~0.5-50 ng/mL),55,56 whereas 
C5 concentration is approximately 100-200 µg/mL in the blood. It requires strong vaccines 
to break the tolerance to produce enough anti-C5 antibodies to significantly reduce C5 
activity in vivo. By combining multiple epitopes and the PADRE peptide, and by using a 
VLP as a carrier, our approaches did indeed develop high titers of anti-C5 autoantibodies 
and decreased C5 activity. However, C5 activity was not completely eliminated in the 
immunized mice. This is significant because of the dangers inherent in the complete 
elimination of complement function. An eventual therapeutic application of this vaccine 
strategy would require a moderation, but not elimination, of C5 activity, which seems to 
be possible on the basis of this initial study.  
Our use of the PADRE peptide was stimulated by its known ability to help break 
immune tolerance and to improve humoral responses against immunized antigens both in 
humans and in C57BL/6 mice.28,29 PADRE works by strongly binding to 15 of 16 of the 
most common HLA-DR types tested to date in humans and I-Ab molecules in mice to boost 
T-helper responses to improve immune responses against both T-cell and B-cell epitopes. 
Tests to support or refute the assumption that these mechanistic factors are important in the 
present application must await further studies.  
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It should also be noted that the use of human C5-depleted serum to induce 
intravascular hemolysis is a new model of situations found in PNH patients. Mouse 
complement is much weaker than human complement in hemolytic activity. The severe 
intravascular hemolysis and hemoglobinuria induced by injecting mice with C5-depleted 
serum, which does not have any hemolytic activity by itself, shows that mouse C5 can 
replace human C5 to form “hybrid” MAC to lyse mouse RBCs in vivo. We believe this 
method will be useful in other proof-of-concept studies testing mouse C5 targeted therapies 
in treating complement-mediated hemolysis or tissue damage. 
2.5. Conclusions 
In summary, we found that immunization of the conservative human C5 did not 
raise cross-reactive antibodies that reduced mouse C5 activity. We showed that 
immunization of a recombinant mouse C5 vaccine composed of multiple potential protein 
surface B-cell epitopes and the PADRE peptides broke immune tolerance of C5 in mice 
and decreased C5 activity. Finally, we demonstrated that immunization of a VLP vaccine 
displaying one of the identified strong mouse C5 surface epitopes together with the PADRE 
peptide elicited strong humoral responses against mouse C5, reduced C5 activity and 
protected mice from complement-mediated hemolysis and hemoglobinuria in a model of 
intravascular hemolysis, which closely mimic the situations found in PNH patients. 
Furthermore, this study serves as a proof-of-concept for the genetic display of peptide 
epitopes on Qb VLPs in the development of vaccines, particularly in the context of self-
antigens. Our results suggest that C5 auto-vaccines, especially the ones on the Qb VLP 
platform, could be developed as a supplement and/or alternative for eculizumab for treating 
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complement-mediated diseases, especially those in which complement activation needs to 
be controlled for the rest of the life.  
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Chapter 3: Genetic display of Fc-binding domains on Qb VLPs 
 
3.1. Abstract 
 Structurally-defined protein nanoparticles are attractive platforms for the 
polyvalent display of targeting ligands or other bioactive molecules for applications in 
biomedicine. Virus-like particles (VLPs) represent a particularly promising scaffold due 
to their chemical and genetic malleability, which allows for the installation of targeting 
motifs as well as the delivery of functional payloads. In this work, we genetically 
incorporated protein domains on the surface of Qb VLPs capable of binding Fc-domains 
with high affinities and decorated the surface of these particles with targeting antibodies 
to direct cytotoxic payloads against specific cell populations. The co-expression of wild-
type Qb coat proteins and coat protein fusions resulted in the assembly of hybrid VLPs 
that were structurally homogenous and displayed the Fc-binding domain on their surface. 
The interior of these particles could be simultaneously loaded with active proteins for 
applications in imaging or pro-drug therapy. As a proof-of-concept, these particles were 
employed for the selective removal of undifferentiated human pluripotent stem cells 
(hPSCs). After labeling with antibodies against the hPSC-specific surface glycan SSEA-
5, particles containing enhanced green fluorescent protein (EGFP) were shown to 
specifically bind undifferentiated cells in culture, and cytosine deaminase (CD)-
containing particles were able to eliminate undifferentiated hPSCs with virtually no 
cytotoxicity to differentiated cells upon treatment with the prodrug 5-fluorocytosine (5-
FC). We further tested the modularity of this system by replacing the displayed antibody 
in order to direct VLPs against validated cancer cells expressing varying levels of human 
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epidermal growth factor receptor 2 (HER2) on their surface. Particles displaying the 
antibody selectively targeted cells expressing HER2; furthermore, these cells could be 
selectively killed upon incubation with CD-containing particles followed by dosing with 
5-FC. Both of these proof-of-concept studies established the efficacy and modularity of 
this technology, which has tremendous potential for the development of a targeted 
chemotherapeutic platform with improved margins of safety.  
3.2. Introduction 
 One of the primary challenges facing the field of biomedicine is the lack of 
suitable strategies for the delivery of therapeutic molecules (i.e., drugs, proteins, nucleic 
acids) to specific sites of disease.1 The ability to selectively deliver therapeutics to 
specific cellular populations, such as tumors, would offer increased drug efficacy at lower 
dosing while reducing the debilitating off-target effects commonly associated with the 
systemic administration of chemotherapeutics. Monoclonal antibody-drug conjugates 
(ADCs) offer a high degree of selectivity but have limited payload capacity.2,3 Therefore, 
combining the specificity of antibody-based therapeutics with platforms that can carry 
larger payloads represents a promising goal in biomedical research.  
Nanoscale platforms are of particular interest in the development of next-
generation therapeutics as several modalities can be simultaneously engineered into a 
single platform over a large surface area, providing for high degrees of functionalization. 
Numerous nanoparticle platforms have been developed for the delivery of drug payloads 
to cellular environments that are marked by the dysregulated expression of cell-surface 
receptors as a consequence of disease.4–6 In particular, proteinaceous nanoparticles offer 
novel platforms that can be engineered at the genetic level with both targeting and 
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effector functions. Although VLPs and other protein nanoparticles have been well-
established as carrier proteins for vaccine development, their broad applicability as 
delivery agents remains to be fully surveyed; however, this class of biomaterials has been 
explored previously for antibody-mediated delivery.  
Francis and colleagues developed an oxidative coupling strategy for the covalent 
modification of MS2 VLPs with antibodies and successfully targeted cancer cells 
expressing epidermal growth factor receptor (EGFR) or human epidermal growth factor 
receptor 2 (HER2) with this platform.7 Despite these promising results in vitro, only 
moderate tumor uptake was observed when the biodistribution of this platform was 
investigated in a murine model of breast cancer.8 It should be noted here that penetration 
of the particle into the tumor is not a necessary requirement for effective delivery of a 
therapeutic, as will be discussed later in this chapter. Vault nanoparticles have also been 
engineered to display antibody-binding peptides (Z domains) derived from 
Staphylococcus aureus protein A and, after labeling with anti-EGFR antibodies, could 
specifically localize to A431 cancer cells.9 Although these constructs demonstrated 
selective targeting, their ability to deliver a cytotoxic payload was not tested.  
In the work presented in this chapter, we sought to build on the technology 
developed by Fiedler and Brown10–12 by simultaneously encapsulating active prodrug-
converting enzymes within Qb VLPs while incorporating ZZ domains on the particle 
surface to mediate targeting antibody display. A dimeric variant of the Z domain 
(approximately 200 amino acids) first reported by Nilsson et al.13was chosen for 
incorporation, hence the “ZZ” designation. As a proof-of-concept, we first explored the 
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utility of our system for the targeted removal of human pluripotent stem cells (hPSCs) in 
cardiomyocyte differentiation cultures.  
Due to their virtually unlimited self-renewal capacity and differentiation potential 
in vitro, hPSCs—comprising human induced pluripotent stem cells (hiPSCs) and human 
embryonic stem cells (hESCs)—remain leading candidates for cell-based regenerative 
therapies.14–18 Despite substantial advances in protocol efficiencies, directed 
differentiation of hPSCs to a desired cell type usually yields a population containing 
residual undifferentiated and potentially tumorigenic cells. Before widespread clinical 
adoption of hPSC-based therapies can be achieved, effective strategies for the removal of 
hPSCs are needed to eliminate the risk of post-transplantation teratoma formation.19–21 To 
this end, making potentially tumorigenic hPSCs sensitive to prodrugs via expression of 
suicide-inducing genes is considered a promising approach.22–27 Transgenic expression of 
the bacterial gene encoding cytosine deaminase (CD), which enables the conversion of 
the negligibly toxic prodrug 5-fluorocytosine (5-FC) to the highly cytotoxic 5-
fluorouracil (5-FU), has been used to selectively eradicate pluripotent stem cells derived 
from mice25 and primates.27 However, since transgenic modification of cells poses the 
risk of deleterious mutagenesis, we explored our system for specific intracellular delivery 
of suicide-inducing macromolecules such as CD to viable hPSCs as a safer alternative for 
clinical applications.  
 Targeted therapeutics have also emerged in recent years as promising approaches 
for the treatment of certain cancers.28 Overexpression of ErbB2/HER2 has been reported 
in ~ 25% of all breast, gastric, and ovarian cancers, where its expression level correlates 
with the aggressiveness of the disease.29–31 Trastuzumab is an FDA-approved monoclonal 
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antibody therapeutic that is employed against HER2+ cancers in combination therapies, 
as it can inhibit growth but is primarily ineffective at eliminating tumors on its own.30 We 
further sought to explore the modular utility of our system by targeting cancer cells 
expressing HER2 by simply replacing the surface-displayed antibody.  
 Our data shows that the antibody-guided delivery of VLPs to specific cell 
populations is highly efficient even at low nanomolar concentrations and is highly 
selective at delivering cytotoxic payloads only to the target cells with no detectable levels 
of off-target toxicity. This extends the engineering of hybrid VLPs presented in Chapter 2 
to much larger protein domains that mediate markedly different functional outcomes 
(cellular targeting vs. epitope presentation). While the work presented here is not the first 
example of cellular targeting mediated by protein domain display on hybrid Qb 
particles,32 it is by far the most modular. Furthermore, it is one of the few examples to 
simultaneously investigate both antibody-mediated targeting as well as delivery of a 
cytotoxic effector using a nanoparticle platform. The ability to develop a single platform 
and alter its tissue tropism by simple exchange of the surface-displayed antibody provides 
for a system that can be directed against multiple disease targets in a “plug-and-play” 
fashion, which is demonstrated by the two studies presented herein.  
3.3. Materials and Methods 
Cell culture 
Human induced pluripotent stem cells [iPS(IMR90)-1, WiCell]33 and human 
embryonic stem cells (H7, WiCell)34 were cultured either on a feeder layer of irradiated 
mouse embryonic fibroblasts (MEF), where they were maintained in hPSC medium 
(KnockOut DMEM, 20% KnockOut Serum Replacement, 2 mM L-glutamine, 0.1 mM 
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non-essential amino acids, 0.1 mM β-mercaptoethanol, 100 U/mL Penicillin-
Streptomycin) supplemented with 8 ng/mL human basic fibroblast growth factor (bFGF), 
or in feeder-free hPSC conditions as previously described.35 Primary human dermal 
fibroblasts (hDFs) were obtained with informed consent from a patient skin biopsy in a 
safe and ethical manner as approved by the Emory University Institutional Review Board 
(IRB). Isolated hDFs were cultured in fibroblast growth medium (DMEM, 10% FBS, 4 
mM L-glutamine, 100 U/mL Penicillin-Streptomycin). MDA-MB-435, MDA-MB-231, 
HT-29, and HEK-293 cells were all cultured in standard growth medium (DMEM, 10% 
FBS, 2 mM GlutaMAXÔ, 1 mM sodium pyruvate, 100 U/mL Penicillin-Streptomycin). 
All cell culture reagents were from Fisher Scientific unless specified.  
Protein expression and purification of Qβ(ZZ) VLPs 
The hybrid VLP constructs were produced and characterized as previously 
described.10 Briefly, ClearColi® BL21(DE3) electrocompetent E. coli cells (Lucigen) were 
co-transformed with one of the following plasmid combinations: pET28-
CP@EGFP/pCDF-CP(ZZ) or pET28-CP(ZZ)/pCDF-CP@CD according to the 
manufacturer’s recommended protocol. The ZZ domain was connected to the C-terminal 
end of the Qb capsid sequence by an 8-amino acid linker; the full sequence of the extended 
coat protein [(Qb)(linker)(Z)(Z)] was as follows, noting that the N-terminal methionine 









Cells were plated on selective super optimal broth (SOB) agar; after 24 h, single 
colonies were isolated and transferred to selective SOB media (1% NaCl; w/v) for 
overnight growth at 37°C. The following morning, cultures were diluted under the same 
conditions and growth was monitored via optical density (600 nm) until the cultures 
reached mid-log phase (i.e., O.D.600 ~ 0.9). Protein expression was induced by the addition 
of IPTG at a final concentration of 1 mM. Cultures were maintained at 30°C for 24 h, after 
which time cells were harvested by centrifugation (6,000 rpm, 10 min). Cell pellets were 
suspended in 1X Tris-buffered saline (TBS; pH 7.06), and cells were lysed with a probe 
sonicator in an ice bath (10 min total, 5 s pulse intervals). Cell debris was removed by 
centrifugation (14,000 rpm, 10 min) and the supernatant was collected. VLPs were 
precipitated by the addition of 30% (NH4)2SO4 (w/v) for 2 h at 4°C, and the precipitate was 
pelleted by centrifugation (14,000 rpm, 10 min). The pellet was dissolved in 1x TBS and 
extracted with a solution of n-BuOH:CHCl3 (1:1, v/v) to remove lipids and aggregates. The 
aqueous phase was collected following centrifugation (14,000 rpm, 10 min) and VLPs were 
further purified on 10-40% sucrose density gradients (28,000 rpm, 4 h). VLP bands were 
isolated via syringe and pelleted by ultracentrifugation (68,000 rpm, 2 h). Subsequent 
pellets were dissolved in 0.1M potassium phosphate buffer and characterized.   
Characterization of Qβ(ZZ) VLPs 
VLP concentration was quantified using Bradford assay with BSA standards 
according to the manufacturer’s protocol (Thermo Fisher) with average yields of 10-20 
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mg/L. Particle purity was assessed by fast protein liquid chromatography (FPLC) with a 
Superose 6 GL column and monitored by absorbance (280 nm). Size of the VLPs was 
determined by dynamic light scattering (DLS) using a Dynapro II plate reader (Wyatt 
Technology), and particle composition was determined by microfluidic gel electrophoresis 
using an Agilent 2100 Bioanalyzer with Series II Protein 80 chips. The relative particle 
composition was determined by comparing peak integrations from the electropherograms 
using the Bioanalyzer software. Due to overlap of the CP(ZZ) and EGFP bands, EGFP 
concentration was calculated by measuring the sample absorbance at 488 nm and using the 
Beer-Lambert law (Abs = εcl; εEGFP = 56,000 M-1cm-1). On average, 4-8 molecules of 
EGFP were packaged, 13-18 molecules of CD were packaged, and 40-60 ZZ-domain 
subunits were incorporated per particle, respectively. 
Antibody-labeling of Qβ(ZZ) VLPs 
Qβ(ZZ)@EGFP or Qβ(ZZ)@CD VLPs were labeled with anti-SSEA-5 or anti-
ErbB2/HER2 antibodies. Briefly, VLPs were diluted to 0.1 mg/mL and 20 µg VLP was 
incubated with 50 µg purified anti-human SSEA-5 mouse IgG1, κ antibody (Clone 8e11, 
BioLegend) or 50 µg purified anti-human ErbB2/HER2 rat IgG2a (Clone ICR55, Thermo 
Fisher) for 2 h at 37°C. A antibody: ZZ-domain mole ratio of 0.75 was used for all labeling 
reactions and was sufficient for uniform labeling of the particles. To serve as a control, the 
same procedure was repeated with purified mouse IgG1, κ isotype control antibody (Clone 
MG1-45, BioLegend).  
Quantification of antibody loading by multi-angle light scattering 
Empty Qβ(ZZ) VLPs were split into two samples at 0.1 mg/mL, and one sample 
was labeled with mouse IgG1, κ isotype control antibody as previously described. Samples 
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were separated over a Superose 6 10/300 GL size exclusion column (GE Healthcare) using 
an Agilent HPLC to maintain a 0.2 mL/min flow rate of 0.1M KPO4 buffer (pH 7.4). 
Samples of 100 µL were injected onto the column. Samples were detected using a UV-vis 
detector (Agilent), a Viscotek SEC-MALS 20 multi-angle light scattering detector 
(Malvern), and a Viscotek VE3580 refractometer (Malvern). The number-average 
molecular weight, Mn, was calculated with OmniSEC 5.0 software and plotted across the 
elution peak. The increase in molecular weight for the antibody-labeled sample was related 
to the number of bound antibodies using the average molecular weight for IgG antibodies 
(~150 kDa). 
Cardiomyocyte differentiation 
hPSCs were induced for cardiac differentiation as described previously.36,37 hPSCs 
were first dissociated using Versene and plated on Matrigel-coated wells plate at density 
of 1.6x105 cells/cm2. Cells were cultured in conditioned medium from MEF (MEF-CM) 
for 2 days and treated with 100 ng/mL activin A (R&D Systems) from differentiation day 
0 till day 1 and 10 ng/mL bone morphogenic protein-4 (BMP4, R&D Systems) from day 1 
till day 5 in RPMI/B27 insulin-free medium. Cells were cultured successively with 
RPMI/B27 medium with insulin and the medium was changed on alternate days. 
Cardiomyocytes showed beating activity at day 9/10 of differentiation. 
Treatment of Cardiac Progenitors with VLPs 
One day before the treatment of cardiac progenitors derived from hPSCs (at day 7 
or 8), the medium was replaced with a blocking solution (medium with 20% KnockOut 
Serum Replacement) to prevent non-specific binding of VLPs. After cultured for 24 h (at 
day 8 or 9), the cells were then treated for 1 h with medium containing 8 nM SSEA-5-
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labeled Qβ(ZZ)@CD VLPs or vehicle (PBS as a control) followed by 24 h incubation with 
100 µM 5-FC.  
Treatment of co-culture of hPSCs and cardiomyocytes with VLPs 
Cardiomyocytes at day 14 were plated on a Matrigel-coated plate at density of 
1.6x105 cells/cm2 and cultured in RPMI/B27 medium until they regained beating activity. 
Undifferentiated hPSCs were then plated at density of 1-5% compared to cardiomyocytes 
(1.6x103 to 8x103 cells/cm2) and cultured in MEF-CM medium. Cells were treated for 1 h 
with medium containing 8 nM SSEA-5-labeled Qβ(ZZ)@CD VLPs or PBS (vehicle as a 
control) followed by 24 h incubation with 100 µM 5-FC.  
Live-cell microscopy and fluorescence imaging 
Procedure for SSEA-5 targeting. For standard live-cell microscopy, cultured cells 
were imaged using a phase contrast and epifluorescence inverted microscope (Zeiss 
AxioVert A1) equipped with Zeiss AxioCam digital camera system. Images were 
processed and exported using Zeiss AxioVision LE imaging software and image merging 
was performed in Adobe Photoshop. For live-cell deconvolution microscopy, 
undifferentiated hPSC colonies were seeded onto a Matrigel-coated glass-bottom chamber 
slide and allowed to adhere overnight before imaging. The following day, the cells were 
incubated for 30 min at 37°C in 25 µL of cell culture medium containing 8 nM of 
Qβ(ZZ)60@EGFP4+SSEA-530 particles, 5 µg/mL membrane-specific wheat germ 
agglutinin, Alexa Fluor 594 conjugate (Invitrogen) and 2 drops/mL of NucBlue® Live 
ReadyProbes® (Life Technologies) in accordance with the manufacturer’s instructions. 
After 30 min, the particle and nuclear probe-containing medium was removed and the cells 
were rinsed twice with cell culture medium before imaging. Live cells were imaged at 37°C 
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using an Olympus® IX71/IX51 temperature-controlled wide-field deconvolution 
fluorescence microscope. Optical sections were acquired using an automated stage and 
deconvolution algorithms. Cells were first imaged in the XY plane at 60X magnification, 
where EGFP and DAPI were excited at 495 nm and 358 nm, respectively, and emission 
was collected at 519 nm, and 461 nm, respectively. Z-series orthogonal image stacks were 
captured using 50 steps at a size of 0.2 µm per step. Pictures were taken using SoftWoRx 
microscopy software (DeltaVision) and files were exported and analyzed using Volocity 
6.3 3D image analysis software (Perkin Elmer).  
Procedure for ErbB2/HER2 targeting. For standard fluorescence microscopy, 
cultured cells were imaged on an Eclipse Ti-U fluorescence microscope (Nikon) equipped 
with a 60x oil immersion objective and a CoolSNAPÔ MYO CCD camera system 
(Photometrics). Prior to imaging, 5x105 cells (MDA-MB-435, MDA-MB-231, and HEK-
293) were seeded onto 8-chambered microscope slides and allowed to adhere overnight. 
The following day, cells were incubated for 2 h at 4°C with 200 µL cell culture media 
containing 10 nM Qb(ZZ)32(Alexa Fluor 488)20 + anti-ErbB2/HER216 or 10 nM 
Qb(ZZ)32(Alexa Fluor 488)20. Following incubation, cells were rinsed twice with 1x PBS 
and fixed with 2% paraformaldehyde for 15 min at room temperature. Cells were 
subsequently rinsed twice with 1x PBS and imaged immediately. Pictures were taken using 
NIS Elements imaging software (Nikon) and files were exported and analyzed using 
ImageJ software.  
Cytotoxicity and viability assays 
Procedure for SSEA-5 targeting. The cytotoxic range of 5-fluorocytosine (5-FC) in 
the presence of Qβ(ZZ)42@CD13+SSEA-521 and 5-fluorouracil (5-FU) in hPSCs was 
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determined using Cell Counting Kit-8 (CCK-8; Dojindo) pursuant to the manufacturer’s 
instructions. CCK-8 is a tetrazolium salt-based calorimetric assay which measures the 
amount of formazan dye generated by cell dehydrogenases, whereby the optical density of 
the dye is directly proportional to the number of living cells. Each condition was performed 
with triplicate wells containing ~ 10,000 cells per well. Cells were incubated for 4 h in 
culture media with a 1:10 dilution of CCK-8 and absorbance was measured at 450 nm with 
a Synergy 2 microplate reader and Gen5 software (BioTek). The EC50 was generated and 
calculated using GraphPad statistical analysis software. The specificity of killing hPSCs in 
a feeder layer co-culture was assessed via microscopy after a 30 min incubation with 4 µM 
fluorescence-dependent ethidium homodimer-1 (EthD-1; Molecular Probes). Dead cells 
are detectable when the cell-impermeable dye EthD-1 enters cells with damaged 
membranes and binds intracellular nucleic acids to emit bright red fluorescence. To identify 
hPSCs, fluorescent StainAlive (DyLight 488) TRA-1-60 anti-human antibody (Stemgent) 
was added directly to the culture media (1:100 dilution) and incubated for 30 min. 
Fluorescent antibodies were excited and captured in accordance with the manufacturer’s 
instructions.  
Procedure for ErbB2/HER2 targeting. Targeted killing of MDA-MB-435 cells was 
assessed using a standard MTT assay to assess cell viability post-treatment. Each condition 
was performed in duplicate wells containing 5x104 cells per well. Briefly, cells were 
incubated for 1 h at 37°C with either Qb(ZZ)42@CD13, Qb(ZZ)42@CD13 + anti-
ErbB2/HER221, or fresh DMEM. The final particle concentration was 5 nM for all treated 
wells. Cells were rinsed twice with PBS and either dosed with fresh media containing 1, 
10, or 100 µM 5-FC (for all particle-treated cells); 1, 10, or 100 µM 5-FU; or left untreated. 
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After 24 h, cells were rinsed twice with PBS and incubated with 1 mM 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) in fresh DMEM for 2 h at 
37°C. Media was removed and 200 µL DMSO was added to dissolve formazan crystals. 
After thorough mixing, absorbance was measured at 540 nm using a microplate reader 
(Thermo Fisher Scientific). 
Colony formation assay 
Colony formation assay was performed to determine if SSEA-5-labeled 
Qβ(ZZ)42@CD13 VLPs selectively kill hPSCs in the presence of 5-FC. Vehicle- or VLP-
treated cells were harvested and plated at 1x105 cells/cm2 onto a feeder layer of irradiated 
MEF (2.5x104 cells/cm2). Cells were cultured with conditioned medium from MEFs and 
hbFGF (8 ng/mL) for 10 more days until colonies were visible. The cells were then fixed 
for the detection of hPSCs by immunocytochemistry. 
qRT-PCR 
RNA was extracted from vehicle- and VLP-treated cells (n=3/group) 3 days after 
the VLP treatment, using Aurum total RNA mini kit (Bio-Rad) as per manufacturer’s 
instructions. Cells were lysed in 350 µL lysis buffer supplemented with 1% β-
mercaptoethanol then stored at -80oC until further processing. Samples were reverse-
transcribed using 100 U of Superscript III enzyme and random primers in 20 µL reaction 
mixture containing Vilo reaction buffer as per manufacturer's instructions (SuperScript® 
VILO™ cDNA Synthesis Kit by Life Technologies). Samples were processed in a Bio-
Rad thermal cycler with following temperature cycles: 25ºC for 10 min, 42ºC for 2 h and 
25ºC for 5 min. The reaction mixture was then diluted 5 times before further use for real-
time PCR (qPCR). Human specific PCR primers (Appendix I) for the genes examined 
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were retrieved from open access websites (http://primerdepot.nci.nih.gov/ or 
http://pga.mgh.harvard.edu/primerbank/). Thermocycler reaction was set up as follows 
using the: initial denaturation step at 95ºC for 10 min, 40 cycles of two-steps with 15 s of 
denaturation at 95ºC followed by 1 min of annealing at 60ºC using Applied Biosystems 
7500 real-time PCR systems. All iTaq SyBr green samples were normalized to the level of 
the housekeeping gene GAPDH. Relative expression levels compared to control samples 
were presented as fold changes calculated by the 2−ΔΔCt method. Data are presented as 
mean ± SD. Relative expression of stem cell marker genes in both vehicle and VLP-treated 
samples was compared to normal cardiomyocytes cultures and 1% spiked cardiomyocytes 
at Day 0 (before 5-FC treatment).  
Ca2+ imaging 
Live cell imaging of intracellular Ca2+ transient was performed to assess functional 
characteristic of cardiomyocytes as described previously.38,39 Cultured cells were 
dissociated using Trypsin/EDTA, seeded onto Matrigel-coated 25x25x1 mm glass 
coverslips (~ 25,000 cells per coverslip), allowed to adhere overnight and then maintained 
in RPMI/B27 medium until they recovered beating activity. Cells were incubated for 15 
min at 37°C in 2 mL RPMI/B27 medium containing 5 µM Fluo-4, AM, a cell permeant-
fluorescent Ca2+ dye (Thermo Fisher, F14201) for cytosolic loading. After 15 min, cells 
were placed in a stimulation chamber on an Olympus FV1000 inverted confocal IX81 
microscope, where they were eluted for 5 min at 37 °C in Tyrode’s solution (148 mM NaCl, 
4 mM KCl, 0.5 mM MgCl2·6H2O, 0.3 mM NaPH2O4·H2O, 5 mM HEPES, 10 mM D-
Glucose, 1.8 mM CaCl2·H2O, pH adjusted to 7.4 with NaOH) to allow for dye de-
esterification. Cells were then continuously bathed in 37 °C Tyrode’s solution while field-
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stimulated (MyoPacer EP Field Stimulator, IonOptix) at 1 Hz, 32 V. Fluo-4 was excited 
by the 488 nm line of an argon laser and emitted fluorescence was captured at >505 nm. 
Recordings were acquired in line-scan (X-T) mode at a sampling rate of ≥500 lines per 
second and a pixel size of 0.155 µm. Lines were preferentially positioned in the center of 
the cell. Recordings of line-scan Ca2+ transients at 40x magnification were processed and 
exported using FV10-ASW 3.0 microscopy software (Olympus). Analysis of recordings 
was performed with Clampfit 10.0 software (Molecular Devices). Transient amplitude data 
are presented as ΔF/F0, where ΔF= fluorescence (F) – basal fluorescence (F0). 
Immunocytochemistry 
Immunocytochemical analyses were done to evaluate presence of hPSCs and 
cardiomyocyte phenotype as described previously.40 Cells were dissociated using 
Trypsin/EDTA and plated on a Matrigel-coated 96 well plate at density of 50,000 cells per 
well, and cultured until they recovered beating activity before fixation. Cells were washed 
with PBS and fixed in 4% (vol/vol) paraformaldehyde (Sigma) at room temperature for 15 
min then permeabilized in cold methanol for 2 min at room temperature. Cells were then 
blocked in 5% normal goat serum (NGS) in PBS at 4°C for 1 h and incubated with primary 
antibodies in 3% NGS overnight at 4°C. After the incubation with the primary antibodies, 
the cells were washed twice with PBS to get rid of unbound primary antibodies. Cells were 
then incubated with the corresponding conjugated secondary antibodies (Table S2) at room 
temperature for 1 h in the dark, washed twice with PBS. Vectorshield mounting medium 
containing DAPI (Vector Laboratories, H-1200) was used to counterstain nuclei. Cells 
were imaged using a phase contrast and epifluorescence inverted microscope (Zeiss 
AxioVert A1) equipped with Zeiss AxioCam digital camera system. Images were 
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processed and exported using Zeiss AxioVision LE imaging software and image merging 
was performed in Adobe Photoshop. 
Video-based analysis of contractility 
Contractility of cardiomyocytes was recorded using a phase contrast inverted 
microscope (Zeiss AxioVert A1) equipped with Zeiss AxioCam digital camera system, 20x 
magnification, 30 s for each sample, 20 ms interval between frames. Video were processed 
and exported using Zeiss AxioVision LE imaging software. Video-based analysis of 
contractility parameters was performed with Matlab R2016b software as described.41  
Flow cytometry 
 MDA-MB-435, MDA-MB-231, HT-29, and HEK-293 cells were grown to 90% 
confluence, detached with Accutase, pelleted, and re-suspended in FACS buffer. 
Approximately 5 x 105 cells were aliquoted for each sample. Qb particles were added 
directly to the cell suspensions at a final concentration of 10 nM and incubated at 4°C for 
2 h. Cells were washed twice with FACS buffer and fixed with 2% paraformaldehyde for 
15 min at room temperature. Following two additional washes, cells were re-suspended in 
FACS buffer and stored at 4°C until analysis. Cell populations were gated for live cells and 
10,000 events were collected using a BD LSRFortessa cell analyzer (BD Biosciences). 
Data analysis was performed using FlowJoÒ software (FlowJo, LLC). 
Statistics 
For calcium imaging analysis and video-based analysis of contractility, significant 
differences between vehicle- and VLP-treated cells were assessed by two-sample t-test. All 
data were expressed as mean ± SD and p values less than 0.05 were considered as 
significant. 
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3.4. Results and Discussion 
3.4.1. Antibody-directed elimination of tumorigenic stem cells 
VLPs are named here as previously described: for example, Qβ(ZZ)n@EGFPm denotes a 
Qβ VLP in which an average of n of the 180 capsid protein subunits have the ZZ domain 
appended to the C-terminus for display on the external surface, and an average of m copies 
of the EGFP protein are encapsidated inside the particle.11 In addition, if the surface ZZ 
domain on the VLPs is bound to an antibody, a + sign appears followed by the antibody’s 
abbreviation. EGFP packaging was engineered by co-transformation of E. coli cells with 
two plasmids, one [designated pET28-CP@EGFP] coding for both the standard capsid 
protein (CP) and EGFP fused to the Rev peptide to assist in packaging,11 and the other 
[pCDF-CP(ZZ)] coding for the CP-ZZ fusion (Figure 1A). IPTG-triggered expression 
from both plasmids routinely yielded particles in a yield of 10-15 mg per L of culture with 
n = 60 and m = 4 (Figure 1B,C). Characterization by dynamic light scattering revealed a 
homogeneous hydrodynamic radius (Rh) of 17.2 nm, somewhat larger than the wild-type 
VLP (14 nm), as expected. Antibody SSEA-5, identified by Weissman, Drukker, and 
colleagues as a binder of an hPSC-specific fucosylated H-1-type carbohydrate antigen,42 
was mixed with these particles to give Qβ(ZZ)60@EGFP4+SSEA-530, which showed an 
increase in apparent Rh to 21.2 nm (Figure 1D), consistent with the presence of  
no more than a single layer of IgG antibodies on the particle surface. Multiple angle 
light scattering (MALS) analysis indicated an increase in particle molecular weight from 
3.2 MDa to 5.5 MDa, corresponding to occupancy of approximately half of the ZZ domains 
by IgG molecules (Figure 1E). 
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Figure 1. SSEA-5-labeled Qβ(ZZ)60@EGFP4 VLPs selectively deliver EGFP 
intracellularly to hPSCs. (A) Schematic of Qβ(ZZ)60@EGFP4 viral coat protein expression 
and particle assembly, followed by VLP labeling with SSEA-5 antibodies. (B) Denaturing 
electrophoretic analysis of Qβ(ZZ)60@EGFP4 VLPs. (C) Fast protein liquid 
chromatography analysis of Qβ(ZZ)60@EGFP4 VLPs. (D) Dynamic light scattering 
histograms of Qβ(ZZ)60@EGFP4 VLPs (red) and Qβ(ZZ) 60@EGFP4+SSEA-530 VLPs 
(blue); %Đ = % dispersity; Rh = hydrodynamic radius. (E) Multiple angle light scattering 
curves show the change in refractive index (blue peak) of the VLPs as a function of the 
elution volume through a size-exclusion column. A comparison between the log MW (red 
trace) of unlabeled (left) and antibody-labeled (right) VLPs indicates approximately half 
of the ZZ domains are occupied by antibodies. (F) Representative microscopy images of 
hPSC colonies grown on mouse embryonic fibroblasts incubated with 8 nM unlabeled, 
IgG1-labeled, or SSEA-5-labeled Qβ(ZZ)60@EGFP4 VLPs for 30 min at 37°C. Only 
hPSCs treated with SSEA-5-labeled Qβ(ZZ)60@EGFP4 showed detectable EGFP 
fluorescence. Scale bars = 100 µm. (G) Live-cell deconvolution fluorescence microscopy 
of hPSCs incubated for 30 min at 37°C with 8 nM Qβ(ZZ)60@EGFP4+SSEA-530, blue 
DAPI nuclear probe, and membrane-specific red wheat germ agglutinin (WGA). Left = 
EGFP and DAPI only; right = EGFP, DAPI, and WGA. XY optical sections are shown 
above orthogonal YZ cross-sections corresponding to the white dashed line in the XY 
plane. Cross-sections show prominent cytoplasmic co-localization of EGFP and DAPI 
along with punctate expression of the membrane-specific WGA dye. XY plane scale bars 




Qβ(ZZ)60@EGFP4+SSEA-530 particles were incubated (5, 10, and 15 nM in particle, 37°C) 
with hESC colonies cultured on mouse embryonic fibroblasts (MEFs). After 30 min, EGFP 
was detected in all the undifferentiated stem cell colonies at all particle concentrations 
(Figure 2A,B). To confirm the antibody-directed nature of EGFP delivery, a blinded 
experiment was performed in which hESC colonies were again cultured on MEFs and 
incubated for 30 min at 37°C with 8 nM of unlabeled, IgG1-labeled (κ isotype control), or 
SSEA-5 labeled Qβ(ZZ)60@EGFP4. Since mouse embryonic fibroblasts do not express the 
SSEA-5 binding motif, they were used as a negative cell control. After 30 min, the excess 
particle-containing supernatant was removed, and the cells were rinsed before imaging. 
Fluorescence images showed green fluorescent stem cell colonies in the wells treated with 
Qβ(ZZ)60@EGFP4+SSEA-530 particles, but virtually no green fluorescence in either the 
MEFs or the hESCs treated with the unlabeled Qβ(ZZ)60@EGFP4 or 
Qβ(ZZ)60@EGFP4+IgG1 isotype control particles (Figure 1F). In addition, live-cell 
deconvolution fluorescence microscopy with three-dimensional optical sectioning showed 
substantial diffuse and intracellular EGFP distribution when live hESC colonies were 
incubated with DAPI as a nuclear probe (blue), a membrane-specific wheat germ agglutinin 
dye (WGA; red), and 8 nM of Qβ(ZZ)60@EGFP4+SSEA-530 particles (green; Figure 1G). 
These results demonstrate that Qβ(ZZ)60@EGFP4+SSEA-530 particles selectively target, 







Figure 2. Qβ(ZZ) virus-like particles bearing the SSEA-5 antibody selectively target EGFP 
to undifferentiated cells in a dose-dependent manner. Fluorescence microscopy images 
show human induced pluripotent stem cell colonies grown on mouse embryonic fibroblasts 
that were incubated for 30 minutes at 37°C with 5, 10, and 15 nM of (A) EGFP-
encapsidated Qβ(ZZ) particles bearing no antibody (i.e. Qβ(ZZ)@EGFP) or (B) GFP-
encapsidated Qβ(ZZ) particles bearing the SSEA-5 antibody (i.e. 
Qβ(ZZ)@EGFP+SSEA5). 
 
Targeted VLPs with cytotoxic capability were generated as above, replacing the 
packaged EGFP protein with a thermostable variant of yeast cytosine deaminase (CD).43 
The resulting Qβ(ZZ)42@CD13 particles were addressed with SSEA-5 in the same manner, 
resulting in very similar yield and physical parameters as the EGFP-containing particles 
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(Figure. 3A-D). The cytotoxic activity of the CD-containing particles was verified first on 
monocultures of hiPSCs and hESCs, which were incubated for 24 h with titrating 
concentrations of either 8 nM Qβ(ZZ)42@CD13+SSEA-521 VLPs in the presence of the 
prodrug 5-fluorocytosine (5-FC), or its product, 5-fluorouracil (5-FU), alone as a positive 
cytotoxicity control. Survival percentages for each treatment were determined using a 
tetrazolium salt-based assay and decreased in a dose-dependent manner in both hPSCs and 
hESCs (Figure 3E). The mean EC50 values of 5-FC in the presence of CD-containing 
particles and 5-FU alone for hESCs and hiPSCs were similar (approximately 1.5 µM), with 
negligible cell survival observed at 100 µM of either small molecule. To test targeting 
specificity, monocultures of primary human fibroblasts (hDFs) were treated for 24 h with 
8 nM Qβ(ZZ)42@CD13+SSEA-521 VLPs and either 5-FC or 5-FU at 0.1 µM to 2 mM. 5-
FU was found to kill these differentiated cells with efficiency comparable to the killing of 
stem cells, but no dose-dependent cell death was observed in the presence of 5-FC and the 
SSEA-5-coated particles containing packaged CD (Figure 3F). 
The use of this system requires the elimination of residual undifferentiated hPSCs 
in a mixed population. Thus, co-cultures of hPSC colonies and MEFs were treated for 15 
h with 8 nM of unlabeled, IgG1-labeled (isotype control), and SSEA-5-labeled 
Qβ(ZZ)42@CD13 VLPs in the presence of 100 µM 5-FC, and 100 µM of 5-FU as a positive 
control. Subsequent staining with ethidium homodimer-1 (a specific red marker of dead 
cells) and a green fluorescent antibody against the hPSC-specific TRA-1-60 surface marker 
gave the results shown in Figure 3G. Negligible cell death was induced by unlabeled and 
isotype control-labeled Qβ(ZZ)42@CD13 VLPs in the presence of 5-FC; in these cases, 
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Figure 3. SSEA-5-labeled Qβ(ZZ)42@CD13 VLPs selectively kill hPSCs in the presence 
of 5-FC. (A) Schematic of Qβ(ZZ)42@CD13 viral coat protein expression and particle 
assembly, followed by VLP labeling with SSEA-5 antibodies. (B) Denaturing 
electrophoretic, (C) FPLC, and (D) dynamic light scattering analyses of Qβ(ZZ)42@CD13 
VLPs. (%Đ = % dispersity; Rh = hydrodynamic radius). (E) EC50 curves showing dose-
dependent decreases in human induced pluripotent stem cell (hiPSC) and human 
embryonic stem cell (hESC) survival after 24 h treatment with both 8 nM 
Qβ(ZZ)42@CD13+SSEA-521 VLPs in the presence of the prodrug 5-fluorocytosine (5-FC) 
or the cytotoxin 5-fluorouracil (5-FU). (F) EC50 curves show dose-dependent decreases in 
human dermal fibroblast (hDF) survival percentages after 24 h treatment with 5-FU, but 
negligible cell death after treatment with 8 nM Qβ(ZZ)42@CD13+SSEA-521 VLPs in the 
presence of 5-FC. (G) Representative microscopy images show co-cultures of hPSC 
colonies and MEFs that were treated for 15 h with 8 nM of unlabeled, IgG1-labeled (isotype 
control), and SSEA-5-labeled Qβ(ZZ)42@CD13 VLPs in the presence of 100 µM 5-FC as 
test conditions, and 100 µM 5-FU as a positive control. Red fluorescence indicates dead 
cells and green fluorescence indicates expression of the pluripotent stem cell-specific TRA-





hPSC colonies remained intact with bright, flat morphology and abundant TRA-1-60 
expression. In contrast, hPSC colonies in co-cultures treated with Qβ(ZZ)42@CD13+SSEA-
521 and 5-FC showed extensive ethidium staining, a dark, barely adherent, mounted 
morphology, and minimal detection of TRA-1-60, likely due to antibody binding to loose 
fragments of dead hPSC membranes. The surrounding MEFs were unaffected, 
demonstrating the specificity of VLP-mediated hPSC killing. Co-cultures treated with 5-
FU exhibited indiscriminate cell death. 
Currently it is still unclear what stages of hPSC-derived cardiomyocytes are most 
efficacious for therapeutic application. Clinical application of this methodology may 
require the killing of undifferentiated cells at an early stage to selectively eliminate residual 
hPSCs without affecting cardiomyocyte differentiation. To test this, such treatment (8 nM 
VLPs for 1 h + 100 µM 5-FC for 24 h) was performed at differentiation day 8 or 9 (Figure 
4A). From initial 1x106 cells seeded, at least 200-300 colonies with stem cell morphology 
and positive for the pluripotent stem cell marker TRA-1-60 were detected in cells expanded 
from progenitors treated with vehicle as a control. In contrast, no hPSC colonies were 
detected in otherwise identical cultures treated with the antibody-directed VLPs + prodrug 
(Figure 4B).  
To examine if the treatment affected cardiomyocyte differentiation, we maintained 
the treated cells in RPMI/B27 medium, monitored cell morphology, and examined the 
expression of cardiomyocyte genes. At differentiation day 14, beating cardiomyocytes 
were observed in cultures derived from cells that were treated with either the VLPs or 
vehicle. Similar to cells derived from control cultures, the majority of the cells derived 
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Figure 4. SSEA-5-labeled Qβ(ZZ)42@CD13 VLPs selectively kill residual hPSCs during 
CM differentiation in the presence of 5-FC. (a) Schematic of experimental design for 
treatments of cardiac progenitors with VLPs. (b) Colony assay for the detection of 
undifferentiated hPSCs. (top panels: blue, DAPI nuclear stain; green, TRA-1-60; scale bars 
= 100 µm). ND = not detected. (c) Expression of cardiomyocyte proteins. Scale bars = 100 
µm. (d) Video-based analysis of contractility. Contraction parameters are presented as 
mean ± standard deviation of n=3 biological samples. (e) Ca2+ transient analyses. Scale 
bars = 5 µm. Ca2+ transient parameters are presented as mean ± standard deviation of n=20 
cells. NS = no significant difference between groups (p value >0.05).  
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from the VLP-treated cultures were positive for cardiac transcription factor NKX2-5, gap 
junction protein connexin 43, and cardiac structural proteins including cardiac troponin I, 
cardiac troponin T and α-actinin as detected by immunocytochemistry (Figure 4C). In 
addition, these cells also expressed similar levels of Ki-67, a marker associated with cells 
at active phases of cell cycle (Figure 4C).  
The contractility of cardiomyocytes derived from VLP-treated cultures was found 
to be indistinguishable from that of vehicle-treated control cultures by video-based analysis 
(Figure 4D), including maximum contraction, maximum relaxation, and beating intervals. 
Furthermore, intracellular Ca2+ transients (observed with the aid of calcium indicator dye 
Fluo-4) of cardiomyocytes derived from VLP-treated cultures were also very similar in 
Ca2+ transient amplitude, 50% peak time, and 50% decay time to those from control 
cultures (Figure 4E). These results suggest that the VLP-based elimination of residual 
hPSCs from early-stage differentiation cultures did not significantly affect cardiomyocyte 
differentiation.  
To mimic a high level of residual hPSCs in a differentiation culture at the late stage, 
we co-cultured 1-5% undifferentiated hPSCs with late-stage cardiomyocyte differentiation 
culture from hPSCs, as commonly used to evaluate specific elimination of stem cells in a 
mixed population. The co-culture was treated with the prodrug-converting VLPs (8 nM) 
for 1 h and then with 5-FC (100 µM) for 24 h (Figure 5A). Immediately after these 
treatments or following further culture, the presence of hPSCs and cardiomyocytes was 
examined by staining with antibodies against markers for stem cells (TRA-1-60) and 
cardiomyocytes (a-actinin). As expected, TRA-1-60-positive hPSC colonies/cells were 
detectable in co-cultures treated with vehicle at all time points examined. The amount of 
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Figure 5. SSEA-5-labeled Qβ(ZZ)42@CD13 VLPs selectively kill hPSCs in co-cultures of 
hPSC and cardiomyocytes in the presence of 5-FC. (A) Schematic of experimental design 
for the VLP treatment for co-cultures of hPSCs and cardiomyocytes. (B) Detection of 
hPSCs and cardiomyocytes in co-cultures. hPSC-specific marker TRA-1-60 (red); 
cardiomyocyte-associated protein α-actinin (green). Scale bars = 100 µm. (C) Detection of 
cardiomyocyte proteins. Scale bars = 100 µm. (D) Detection of the expression of 
cardiomyocyte genes by qRT-PCR. Data are presented as mean ± standard deviation of 
n=3 biological samples. (E) Video-based analysis of contractility. Contraction parameters 
are presented as mean ± standard deviation of n=6 biological samples. (F) Ca2+ transient 
analyses. Representative line-scan images show calcium transients in vehicle- and VLP-
treated cells in co-cultures from the area indicated by the white lines. Scale bars = 5 µm. 
Ca2+ transient parameters are presented as mean ± standard deviation of n=22 cells. NS = 
no significant difference between groups (p value>0.05).  
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TRA-1-60 positive cells decreased overtime in the VLP-treated cultures, and the signal for 
TRA-1-60 was undetectable 3 days after the VLP treatment (Figure 5B). In contrast, the 
signal for a-actinin was detectable in the majority of TRA-1-60 negative cells in all 
cultures and was comparable in the vehicle- and VLP-treated cultures (Figure 5B). These 
results suggest that the VLP treatment can specifically eliminate undifferentiated hPSCs in 
the mixture. 
To determine if the VLP + prodrug treatment affected molecular and functional 
properties of cardiomyocytes, the expression of cardiomyocyte genes, cardiomyocyte 
contractility and intracellular Ca2+ transients were examined after the co-cultures were 
treated with vehicle or VLP + 5-FC. In both vehicle- and VLP-treated co-cultures, beating 
cells were observed, which expressed cardiomyocyte transcription factor NKX2-5, 
connexin 43, cardiac troponin I, cardiac troponin T,  a-actinin, and proliferation marker 
Ki-67 to similar extents (Figure 5C). In addition, the expression levels of genes associated 
with cardiomyocytes (cTnT, NKX2-5, MYH6, MYH7, MYL2 and MYL7) were comparable 
between the vehicle- and VLP-treated samples (Figure 5D). Measurements of cardiac 
contractility were also similar between vehicle- and VLP-treated cells with no significant 
differences observed in maximum contraction, maximum relaxation, and beating interval 
as analyzed by a video-based method (Figure 5E). Key parameters of intracellular Ca2+ 
transient recordings were similar between vehicle- and VLP-treated cells (Figure 5F). 
These results suggest that the VLP treatment does not alter molecular and functional 




3.4.2. Antibody-guided targeting of HER2+ cancers 
Given the high selectivity and efficacy of the Qb(ZZ) platform at targeting hPSCs, 
we sought to further expand the utility of this technology by directing cytotoxic activity 
against cancer cell populations expressing ErbB2/HER2. Qb(ZZ)32(Alexa Fluor 488)20 + 
anti-ErbB2/HER216, Qb(ZZ)32(Alexa Fluor 488)20 + isotype control, and Qb(ZZ)32(Alexa 
Fluor 488)20 particles were incubated (10 nM, 4°C) with MDA-MB-435 (melanoma), HT-
29 (colorectal), and MDA-MB-231 (breast) carcinoma cells, respectively. HEK-293 
(kidney) cells were treated as a negative control line in the same manner . After 2 hours, 
specific staining was observed for all cancer cell lines screened by flow cytometry, but no 
staining was observed for HEK-293 cells (Figure 6A-D). Interestingly, staining correlated 
with the reported levels of ErbB2/HER2 expression in each cell line. MDA-MB-435 and 
HT-29 cell lines have both been reported to express high levels of ErbB2/HER2 on their 
surface,44,45 and these cell lines both showed the highest level of staining by VLPs 
displaying anti-ErbB2/HER2 antibodies, with MDA-MB-435 showing the highest signal 
over background (Figure 6A,B). MDA-MB-231 cells have been consistently reported as a 
HER2-negative cell line;44 however, there are also reports in the literature showing 
moderate surface expression of HER2.46,47 Consistent with these observations, MDA-MB-
231 cells displayed significantly lower staining by Qb(ZZ)32(Alexa Fluor 488)20 + anti-
ErbB2/HER216 that was only slightly above background (Figure 6C). HEK-293 cells 
displayed no significant binding over background (Figure 6D). In all cases, unlabeled 
VLPs or VLPs labeled with an isotype control antibody showed levels of non-specific 
binding that varied among cell lines.  
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Figure 6. Flow cytometry histograms illustrating binding of Qb(ZZ)32(Alexa Fluor 488)20 
+ anti-ErbB2/HER216 to cells expressing HER2. (A) MDA-MB-435, (B) HT-29, (C) 
MDA-MB-231, and (D) HEK-293 cells were all incubated for 2 h at 4°C under the 
following treatments: Qb(ZZ)32(Alexa Fluor 488)20 + anti-ErbB2/HER216 (green), 
Qb(ZZ)32(Alexa Fluor 488)20 + isotype control (grey), Qb(ZZ)32(Alexa Fluor 488)20 (red), 
or DMEM (open). Total particle concentration was 10 nM for all treated cells. Histograms 
representative of two replicate experiments.   
 
Specific binding was also confirmed by fluorescence microscopy, which showed staining 
of MDA-MB-435 and HT-29 cells and virtually no detectable fluorescence in HEK-293 
cells (Figure 7). Furthermore, the particles primarily appear to localize to the membrane 
of the target cell populations, although internalization of VLPs may occur with cells 
cultured at physiological temperatures. 
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Figure 7. Analysis of cellular targeting by fluorescence microscopy. MDA-MB-435, HT-
29, and HEK-293 cells were incubated with either 10 nM Qb(ZZ)32(Alexa Fluor 488)20 + 
anti-ErbB2/HER216 (upper panels) or 10 nM Qb(ZZ)32(Alexa Fluor 488)20 (lower panels) 
for 2 h at 4°C. Brightfield images are shown in the first two rows; corresponding 
fluorescence images are shown in the bottom two rows. Threshold for fluorescence images 





Finally, we investigated if these particles could effectively mediate conversion of 
5-FC to induce selective cell death in the same manner as was used in the removal of hPSCs 
earlier in this chapter. MDA-MB-435 cells were treated with Qb(ZZ)42@CD13 particles (5 
nM, 37°C) for 1 hour and subsequently dosed with increasing concentrations of 5-FC (1-
100 µM). There was no observed cytotoxicity for cells treated with untargeted VLPs, 
suggesting that the non-specific binding of particles observed with flow cytometry is 
negligible and does not impact the specificity of this treatment. Particles bearing the anti-
ErbB2/HER2 antibody induced noticeable levels of cytotoxicity with increasing dosing of 
the prodrug 5-FC; furthermore, the degree of cell death was comparable to that observed 
with comparable dosing of 5-FU, suggesting the targeted particles are efficiently 
converting the administered prodrug to the toxic product (Figure 8). These preliminary 
studies suggest that this platform may serve as a viable method for selectively targeting 
cancers overexpressing HER2 or other membrane-bound markers.  
3.5. Conclusions 
In summary, we found that the genetic display of antibody-binding Z-domains on 
the surface of virus-like particles allowed for the generation of a modular platform for 
therapeutic delivery that was highly efficient and selective for the target cell population. 
The marriage of genetic engineering to mediate antibody display on the particle surface 
with the ability to encapsulate prodrug-converting enzymes on the interior provided for a 
powerful therapeutic platform that can be applied in numerous contexts. Our initial proof-
of-concept study focused on the elimination of residual pluripotent stem cells in 
cardiomyocyte differentiation cultures.  
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Figure 8. Anti-ErbB2/HER2-labeled VLPs selectively target and kill cancer cells 
expressing HER2 in an antibody-dependent fashion. MDA-MB-435 cells were treated with 
5 nM Qb(ZZ)42@CD13 + anti-ErbB2/HER221 or 5 nM Qb(ZZ)42@CD13 for 1 h, followed 
by incubation with 1, 10, or 100 µM 5-FC for 24 h. As a control, cells were separately 
treated with the same doses of 5-FU. Viability of cells was assessed by MTT assay 
following treatments and absorbance was related to that of untreated cells (black bar; left) 
to calculate cell viability. 
 
Overall, VLPs encapsulating prodrug-converting enzymes were able to selectively 
kill tumorigenic stem cells in mixed differentiation cultures without harming surrounding 
fibroblast cells. Operationally, this method for the targeted elimination of stem cells is 
simple to perform, requiring no gene transfection or editing and only a simple medium 
change. The resulting stem cell-derived cardiomyocytes were seemingly unaffected by 
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this treatment, rendering it an interesting possibility for improving the safety of stem cell-
based therapies. We extended the potential applications of this platform by substituting 
the targeting antibody on the particle surface to direct VLPs against cancer cells 
expressing HER2. Similar levels of selective targeting were observed against cells 
displaying moderate-to-high levels of HER2, demonstrating the modular utility of this 
platform in its ability to be directed against different cell populations by simple exchange 
of the targeting antibody. Furthermore, these particles mediated selective killing of 
cancer cells expressing HER2, thereby demonstrating the potential utility of this 
technology in multiple clinical settings.  
The technology developed in this chapter has broad applications in the realm of 
targeted therapeutics. This platform benefits from the selectivity of the displayed 
antibody while concurrently raising the associated level of safety by linking the toxic 
payload to enzymatic conversion. The combination of cytotoxic efficiency and selectivity 
in this system derives from the production of only small amounts of toxic molecule 
overall, yet high enough concentrations at the target cells by virtue of localized delivery 
and enzymatic turnover to mediate cytotoxicity. In addition, the VLP protects the cargo 
enzymes from degradation by proteases and other factors, and the particles can be 
produced easily and at large scale. The work presented here highlights the similarities in 
VLP construct design to generate materials for diverse functional applications. 
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Chapter 4: Chemical modification of Qb VLPs to alter trafficking 
 
4.1. Abstract 
The lungs are an organ where macrophages (MF) are present in high abundance 
in order to intercept invading microorganisms that gain access through the mucosal 
surfaces of the airways. Several bacterial pathogens have evolved the capacity to evade 
the innate immune response by establishing infections within pulmonary MF upon 
phagocytosis, leading to prolonged disease that can be fatal if left untreated. These 
infections are often difficult to control as the compounds administered for treatment do 
not accumulate within the infected cells at therapeutically relevant concentrations. 
Macrolide antibiotics, such as azithromycin and clarithromycin, are well-known to 
accumulate in phagocytic cells and have been shown to preferentially distribute in tissues 
where these populations of cells reside. In this study, we employed this class of 
molecules as targeting ligands to direct a virus-like particle (VLP) platform to lung-
resident MF as a proof-of-concept for the development of an intracellular drug delivery 
vehicle. We first prepared a series of VLP-macrolide conjugates and assessed their 
uptake in RAW 264.7 MF cells. Enhanced uptake was observed for all conjugates tested 
relative to particles without macrolide, with azithromycin displaying the greatest effect; 
distinct differences in uptake were also observed depending on the macrocycle structure 
and orientation on the particle surface. Activation of MF cells was stimulated by particle 
uptake and biased towards an M2b phenotype. We next investigated the ability of 
azithromycin to direct VLPs to the lungs in mice, and VLPs were found to significantly 
accumulate in the lungs within 2 hours. The results of this study indicate that this new 
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class of bioconjugate could serve as an effective platform for intracellular drug delivery 
in the context of pulmonary infections.  
4.2. Introduction 
As evidenced in the previous chapter, genetic engineering of virus-like particle 
(VLP) platforms offers a powerful methodology for developing targeted therapeutics; 
however, chemical modification represents an equally promising strategy for materials 
development. While antibodies offer highly selective targeting capabilities, their target 
repertoire is not all-encompassing. Although it is possible to generate antibodies against 
any number of specific targets through protein engineering or focused immunological 
design,1,2 many cell types do not possess protein or glycan surface signatures that are 
wholly unique from other cells. When considering that a specific protein or glycan target 
needs to be recognized in its native conformation for successful antibody targeting, the 
selection of reagents may become even more limited.3 In this sense, small molecule 
conjugations may provide a useful alternative should an antibody target be unavailable to 
mediate therapeutic delivery.  
The display of small molecules on the surface of nanoparticles has been explored 
previously for applications to mediate cell uptake and targeting. Manchester and 
colleagues specifically studied the derivatization of cowpea mosaic virus (CPMV) with 
folic acid and subsequent targeting of tumors bearing the folate receptor, which is 
frequently upregulated in various cancers.4 Other small molecules that bind specifically 
to the extracellular domains of cancer-related proteins have been employed in similar 
fashion. Anisamide-conjugated liposomes have been explored for the delivery of 
doxorubicin to human prostate cancer cells overexpressing sigma receptors.5  
 106 
Carbohydrates can also serve as effective targeting ligands, although increased 
valency of the targeting species is often required as individual ligand-receptor 
interactions are too weak to stimulate effective responses. Efficient and selective delivery 
to the liver was achieved using a bicyclic derivative of galactosamine to target the 
asialoglycoprotein receptor (ASGPR) on hepatocytes but required the use of di- or tri-
valent analogues to achieve efficient cargo uptake.6 The polyvalent display of mannose-
based ligands has also been used to target DC-SIGN, a C-type lectin receptor 
preferentially expressed on dendritic cells, to direct the enhanced uptake of vaccine 
nanoparticles.7 As evidenced, small molecules can be employed to direct the targeting 
and trafficking of nanoparticles to various tissues and cell types; the work discussed in 
this chapter will focus on the chemical functionalization of VLPs for selective delivery to 
macrophages.  
Macrophages are an incredibly versatile class of immune cells that are distributed 
throughout the body and perform critical roles in preventing infection and disease, and 
they are largely localized to tissues where infection or accumulation of foreign particles 
is most likely to occur.8 The lungs are one such locale whereby inhaled pathogens can 
gain direct access for establishing an infection, and macrophages play a critical role in 
mediating immune responses to prevent this occurrence.9,10 Numerous intracellular 
pathogens, such as Mycobacterium tuberculosis11 and Legionella pneumophila,12 usurp 
the phagocytic activity of macrophages and use the cells as an established breeding 
ground for prolonged infection.13 These types of infections are often difficult to treat as 
administered drugs do not accumulate in macrophages at therapeutic levels;14 however, 
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advances in nanotechnology now allow for the controlled design and preparation of 
targeted drug delivery vehicles for addressing specific cell populations.14,15  
Virus-like particles are a class of nanomaterials that provide robust utility, as 
evidenced by their applications in materials science16,17 and medicine.18,19 VLPs are often 
highly stable towards extremes of temperature,20,21 pH,20 and solvent composition,22 
making them amenable to a wide variety of chemical modifications while retaining the 
biocompatibility of a protein. Indeed, previous studies have explored the attachment of 
glycans,23 peptides,24 and polymers25 to the surface of VLPs for applications in cellular 
targeting. VLPs have also been shown to be amenable to modifications on the interior of 
the capsid for the encapsulation of proteins26 and therapeutic small molecules,27 further 
demonstrating their capacity as a platform for drug delivery.  
Certain macrolide antibiotics, such as azithromycin and clarithromycin, have been 
shown to accumulate extensively within lung and liver tissues, leading to more than 100-
fold enrichment in these tissues relative to the bloodstream.28–30 The ability of these 
molecules to gain entry into phagocytic cells is causal to this effect, but the mechanism 
that mediates macrolide uptake is still uncertain. Current studies suggest macrolides may 
engage the mannose receptor, which is ubiquitously expressed on macrophages; however, 
there is evidence that an uncharacterized active transport system for macrolides may also 
exist.31  
Polyvalent display of azithromycin and clarithromycin on gold nanorods was 
previously shown to promote enhanced uptake in RAW 264.7 macrophages for 
application as nanotherapeutics in cancer therapy, indicating that these macrocycles can 
influence the trafficking of nanoscale constructs.32 Dreaden and coworkers showed that 
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macrolide-functionalized gold nanorods induced a cytotoxic phenotype in macrophages 
capable of eliminating cancer cells in co-culture even in the absence of irradiation. This 
study did not investigate the cytokine profiles associated with the observed phenotype, 
albeit numerous studies have previously shown that gold nanostructures stimulate 
inflammatory cytokine production in macrophages.33,34 In the work presented here, we 
have further explored the use of macrolide antibiotics as targeting ligands by conjugation 
to the surface of VLPs derived from the bacteriophage Qb, a 28-nm icosahedral virus that 
has been previously studied as a vehicle for drug delivery.19,35 A series of Qb conjugates 
(3-9) displaying different macrocycles was prepared, and the uptake of these conjugates 
in RAW 264.7 macrophages was quantified by fluorescence microscopy. Phenotypic 
changes and cytokine production in the macrophages were also investigated as a function 
of VLP treatment to more fully assess responses. Finally, we investigated the ability of 
azithromycin to direct Qb particles to macrophage populations in the lung as a proof-of-
concept for pulmonary drug delivery.  
4.3. Materials and Methods 
Cell Culture 
All cell culture reagents were purchased from Invitrogen, unless otherwise 
indicated. RAW 264.7 macrophage cell line (ATCC) was cultured in phenol red-free 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine 
serum (FBS), GlutaMAX (2 mM), sodium pyruvate (1 mM), penicillin (100 units/mL), 
and streptomycin (100 µg/mL). Cells were maintained at 37°C in a humidified incubator 
with 5% CO2. 
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Protein Production and Characterization of VLPs 
The Qβ VLPs were produced and characterized following previously published 
protocols.23 Briefly, electrocompetent ClearColi BL21(DE3) E. coli cells (Lucigen) were 
transformed with either pET28 plasmid vector harboring the viral coat protein (CP) gene 
or bicistronic pCDF vector harboring the CP gene and the mCherry gene. Cells were 
plated on selective SOB agar. After 24 h, isolated colonies were selected into SOB media 
(1% NaCl; 25 mL) containing appropriate antibiotic and grown overnight at 37°C. 
Cultures were diluted into selective SOB media (1% NaCl; 500 mL) the following day 
and grown at 37°C until cells reached mid-log phase growth (O.D.600 ~ 0.9). Protein 
expression was induced by the addition of IPTG to a final concentration of 1 mM, and 
cultures were maintained at 30°C for 16 h before cells were harvested by centrifugation at 
6,000 rpm for 10 min. Cells were lysed using a probe sonicator (10 min total, 75 W, 5 sec 
intervals) in an ice bath. Cell lysates were clarified by centrifugation at 14,000 rpm for 10 
min, and supernatant collected. VLPs were precipitated by the addition of 30% 
(NH4)2SO4 (w/v) at 4°C for 2 h, and precipitate was pelleted by centrifugation at 14,000 
rpm for 10 min. The resulting pellet was dissolved in 1x TBS and extracted with n-
BuOH:CHCl3 (1:1, v/v) to remove lipids and aggregates. The samples were centrifuged at 
14,000 rpm for 10 min, and the aqueous phase collected and subsequently loaded onto 
10-40% sucrose density gradients. VLPs were purified by centrifugation at 28,000 rpm 
for 4 h, and VLP bands were isolated from the gradient via syringe. Particles were 
pelleted by centrifugation at 68,000 rpm for 2 h, and pellets were dissolved in 0.1M 
potassium phosphate buffer.  
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The protein concentration of the VLP samples was determined by Bradford assay using 
BSA standards. Samples were characterized by FPLC size-exclusion chromatography 
(Superose 6 10/300 GL) monitored by absorbance at 280 nm, dynamic light scattering 
(Wyatt Dynapro plate reader), microfluidic gel electrophoresis (Agilent 2100 Bioanalyzer 
with Series II Protein 80 chips), and mass spectrometry (Agilent 6230B TOF LC/MS). 
All conjugations were performed as described and characterized using these same 
methods. 
Synthesis of VLP-Macrolide Conjugates 
Qb@mCherry-(N3)135: A solution of Qb@mCherry (0.36 mL from 10 mg/mL stock 
solution in 0.1M KPO4, pH 7.4, 0.255 µmol subunit, 1.02 µmol reactive amines) was 
cooled in an ice bath. To this solution was added 10.2 µL NHS-PEG12-N3 (100 mM stock 
solution in DMSO, ~ 4 equiv per reactive amine). The tube was gently inverted to mix 
reagents and incubated overnight at 4°C. The degree of acylation was quantified by LC-
ESI-TOF analysis (135 per particle, 0.75 per subunit). Particles were purified using PD-
10 prepacked Sephadex columns (GE Healthcare) according to manufacturer’s 
instructions. Particles were further concentrated to 7.7 mg/mL using Amicon Ultra-4 
centrifugal filters with 100 kDa molecular weight cutoff.  
Qb@mCherry-(N3)170: A solution of Qb@mCherry (1.5 mL from 10 mg/mL stock 
solution in 0.1M KPO4, pH 7.4, 1.06 µmol subunit, 4.25 µmol reactive amines) was 
cooled in an ice bath. To this solution was added 54 µL NHS-PEG12-N3 (100 mM stock 
solution in DMSO, 5 equiv per reactive amine). The tube was gently inverted to mix 
reagents and incubated overnight at 4°C. The degree of acylation was quantified by LC-
ESI-TOF analysis (170 per particle, 0.95 per subunit). Particles were purified using PD-
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10 prepacked Sephadex columns (GE Healthcare) according to manufacturer’s 
instructions. Particles were further concentrated to 7.7 mg/mL using Amicon Ultra-4 
centrifugal filters with 100 kDa molecular weight cutoff.  
Conjugate 3: Qb@mCherry-(Clarith1)30(HPG)120: A solution of Qb@mCherry-(N3)170 
(200µl from 7.7 mg/mL stock solution in 0.1M KPO4, pH 7.4, 0.109 µmol subunit, 96 
nmol reactive azide) was diluted with 33 µl of DMSO. To this solution was added a 
mixture of 49.7 µL of 10 mM macrolide (5 equiv to reactive azide) and 7.95 µL of 50 
mM HPG (4 equiv to reactive azide) in one portion. The tube was slowly inverted to 
create a homogenous solution. The reaction mixture turned cloudy and opaque. 
Subsequently, 24.9 µL of 40 mM CuSO4 (10 equiv to azide) was added along with 24.9 
µL of 200 mM THPTA (50 equiv to azide) in a single portion along with 19.9 µL of 500 
mM aminoguanidine (100 equiv to azide). The tube was again slowly inverted to mix all 
components and the reaction was initiated by the addition of 19.9 µL of 500 mM sodium 
ascorbate (100 equiv to azide). After mixing, the reaction was incubated at 55 °C for 3 
hours. The reaction mixture was purified by centrifugal filtration against 0.1M KPO4 (3 x 
15 mL, dilution >10,000x, 4000x g, 4 °C, 7 min runs) using Amicon Ultra-4 centrifugal 
filters with 100 kDa MWCO and was concentrated to ~2.5 mg/mL. The sample was 
sterile filtered through a 0.22 µm PVDF syringe filter, and the total protein content was 
quantified by Bradford assay using BSA standards. Recovery of protein was 
approximately 30 %. The extent of modification was determined by LC-ESI-TOF and the 
quality of the sample was further checked with electrophoresis. The final modified 
particles were composed of >95% intact particles as determined by DLS and FPLC. 
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Note: Some of the particles were modified more heavily than 30 macrolides, but they 
precipitated overnight. Clarithromycin derivatives displayed marked solubility issues. 
Conjugate 4: Qb@mCherry-(Clarith2)60(HPG)90: A solution of Qb@mCherry-(N3)170 
(200 µl from 7.7 mg/mL stock solution in 0.1M KPO4, pH 7.4, 0.109 µmol subunit, 96 
nmol reactive azide) was diluted with 33 µl of DMSO.  To this solution was added a 
mixture of 49.7 µL of 10 mM macrolide (5 equiv to reactive azide) and 7.95 µL of 50 
mM HPG (4 equiv to reactive azide) in one portion. The tube was slowly inverted to 
create a homogenous solution. The reaction mixture turned cloudy and opaque. 
Subsequently, 24.9 µL of 40 mM CuSO4 (10 equiv to azide) was added along with 24.9 
µL of 200 mM THPTA (50 equiv to azide) in a single portion and 19.9 µL of 500 mM 
aminoguanidine (100 equiv to azide). The tube was again slowly inverted to mix all 
components and the reaction was initiated by the addition of 19.9 µL of 500 mM sodium 
ascorbate (100 equiv to azide). After mixing, the reaction was incubated at 55 °C for 3 
hours. The reaction mixture was purified by centrifugal filtration against 0.1M KPO4 (3 x 
15 mL, dilution >10,000x, 4000x g, 4 °C, 7 min runs) using Amicon Ultra-4 centrifugal 
filters with 100 kDa MWCO and was concentrated to ~2.5 mg/mL. The sample was 
sterile filtered through a 0.22 µm PVDF syringe filter, and the total protein content was 
quantified by Bradford assay using BSA standards. Recovery of protein was 
approximately 40 %. The extent of modification was determined by LC-ESI-TOF and the 
quality of the sample was further checked with electrophoresis. The final modified 
particles were composed of >95% intact particles as determined by DLS and FPLC. 
Conjugate 5: Qb@mCherry-(TriKeto)90(HPG)70: A solution of Qb@mCherry-(N3)170 
(200 µl from 7.7 mg/mL stock solution in 0.1M KPO4, pH 7.4, 0.109 µmol subunit, 96 
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nmol reactive azide) was diluted with 33 µl of DMSO.  To this solution was added a 
mixture of 49.7 µL of 10 mM macrolide (5 equiv to reactive azide) and 7.95 µL of 
50 mM HPG (4 equiv to reactive azide) in one portion. The tube was slowly inverted to 
create a homogenous solution. The reaction mixture turned cloudy and opaque. 
Subsequently, 24.9 µL of 40 mM CuSO4 (10 equiv to azide) was added along with 24.9 
µL of 200 mM THPTA (50 equiv to azide) in a single portion and 19.9 µL of 500 mM 
aminoguanidine (100 equiv to azide). The tube was again slowly inverted to mix all 
components and the reaction was initiated by addition of 19.9 µL of 500 mM sodium 
ascorbate (100 equiv to azide). After mixing, the reaction incubated at 55 °C for 3 hours. 
The reaction mixture was purified by centrifugal filtration against 0.1M KPO4 (dilution 
>10,000x, 4,000x g, 4 °C, 7 min runs) using Amicon Ultra-4 centrifugal filters with 100 
kDa MWCO and was concentrated to ~2.5 mg/mL concentration. The sample was sterile 
filtered through a 0.22 µm PVDF syringe filter, and the total protein content was 
quantified by Bradford assay using BSA standards. Recovery of protein was 
approximately 60 %. The extent of modification was determined by LC-ESI-TOF and the 
quality of the sample was further checked with electrophoresis. The final modified 
particles were composed of >95% intact particles as determined by DLS and FPLC. 
Conjugate 6: Qb@mCherry-(TriKeto)180: A solution of Qb@mCherry-(N3)170 (100 µL 
from 8.5 mg/mL stock solution in 0.1M KPO4, pH 7.4, 60.2 nmol subunit, 85.6 nmol 
reactive azide) was diluted with 33 µL of DMSO. To this solution was added 42.3 µL of 
10 mM macrolide (5 equiv to reactive azide). The tube was slowly inverted to create a 
homogenous solution. The reaction mixture turned cloudy and opaque. Subsequently, 
8.57 µL of 200 mM CuSO4 (20 equiv to azide) was added along with 8.57 µL of 1M 
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THPTA (100 equiv to azide) in a single portion and 17.1 µL of 500 mM aminoguanidine 
(100 equiv to azide). The tube was again slowly inverted to mix all components and the 
reaction was initiated by the addition of 17.1 µL sodium ascorbate (100 equiv to azide). 
After mixing, the reaction was incubated at 55 °C for 3 hours. The reaction mixture was 
purified by centrifugal filtration against 0.1M KPO4 (dilution >10,000x, 14,000x g, 4 °C, 
3 min runs) using Amicon Ultra-0.5 centrifugal filters with 100 kDa MWCO and 
concentrated to ~2.5 mg/mL. The sample was sterile filtered through a 0.22 µm PVDF 
syringe filter, and the total protein content was quantified by Bradford assay using BSA 
standards. Recovery of protein was approximately 50 %. The extent of modification was 
determined by LC-ESI-TOF and the quality of the sample was further checked with 
electrophoresis. The final modified particles were composed of >95% intact particles as 
determined by DLS and FPLC. 
Conjugate 7: Qb@mCherry-(Azith1)90(HPG)40: A solution of Qb@mCherry-(N3)135 
(30 µl from 8.5 mg/mL stock solution in 0.1M KPO4, pH 7.4, 18.9 nmol subunit, 17 nmol 
reactive azide) was diluted with 5 µl of DMSO. To this solution was added a mixture of 7 
µL of 10 mM macrolide (5 equiv to reactive azide) and 0.83 µL of 50 mM HPG (4 equiv 
to reactive azide) in one portion. The tube was slowly inverted to create a homogenous 
solution. The reaction mixture turned cloudy and opaque. Subsequently, 3.48 µL of 40 
mM CuSO4 (10 equiv to azide) was added along with 3.48 µL of 200 mM THPTA (50 
equiv to azide) in a single portion and 2.78 µL of 500 mM aminoguanidine (100 equiv to 
azide). The tube was again slowly inverted to mix all components and the reaction was 
initiated by addition of 2.78 µL of 500 mM sodium ascorbate (100 equiv to azide). After 
mixing, the reaction was incubated at 55 °C for 3 hours. The reaction mixture was 
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purified by centrifugal filtration against 0.1M KPO4 (dilution >10,000x, 14,000x g, 4 °C, 
3 min runs) using Amicon Ultra-0.5 centrifugal filters with 100 kDa MWCO and 
concentrated to ~2.5 mg/mL. The sample was sterile filtered through a 0.22 µm PVDF 
syringe filter, and the total protein content was quantified by Bradford assay using BSA 
standards. Recovery of protein was approximately 50 %. The extent of modification was 
determined by LC-ESI-TOF and the quality of the sample was further checked with 
electrophoresis. The final modified particles were composed of >95% intact particles as 
determined by DLS and FPLC. 
Conjugate 8: Qb@mCherry-(Azith2)50(HPG)110: A solution of Qb@mCherry-(N3)170 
(200 µl from 7.7 mg/mL stock solution in 0.1M KPO4, pH 7.4, 0.109 µmol subunit, 96 
nmol reactive azide) was diluted with 28 µl of DMSO.  To this solution was added a 
mixture of 55 µL of 10 mM macrolide (5.5 equiv to reactive azide) and 5 µL of 50 mM 
HPG (2.5 equiv to reactive azide) in one portion. The tube was slowly inverted to create a 
homogenous solution. The reaction mixture turned cloudy and opaque. Subsequently, 
24.9 µL of 40 mM CuSO4 (10 equiv to azide) was added along with 24.9 µL of 200 mM 
THPTA (50 equiv to azide) in a single portion and 19.9 µL of 500 mM aminoguanidine 
(100 equiv to azide). The tube was again slowly inverted to mix all components and the 
reaction was initiated by the addition of 19.9 µL of 500 mM sodium ascorbate (100 equiv 
to azide). After mixing, the reaction was incubated at 55 °C for 3 hours. The reaction 
mixture was purified by centrifugal filtration against 0.1M KPO4 (3 x 15 mL, dilution 
>10,000x, 4,000x g, 4 °C, 7 min runs) using Amicon Ultra-4 centrifugal filters with 100 
kDa MWCO and was concentrated to ~2.5 mg/mL concentration. The sample was sterile 
filtered through a 0.22 µm PVDF syringe filter, and the total protein content was 
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quantified by Bradford assay using BSA standards. Recovery of protein was 
approximately 60 %. The extent of modification was determined by LC-ESI-TOF and the 
quality of the sample was further checked with electrophoresis. The final modified 
particles were composed of >95% intact particles as determined by DLS and FPLC.  
Conjugate 9: Qb@mCherry-(Azith2)145: A solution of Qb@mCherry-(N3)170 (150 µl 
from 7.7 mg/mL stock solution in 0.1M KPO4, pH 7.4, 77 nmol subunit, 70 nmol reactive 
azide) was diluted with 20 µl of DMSO.  To this solution was added a mixture of 49 µL 
of 10 mM macrolide (7 equiv to reactive azide). The tube was slowly inverted to create a 
homogenous solution. The reaction mixture turned cloudy and opaque. After this 1.74 µL 
of 250 mM CuSO4 (10 equiv to azide) was added along with 1.74 µL of 1.25 M THPTA 
(50 equiv to azide) in a single portion and 14 µL of 500 mM aminoguanidine (100 equiv 
to azide). The tube was again slowly inverted to mix all components and the reaction was 
initiated by the addition of 14 µL of 500 mM sodium ascorbate (100 equiv to azide). 
After mixing, the reaction was incubated at 55 °C for 3 hours. The reaction mixture was 
purified by centrifugal filtration against 0.1M KPO4 (3 x 15 mL, dilution >10,000x, 
4,000x g, 4 °C, 7 min runs) using Amicon Ultra-4 centrifugal filters with 100 kDa 
MWCO and was concentrated to ~2.5 mg/mL concentration. The sample was sterile 
filtered through a 0.22 µm PVDF syringe filter, and the total protein content was 
quantified by Bradford assay using BSA standards. Recovery of protein was 
approximately 60 %. The extent of modification was determined by LC-ESI-TOF and the 
quality of the sample was further checked with electrophoresis. The final modified 
particles were composed of >95% intact particles as determined by DLS and FPLC. 
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Conjugate 10: Qb@mCherry-(tolyl)115(HPG)55: A solution of Qb@mCherry-(N3)170 
(200 µl from 7.7 mg/mL stock solution in 0.1M KPO4, pH 7.4, 0.109 µmol subunit, 96 
nmol reactive azide) was diluted with 33 µl of DMSO.  To this solution was added a 
mixture of 49.7 µL of 10 mM p-tolylacetylene (5 equiv to reactive azide) and 7.95 µL of 
50 mM HPG (4 equiv to reactive azide) in one portion. The tube was slowly inverted to 
create a homogenous solution. The reaction mixture was clear after mixing. 
Subsequently, 24.9 µL of 40 mM CuSO4 (10 equiv to azide) was added along with 24.9 
µL of 200 mM THPTA (50 equiv to azide) in a single portion and 19.9 µL of 500 mM 
aminoguanidine (100 equiv to azide). The tube was again slowly inverted to mix all 
components and the reaction was initiated by the addition of 19.9 µL of 500 mM sodium 
ascorbate (100 equiv to azide). After mixing, the reaction was incubated at 55 °C for 3 
hours. The reaction mixture was purified by centrifugal filtration against 0.1M KPO4 (3 x 
15 mL, dilution >10,000x, 4,000x g, 4 °C, 7 min runs) using Amicon Ultra-4 centrifugal 
filters with 100 kDa MWCO and was concentrated to ~2.5 mg/mL concentration. The 
sample was sterile filtered through a 0.22 µm PVDF syringe filter, and the total protein 
content was quantified by Bradford assay using BSA standards. Recovery of protein was 
approximately 80 %. The extent of modification was determined by LC-ESI-TOF and the 
quality of the sample was further checked with electrophoresis. The final modified 
particles were composed of >95% intact particles as determined by DLS and FPLC. 
Conjugate 9-IR800CW: Qb-(Azith2)153(HPG)75: A solution of wild-type Qb (250 µL 
from 10 mg/mL stock solution in 0.1M KPO4, pH 7.4, 352 nmol subunit, 1.4 µmol 
reactive amines) was diluted with 148 µL 0.1M KPO4 and reacted with 102 µL IRDyeÒ 
800CW NHS ester (1 mg/mL stock solution in DMSO, 0.25 equiv per protein subunit). 
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The tube was gently inverted to mix reagents, sealed with foil, and incubated overnight at 
4°C. The reaction mixture was purified by centrifugal filtration against 0.1M KPO4 (3 x 
15 mL, dilution >10,000x, 4000x g, 4 °C, 7 min runs) using Amicon Ultra-4 centrifugal 
filters with 100 kDa MWCO and was concentrated to ~5 mg/mL. Dye loading was 
assessed by absorbance measurements and calculations using the molar extinction 
coefficient for the dye (eIRDye = 270,000 M-1cm-1; 24 dye molecules per particle). 
Particles were subsequently reacted with 28.2 µL NHS-PEG12-N3 (100 mM stock 
solution in DMSO, ~4 equiv per reactive amine) overnight at 4°C and purified by 
centrifugal filtration against 0.1M KPO4 (3 x 15 mL, dilution >10,000x, 4000x g, 4 °C, 7 
min runs) using Amicon Ultra-4 centrifugal filters with 100 kDa MWCO. Degree of 
acylation was quantified by ESI-TOF analysis (237 per particle, 1.3 per subunit) and 
protein concentration was determined by Bradford assay using BSA standards. Finally, a 
solution of particles (125 µL from 5.53 mg/mL stock solution in 0.1M KPO4, pH 7.4, 
48.7 nmol subunit, 64.3 nmol reactive azide) was diluted with 13 µL DMSO. To this 
solution was added a mixture of 30.5 µL of 10 mM macrolide (5 equiv to reactive azide) 
and 3 µL of 50 mM HPG (2.5 equiv to reactive azide) in one portion. The tube was 
slowly inverted to create a homogenous solution. The reaction mixture turned cloudy and 
opaque. After this 0.76 µL of 400 mM CuSO4 (5 equiv to azide) was added along with 
15.3 µL of 100 mM THPTA (25 equiv to azide) in a single portion and 9 µL of 200 mM 
aminoguanidine (30 equiv to azide). The tube was again slowly inverted to mix all 
components and the reaction was initiated by the addition of 3.7 µL of 500 mM sodium 
ascorbate (30 equiv to azide). After mixing, the reaction was incubated at 55 °C for 3 
hours. The reaction mixture was purified by centrifugal filtration against 0.1M KPO4 
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(dilution >10,000x, 14,000x g, 4 °C, 3 min runs) using Amicon Ultra-0.5 centrifugal 
filters with 100 kDa MWCO and was concentrated to ~1.5 mg/mL concentration. The 
sample was sterile filtered through a 0.22 µm PVDF syringe filter, and the total protein 
content was quantified by Bradford assay using BSA standards. Recovery of protein was 
approximately 60 %. The extent of modification was determined by ESI-TOF HRMS. 
The final modified particles were composed of >95% intact particles as determined by 
DLS.   
Conjugate 10-IR800CW: Qb-(tolyl)130: A solution of wild-type Qb (2 mL from 3.5 
mg/mL stock solution in 0.1M KPO4, pH 7.4, 496 nmol subunit, 1.98 µmol reactive 
amines) was diluted reacted with 248 µL IRDyeÒ 800CW NHS ester (1 mg/mL stock 
solution in DMSO, 0.5 equiv per protein subunit). The tube was gently inverted to mix 
reagents, sealed with foil, and incubated overnight at 4°C. The reaction mixture was 
purified by centrifugal filtration against 0.1M KPO4 (3 x 15 mL, dilution >10,000x, 
4000x g, 4 °C, 7 min runs) using Amicon Ultra-4 centrifugal filters with 100 kDa 
MWCO and was concentrated to ~5 mg/mL. Dye loading was assessed by absorbance 
measurements and calculations using the molar extinction coefficient for the dye (eIRDye = 
270,000 M-1cm-1; 20 dye molecules per particle). Particles were subsequently reacted 
with 28.2 µL NHS-PEG12-N3 (100 mM stock solution in DMSO, ~4 equiv per reactive 
amine) overnight at 4°C and purified by centrifugal filtration against 0.1M KPO4 (3 x 15 
mL, dilution >10,000x, 4000x g, 4 °C, 7 min runs) using Amicon Ultra-4 centrifugal 
filters with 100 kDa MWCO. Degree of acylation was quantified by ESI-TOF analysis 
(135 per particle, 0.75 per subunit) and protein concentration was determined by 
Bradford assay using BSA standards. Finally, a solution of particles (400 µL from 3.4 
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mg/mL stock solution in 0.1M KPO4, pH 7.4, 96.3 nmol subunit, 72.2 nmol reactive 
azide) was diluted with 250 µL DMSO. To this solution was added 12.6 µL of 50 mM 4-
ethynyltoluene (9 equiv to reactive azide). The tube was slowly inverted to create a 
homogenous solution. The reaction mixture turned cloudy and opaque. After this 2.8 µL 
of 250 mM CuSO4 (10 equiv to azide) was added along with 2.8 µL of 1.25 M THPTA 
(50 equiv to azide) in a single portion and 2.9 µL of 2.4 M aminoguanidine (100 equiv to 
azide). The tube was again slowly inverted to mix all components and the reaction was 
initiated by the addition of 7 µL of 1 M sodium ascorbate (100 equiv to azide). After 
mixing, the reaction was incubated at 55 °C for 3 hours. The reaction mixture was 
purified by centrifugal filtration against 0.1M KPO4 (dilution >10,000x, 14,000x g, 4 °C, 
3 min runs) using Amicon Ultra-0.5 centrifugal filters with 100 kDa MWCO and was 
concentrated to ~1.5 mg/mL concentration. The sample was sterile filtered through a 0.22 
µm PVDF syringe filter, and the total protein content was quantified by Bradford assay 
using BSA standards. Recovery of protein was approximately 70 %. The extent of 
modification was determined by ESI-TOF HRMS. The final modified particles were 
composed of >95% intact particles as determined by DLS.      
Live-Cell Microscopy and Fluorescence Imaging 
RAW 264.7 cells were grown to 80% confluence and seeded onto 8-chambered 
microscope slides at 1:10 dilution. After 24 h, cells were treated with Qβ conjugates (2.5 
nM) and incubated for 24 h at 37°C in a humidified incubator with 5% CO2. At each 
respective time point, cells were rinsed twice with fresh DMEM and subsequently 
imaged on an Eclipse Ti-U fluorescence microscope (Nikon) equipped with a 60x oil 
immersion objective. Images were analyzed using ImageJ software. Cells were manually 
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selected by freeform drawing, and the area integrated density was calculated for each 
selection. Background fluorescence was calculated in the same manner as an average 
from three randomly selected points in the image where no cells were present. The 
corrected fluorescence per cell (CFPC) was calculated using the following equation: 
𝐶𝐹𝑃𝐶 = 𝐼𝑛𝑡𝑒𝑔𝑟𝑎𝑡𝑒𝑑	𝐷𝑒𝑛𝑠𝑖𝑡𝑦 − (𝐴𝑟𝑒𝑎	𝑜𝑓	𝑐𝑒𝑙𝑙 ∗ 𝑀𝑒𝑎𝑛	𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑	𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒) 
Nitrite Assay 
Nitrite production in RAW 264.7 cells was quantified using a Griess assay (Thermo 
Fisher Scientific). Briefly, RAW 264.7 cells were seeded in 12-well plates (2x105 
cells/well) and maintained 24 h prior to treatment with Qβ conjugates (2.5 nM), 
azithromycin (150 nM), clarithromycin (150 nM), dendrimer-AZM (12.5 nM), dendrimer-
CLA (12.5 nM), or LPS (100 ng/mL). At 24 h post-treatment, 75 µL of cell culture 
supernatant was transferred to a 96-well plate for analysis in duplicate. Samples were 
diluted in 65 µL sterile water, and 10 µL Griess Reagent added to each sample. Griess 
Reagent was prepared by mixing together equal volumes of N-(1-
naphthyl)ethylenediamine and sulfanilic acid. Samples were incubated at room 
temperature for 30 min and absorbance was measured at 548 nm on a microplate reader 
(Thermo Fisher Scientific). Nitrite concentrations in samples were calculated from 
standard curve using the nitrite standard provided by the manufacturer.  
Arginase Assay 
Arginase activity in RAW 264.7 cells was quantified using the QuantiChrom 
arginase assay kit (BioAssay Systems) following the manufacturer’s protocol. Briefly, 
RAW 264.7 cells were seeded in 12-well plates (2x105 cells/well) and maintained 24 h 
prior to treatment with Qβ conjugates (2.5 nM), azithromycin (150 nM), clarithromycin 
 122 
(150 nM), dendrimer-AZM (12.5 nM), dendrimer-CLA (12.5 nM), or LPS (100 ng/mL). 
At 24 h post-treatment, cells were harvested for each sample, washed with PBS, and 
centrifuged at 1,000x g for 10 min. Cell pellets were lysed for 10 min using 150 µL of 
10mM Tris-HCl (pH 7.4) containing cOmplete™ EDTA-free protease inhibitor tablet 
(Roche) and 0.4% (w/v) Triton X-100 (Sigma). Lysates were centrifuged for 10 min at 
14,000x g and supernatant collected for assay. 50 µL urea standard (1 mM; O.D.standard) 
and 50 µL sterile water (O.D.water) were added to separate wells of a 96-well plate, while 
40 µL of each sample was added to 2 separate wells. One of the sample wells was left 
untouched (O.D.blank) while 10 µL of 5x substrate buffer was added to the other sample 
well (O.D.sample). The plate was incubated at 37 °C for 1 h, after which 200 µL urea 
reagent (prepared from equal volumes of kit reagents A and B) was added to all wells 
followed by 10 µL of 5x substrate buffer to the O.D.blank wells. The plate was incubated at 
room temperature for 1 h and absorbance was measured at 430 nm on a microplate reader 
(Thermo Fisher Scientific). Arginase activity was calculated using the following 
equation: 
𝐴𝑟𝑔𝑖𝑛𝑎𝑠𝑒	𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 = 	
(𝑂. 𝐷.BCDEFG− 𝑂. 𝐷.HFCIJ )
(𝑂. 𝐷.BKCILCML− 𝑂.𝐷.NCKGM )
	× 	10.4	(𝑈 𝐿⁄ ) 
Cytokine Analysis 
Cytokine production was measured in culture supernatants using ELISA kits 
(PeproTech) according to the manufacturer’s protocol. Culture supernatants were 
analyzed in duplicate from the same samples as used for the nitrite and arginase assays.  
Mice and Biodistribution Analysis 
CD-1 IGS mice (8-12 weeks) were purchased from Charles River Laboratories 
and maintained in the animal facility of the Georgia Institute of Technology. All animal 
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care and experimental procedures were approved by the Institutional Care and Use 
Committee of the Georgia Institute of Technology. Mice were administered 50 µg VLP 
conjugates labeled with IRDye® 800cw (LI-COR, Inc.; see Supplemental Methods) via 
tail vein injection and returned to cage for 2h or 24 h (n=2 per time point), after which 
mice were imaged using an IVIS Spectrum CT imaging cabinet (Bruker). Mice were 
subsequently euthanized and tissues collected for ex vivo imaging and quantitative 
analysis.  
Liver and lung tissues were harvested from mice treated with VLP conjugates 
labeled with IRDye® 800cw (LI-COR, Inc.) at 2 h or 24 h (n = 2). Tissues were rinsed 
twice with chilled 1x PBS and blotted dry, after which samples were imaged ex vivo 
using an IVIS Spectrum CT imaging cabinet (Bruker). All image analysis was performed 
in Living Image software. Regions of interest (ROIs) were manually set around each 
tissue sample, and the total radiant efficiency was calculated for each ROI. 
4.4. Results and Discussion 
4.4.1. Particle design and characterization 
Qb VLPs were prepared from recombinant expression in E. coli, either as wild-
type particles or engineered to encapsulate mCherry (designated Qb@mCherry) as 
previously described.36 To prepare Qb conjugates with macrolide ligands, variants of 
azithromycin (Azith1, Azith2), clarithromycin (Clarith1, Clarith2), and a tricyclic 
ketolide (TriKeto) were synthesized bearing an alkyne functional group to allow for 
attachment to the VLP by the copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) 
reaction. Qb VLPs, which display 720 amine groups on their surface,37 were prepared 
through acylation with an excess of N-hydroxysuccinimide ester 1 to install azide  
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Scheme 1. Conjugation of macrolides to Qb VLPs via CuAAC. 
functionalities. After purification away from the excess small molecules, the azide-
functionalized VLPs were reacted with Clarith1 and homopropargylglycine (HPG; to 
yield 3), Clarith2 and HPG (to yield 4), TriKeto and HPG (to yield 5), TriKeto alone 
(to yield 6), Azith1 and HPG (to yield 7), Azith2 and HPG (to yield 8), Azith2 alone (to 
yield 9) or 4-ethynyltoluene and HPG (to yield negative control particle 10; Scheme 1). 
Loadings ranging from 30-150 modifications could be achieved with 5 equivalents of 
alkyne per reactive azide group (Scheme 1), but the solubility of VLP conjugates 
decreased dramatically with increased loading density. HPG was simultaneously 
conjugated to the particles to offset the decreased solubility of the VLP conjugates.  
 The conjugates were characterized by liquid chromatography coupled to an 
electrospray ionization time-of-flight (ESI-TOF) mass spectrometer, which revealed 
labeling of an average of one azide per subunit for 2, and subsequent attachment of 
macrolides and HPG on 3-10 (Figure 1). The average loading for each species was 
determined by the relative intensities of the corresponding peaks in the mass spectra.  
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Figure 1. Deconvolved high-resolution LC-MS spectra for Qb-macrolide conjugates. 
 
Electrophoretic analysis further confirmed the level of modification with macrolides. Size 
exclusion chromatography, electrophoretic analysis, and dynamic light scattering gave 
data characteristic of intact monodisperse particles for 3-10 (Figures 2 and 3). The  
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Figure 2. Electrophoretic analysis of Qb-macrolide conjugates under denaturing 
conditions. Labels at the top of each lane denote the identity of each respective sample. 
 
 
Figure 3. DLS analysis of Qb-macrolide conjugates. (A) Histogram overlay showing the 
hydrodynamic radius (Rh) for indicated samples. (B) Table listing of Rh and percent 
polydispersity for Qb-macrolide conjugates. 
 
hydrodynamic radii of the macrolide conjugates were slightly larger than that for 
unmodified VLPs (~ 14 nm), mostly attributed to interactions of the attached 
macrocycles with the solvent. 
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4.4.2. Assessment of macrophage uptake and activation 
The multivalent attachment of azithromycin, clarithromycin, and the tricyclic 
ketolide have all been previously shown to promote enhanced uptake of gold nanorods by 
macrophages in a ligand-dependent manner.32 In order to further investigate this 
phenomenon using a different nanoparticle platform, we first chose to quantify the uptake 
of macrolide-labeled Qβ@mCherry VLPs by RAW 264.7 macrophages. All VLP-
macrolide conjugates screened (3-9) showed significant accumulation in macrophages 
over the course of 24 h relative to control particles (10; Figure 4A, B). Interestingly, 4 
(Clarith2) and 8 (Azith2) displayed significantly greater uptake compared to 3 
(Clarith1) and 7 (Azith1), respectively, despite only differing by the point of attachment 
on the macrocycle to the VLP. These differences in uptake were attributed to steric 
hindrance of key functionalities on the macrocycle that are important for the mechanism 
of macrolide uptake in phagocytic cells. In particular, the tertiary amine that serves as the 
point of attachment in 3 and 7 might play a key role, as it is distal to the VLP surface in 4 
and 8, and studies to explore these structural influences on the mechanism of uptake are 
ongoing. 
Comparison of azithromycin (8, 9) and ketolide (5, 6) particles revealed a sharp 
dependence of uptake on the density of macrolide display for the former but not the latter 
(Figure 5). This could derive, wholly or in part, from at least three potential effects: (i) a 
heretofore unappreciated polyvalent effect for azithromycin interaction with a cell-
surface receptor for active transport into phagocytic cells,31 (ii) a change in the physical 
properties of the particle with the difference in azithromycin, but not ketolide, density so 
as to enhance passive uptake, or (iii) differences in P-glycoprotein (P-gp) mediated efflux  
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Figure 4. VLPs modified with macrolides show enhanced uptake in RAW 264.7 
macrophages. (A) Representative microscopy images of RAW 264.7 macrophages after 
24 h. Upper panels, brightfield. Lower panels, mCherry fluorescence. (B) Quantification 
of VLP uptake as measured by the corrected fluorescence per cell. Bars represent the 
average +/- standard error (n = 20). 
 
of particles. P-gp has been shown to play a significant role in the accumulation and 
cellular trafficking of macrolide antibiotics, and a previous study showed that uptake and  
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Figure 5. Density-dependent uptake of VLP-macrolide conjugates. (A) Representative 
fluorescence microscopy images of RAW 264.7 macrophages after 24 h showing intense 
punctate staining with increased loading of azithromycin on Qb VLPs. (B) Quantification 
of VLP uptake as measured by the corrected fluorescence per cell. Bars represent the 
average +/- standard error (n = 20). 
 
efflux of gold nanorods modified with azithromycin and clarithromycin, but not the 
tricyclic ketolide, occurred in a P-gp-dependent manner,38 corresponding with the 
expected binding affinities of each molecule for the transporter.39 In this case, a higher  
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Figure 6. Analysis of MF polarization as a function of arginine metabolism in cells 
treated with Qb-macrolide conjugates after 24 h. (A) Quantification of nitrite production 
as a by-product of nitric oxide synthase activity, indicative of M1 polarization. (B) 
Quantification of arginase activity, indicative of M2 polarization. Cells were dosed with 
VLP-macrolide conjugates (1.3-5 nM in particle), free macrolides (150 nM), dendrimer 
species (12.5 nM in dendrimer), or LPS (100 ng/mL), respectively. Data are presented as 
mean +/- standard error from two individual experiments. N.D. = not detected. 
 
density of azithromycin display would have to inhibit either P-gp transport or recycling.  
Studies to distinguish among these possibilities have not yet been performed.  
 We next chose to investigate if the polyvalent display of macrolides on the 
particle surface influenced macrophage polarization. In order to assess the effects of 
valency, VLP conjugates were compared against free macrolide (azithromycin, 
clarithromycin) and macrolide-modified dendrimer species (Den-AZM, Den-CLA). 
Activated macrophages are typically polarized towards an M1 (Th1) phenotype or an M2 
(Th2) phenotype, although there is evidence that suggests these states are not mutually 
exclusive.40 Polarization along either axis can be categorized in part by monitoring 
arginine metabolism through cellular activities of arginase (M2) or nitric oxide synthase 
(M1), as well as by characteristic cytokine profiles.41 RAW 264.7 macrophages treated 
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with macrolide-labeled VLPs displayed signals that were not consistent with polarization 
towards any of the known macrophage phenotypes (Table 1). 
 
Table 1. Summary of MF polarization states and profiles from VLP-treated cells.  
 Nitrite Arginase TNF-a IL-6 IL-10 IL-12 
M1 High Low High High Low High 
M2a Low High Low Low High Low 
M2b Medium/High High High High High Low 
M2c Low High Low Low High Low 
Macrolide conjugate treatment 
3 (Clarith1) Low Low High Low High Low 
4 (Clarith2) High High High High High Low 
5 (TriKeto) Medium Medium High Low Medium Low 
7 (Azith1) Medium High High High High Low 
8 (Azith2) Medium High High Low High Low 
Den-AZM/CLA Low Low Low Low Low Low 
Free AZM/CLA Low Low Low Low Low Low 
10 (Tolyl) Low Low Low Low Low Low 
LPS High High High Medium High High 
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Figure 7. Elevated cytokine production in RAW 264.7 MF cells treated with VLP-
macrolide conjugates after 24 hours. (A) TNF-a, (B) IL-6, (C) IL-12, and (D) IL-10 were 
all measured by ELISA after dosing with VLP-macrolide conjugates (1.3-5 nM in 
particle), free macrolides (150 nM), dendrimer species (12.5 nM in dendrimer), or LPS 
(100 ng/mL), respectively. Macrolide concentration was normalized across all samples to 
150 nM. Data are presented as mean +/- standard error from two individual experiments. 
 
Conjugates 4 (Clarith2), 5 (TriKeto), 7 (Azith1), and 8 (Azith2) all induced significant 
nitrite levels after 24 h relative to cells treated with free macrolides or dendrimers 
(Figure 6A), typically a signature of M1 macrophages. Interestingly, 4 (Clarith2) 
induced significant nitrite production, whereas 3 (Clarith1) did not stimulate any 
detectable levels. Control particle 10 (Tolyl) did not elicit a detectable response. 
Conjugates 4 (Clarith2), 7 (Azith1), and 8 (Azith2) also induced significant arginase 
activity, seemingly indicative of a mixed activation state among these cell populations. 
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Conjugates 3 (Clarith1) and 5 (TriKeto) induced much lower but detectable levels of 
arginase activity; control molecules, including unconjugated particles (10; Tolyl), free 
macrolides and macrolide-modified dendrimers, stimulated no increase in arginase 
activity compared to the untreated cells (Figure 6B). Cytokine levels were screened and 
also did not correlate well with any known phenotype among macrophages treated with 
VLP-macrolide conjugates. Conjugates 3 (Clarith1), 4 (Clarith2), 5 (TriKeto), 7 
(Azith1), and 8 (Azith2) all stimulated significant production of TNF-a after 24 h 
relative to cells treated with conjugate 10 (Tolyl), free macrolides, or dendrimers (Figure 
7A). Interestingly, only conjugates 4 (Clarith2) and 7 (Azith1) stimulated significant 
production of IL-6, while conjugates 3 (Clarith1), 5 (TriKeto), and 8 (Azith2) gave rise 
to levels that were notably diminished but still significant (Figure 7B). Macrophages 
treated with conjugates 3-9 also produced significant levels of IL-12 relative to control-
treated cells, although the amount of IL-12 produced was significantly lower than that of 
other cytokines (Figure 7C). Despite the increased production of these cytotoxic 
molecules, macrophages treated with these conjugates did not exhibit killing activity 
against cancer cells, as was shown previously with macrolide-functionalized gold 
nanorods.32 Interestingly, conjugates 3 (Clarith1) and 4 (Clarith2) gave rise to 
significant IL-10 production; conjugates 5 (TriKeto), 7 (Azith1), and 8 (Azith2) all 
stimulated levels that were much lower but still higher than control-treated cells (Figure 
7D). Production of IL-10 in conjunction with IL-6 and TNF-a has been observed with 
polarization towards the M2b subset;42 however, it is likely that the polarization of these 
macrophage populations is highly dynamic, and that these cells experience phenotypic 
changes over time. It is possible that these cells are in an intermediary activation state 
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between the M1 and M2a phenotypes, which is consistent with their mixed phenotypic 
signatures and cytokine profiles.43 Extensive investigations of this phenomenon will 
further elucidate the effect of these conjugates on macrophages. 
4.4.3. Trafficking of modified particles in mice 
Finally, we investigated the trafficking of dye-labeled VLPs modified with azithromycin 
(Azith2; 9) in mice to determine if attachment of the macrocycle could direct particles to 
tissues where the free macrolides are known to accumulate. Previous studies have shown 
that azithromycin accumulates in macrophages, leading to greater than 100-fold 
enrichment in the lungs and liver compared to circulation.28–30 Indeed, we found that 9 
(Azith2) particles showed significant accumulation in lung tissue after 2 h compared to 
control particles (10; Tolyl), where no signal was detected after 2 h (Figure 8A, C). Qb 
VLPs do not naturally traffic to the lung, indicating that the conjugated macrolide is 
directing particles to accumulate in lung-resident macrophages. Particles were also found 
in the livers of both cohorts after 2 h, with mice administered 9 (Azith2) displaying 
significantly higher signal in tissue compared to mice administered 10 (Tolyl; Figure 
8A, D). After 24 h, no signal could be detected in the lungs of mice from either cohort, 
and signals from the livers in both cohorts were equivalent (Figure 8B). 
4.5. Conclusions 
As there are several pathogenic organisms known to establish infections within 
pulmonary macrophages (i.e., M. tuberculosis, L. pneumophila),11,12 intracellular drug 
delivery would be highly beneficial for the treatment of persistent lung infections. In this 
study, we demonstrated the ability of macrolide antibiotics to function as targeting 
ligands to direct a virus-like particle platform to the lungs for selective accumulation in  
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Figure 8. Quantitative imaging of Qb-azithromycin conjugates trafficking to the lungs 
and liver. (A) Representative image of isolated liver (top) and lung tissue (bottom) from 
mice administered Qb-azithromycin (9) or Qb-tolyl (10) after 2 h. Image shows 
accumulation only in lungs for mice administered 9. Azithromycin also promotes 
increased uptake in the liver relative to control particles. (B) Representative image of 
isolated liver (top) and lung tissue (bottom) from mice administered Qb-azithromycin (9) 
or Qb-tolyl (10) after 24 h. No fluorescence was detected in the lungs of mice from either 
cohort and fluorescence in the liver was equivalent. (C) Quantitative analysis ex vivo of 
lung tissue fluorescence 2 h after intravenous administration of 9 or 10, respectively. (D) 
Quantitative analysis ex vivo of liver tissue fluorescence 2 h after intravenous 
administration of 9 or 10, respectively. 
 
pulmonary macrophages. Azithromycin promoted the highest uptake by macrophages in 
vitro among all of the ligands tested, and the uptake was found to be dependent on both 
the orientation of the macrolide on the particle surface as well as the density of surface 
coverage. These findings are consistent with the existence of an active transport system 
for macrolides in phagocytic cells31 and also correlate with observations for P-gp-
dependent trafficking in macrophages.38 The differential responses in cellular uptake 
based on the attachment point to the macrocycle suggest that specific functional groups 
must be accessible for receptor engagement, and increased uptake corresponding to 
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macrolide density also suggests that specific ligand-receptor engagement is occurring. 
Investigations to further characterize the mechanism of uptake with the Qb platform are 
ongoing. Furthermore, we found that the polyvalent display of macrolides on the surface 
of Qb VLPs potentiates macrophage activation with metabolic and cytokine signatures 
that do not wholly match any of the canonical activation states.40 Activation and 
polarization were not observed with the treatment of free macrolides; display on a 
dendrimer scaffold, albeit at lower valency; or with Qb bearing a tolyl group. This stands 
in contrast to the earlier report by Dreaden and colleagues showing that macrolide-
functionalized gold nanorods stimulated a cytotoxic phenotype.32 It should be noted, 
however, that the platforms from that study were modified with ~ 1000 macrolides, 
significantly higher than the degrees of functionalization achieved in this work. Given the 
disparity in both loadings and platform properties, it is unclear whether macrophage 
activation is potentiated solely by polyvalent display of macrolides or if uptake of the 
display platform is governing these phenomena. Further studies are ongoing to 
investigate the factors governing macrophage activation in this context. Most 
importantly, we found that polyvalent display of azithromycin on the VLP surface directs 
particles to pulmonary macrophages within a few hours of administration, which could 
allow Qb VLPs to be used as drug delivery agents for pulmonary infections. The 
conjugation of small molecule drugs to both the interior and exterior of VLPs has been 
well-documented,44–46 and efforts to screen delivery of these Qb-macrolide conjugates to 
patient-derived macrophages are currently ongoing with the hopes of transitioning this 
platform towards clinical applications. To our knowledge, this is the first example of a 
macrolide-nanoparticle conjugate being applied for cellular targeting in vivo and 
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represents potential for the development of a novel pulmonary drug delivery platform. 
This work further exemplifies the diverse modification strategies that can be employed 
for the development of targeted VLP platforms, particularly if a motif accessible by gene 
engineering is not available.  
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Chapter 5: Investigating the immune response to hybrid protein-polymer VLPs 
 
5.1. Abstract 
Covalent attachment of polymeric species to the surface of proteins and 
nanoparticles has proven to be a critical aspect in the development of effective biomedical 
platforms capable of avoiding immune surveillance. The most widely-employed polymer 
for these applications has been poly(ethylene glycol) (PEG), yet recent evidence has 
suggested that more advanced polymer architectures significantly improve the in vitro and 
in vivo properties of protein-polymer hybrid materials. Moreover, there has been limited 
research directly investigating the performance of PEG against these more advanced 
polymer architectures. In this work, we describe the assembly and characterization of a 
series of virus-like particle (VLP)-polymer conjugates (poly(oligo(ethylene glycol) 
methacrylate) and poly(methacrylamido glucopyranose)), and the subsequent investigation 
of their ability to shield from antibody recognition as functions of polymer loading density, 
polymer chain length, polymer architecture, and conjugation site. Increasing chain length 
and loading density were both found to significantly diminish antibody recognition of the 
VLP conjugates; the conformation adopted by different polymer architectures was also 
found to greatly influence antibody recognition. A direct comparison of these conjugates 
against PEGylated VLPs in vivo showed that all formulations gave rise to similar antibody 
titers that were significantly diminished relative to unmodified particles. Interestingly, the 
quality of the antibody response was impacted by the properties of the conjugate, with 
differences in observed affinity and avidity showing a complex dependence on loading 
density, chain length, and architecture.  
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5.2. Introduction 
The covalent attachment of hydrophilic polymer chains to the surface of 
biomolecules and nanoparticles has allowed for the development of hybrid macromolecular 
assemblies with unique properties that are finding increased use in the field of 
biomedicine.1–4 Conjugation of linear poly(ethylene glycol) (PEG) has been widely used 
to dampen the immunogenicity of proteins and other materials,5,6 and all of the protein-
polymer hybrid drugs currently approved by the FDA are PEGylated conjugates.7 
Furthermore, attachment of polymers has also been shown to improve the circulation 
lifetime of proteins, which is a critical factor for advancing protein-based therapeutics into 
the clinic.8–10 Protein-polymer hybrids are typically generated using either “graft-to”11,12 or 
“graft-from”13,14 methodologies. The former relies on the total synthesis of the desired 
polymer prior to conjugation,15 while the latter involves direct growth of the polymer chain 
from the protein surface after installation of an initiator moiety.16,17 While the “graft-from” 
approach offers high yielding reactions, grafting a preformed polymer onto a protein often 
allows for a more defined material as the polymer can be more readily characterized prior 
to attachment. Coverage of the polymer on the biomolecule is often lower, however, due 
to the inherent difficulty of covalently ligating two large molecules at relatively low 
concentrations.11                
Recent examples in the literature indicate that advanced polymer architectures 
provide significant advantages at protecting and stabilizing conjugate proteins and 
reducing clearance rates compared to linear PEG chains.18–21 Controlled radical 
polymerizations (CRPs), such as atom-transfer radical polymerization (ATRP) and 
reversible-addition fragmentation chain-transfer (RAFT), typically yield polymers with 
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brush-type architectures and are commonly employed methodologies in the development 
of protein-polymer materials due to their compatibility with aqueous conditions.17,22–24 
Brush polymer architectures have recently been shown to impart greater shielding 
capabilities than linear PEG when conjugated to the model therapeutic protein L-
asparaginase,25 exemplifying the impact of polymer architecture on the biomedical 
properties of protein-polymer materials.  
In addition to polymer architecture, several other structural features of conjugate 
assembly have also been shown to influence recognition by the immune system. Rats 
administered PEGylated adenovirus developed significantly lower immunoglobulin levels 
with increasing degrees of polymer modification, resulting in improved efficacy for 
therapeutic applications.26 Furthermore, the chain length of the conjugate polymers has 
been shown to influence the immune response against protein-based therapeutics. Cowpea 
mosaic virus (CPMV) was modified with PEG, and cellular uptake was found to be 
significantly inhibited with increasing molecular weight of the PEG chains.27 Despite these 
and other numerous reports investigating different factors governing the immune response 
to protein-polymer conjugates, to our knowledge there has not been a comprehensive study 
examining all of these components on a singular platform.  
Icosahedral virus-like particles (VLPs) represent emerging platforms for 
applications in biomedicine ranging from drug delivery and imaging to vaccine 
development.28–31 Their structural stability, monodispersity, and periodicity make them 
ideal for the development of well-defined delivery vehicles using a variety of different 
chemical modifications.32,33 In addition to modifying the particle surface, the interior of 
VLPs has also been addressed for the packaging of drugs,34 therapeutic proteins,35,36 and 
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polymers37,38 for different biomedical applications. Despite these extensive efforts in 
developing VLPs as therapeutics, recognition by the immune system remains a significant 
hindrance towards implementing VLPs in clinical applications. Due to their size and 
repetitive organization, VLPs are readily recognized by components of both the innate and 
adaptive immune system,39 which limits the efficacy of repetitive treatment regimens. 
However, cellular uptake and protein-protein interactions involved in these processes can 
be mitigated by the covalent attachment of polymeric species to the particle surface.      
The immune response against protein-polymer hybrids is likely influenced by a 
combination of factors relating to the global structure and composition of the conjugate 
hybrid material. Prior research efforts have focused on evaluating a single aspect of these 
structures (i.e., density, chain length, conformation) rather than simultaneously 
investigating all of these factors. This study describes the investigation of all of these 
aspects using a series of polymers conjugated to VLPs derived from the bacteriophage Qb, 
a 28-nm particle with well-defined structure known to atomic resolution.40 In addition, we 
directly compared structural features of these conjugates to PEGylated VLPs by assessing 
their ability to block antibody recognition. We further investigated the performance of 
these materials in vivo, and we found that their ability to shield particles from the immune 
system was on par with that of PEGylated conjugates. Surprisingly, despite eliciting similar 
IgG titers, the quality of the antibody response was impacted by the structural organization 
and composition of the polymer conjugates. This data represents the first comprehensive 
evaluation of structural features in a defined set of protein-polymer materials and how those 
features impact protein-protein interactions and recognition by the immune system. 
Furthermore, these data suggest that more advanced polymer architectures rival PEG with 
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respect to immunological shielding and could serve in the development of biomedical 
materials with novel properties without sacrificing in vivo performance.  
5.3. Materials and Methods 
Protein purification and characterization 
The Qb VLPs were prepared as described in previously published protocols.41 
Briefly, chemically competent BL21(DE3) E. coli cells were transformed with pET28 
vector harboring the viral coat protein (CP) gene. Cells were plated on selective SOB agar 
and grown overnight. After 24 h, a single colony was selected for inoculation into SOB 
media (25 mL; Kan+) for overnight outgrowth at 37°C. Cultures were diluted into selective 
SOB media (500 mL; Kan+) the following day and maintained at 37°C until mid-log phase 
growth was achieved (O.D.600 ~ 0.9). Protein expression was subsequently induced by the 
addition of IPTG to a final concentration of 1 mM, and cultures were maintained at 30°C 
for 16 h. Cells were harvested by centrifugation at 6,000 rpm for 10 min, and pellets were 
suspended in 1x TBS for lysis using a probe sonicator (10 min total, 75 W, 5 sec intervals) 
in an ice bath. Lysates were clarified by centrifugation at 14,000 rpm for 10 min, and VLPs 
precipitated from the collected supernatant by the addition of 30% (NH4)2SO4 (w/v) at 4°C 
for 1 h. Precipitate was pelleted by centrifugation at 14,000 rpm for 10 min, and the 
resulting pellet was dissolved in 1x TBS. Proteins were extracted from lipids and 
aggregates with n-BuOH:CHCl3 (1:1; v/v) and subsequent centrifugation at 14,000 rpm for 
10 min. The aqueous phase was collected and loaded onto 10-40% sucrose density 
gradients, where VLPs were further purified by centrifugation at 28,000 rpm for 4 h. VLPs 
were isolated from gradient via syringe and pelleted by centrifugation at 68,000 rpm for 2 
h. Pellets were dissolved in 0.1M KPO4 buffer and subsequently characterized.  
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Protein concentration of all VLP samples was determined by Bradford assay with 
BSA as standards. Samples were characterized by FPLC size-exclusion chromatography 
(Superose 6 10/300 GL) monitored by absorbance at 280 nm, dynamic light scattering 
(Wyatt Dynapro plate reader), and mass spectrometry (Agilent 6230B TOF LC/MS). All 
conjugations were performed, and products characterized as described in subsequent 
sections. 
VLP-polymer conjugate synthesis  
Qb-(PEG4-N3)600: A solution of wild-type Qb VLPs (0.2 mL from 25 mg/mL stock solution 
in 0.1M KPO4, pH 7.4, 0.352 µmol subunit, 1.41 µmol reactive amines) was diluted with 
660 µL 0.1M KPO4 and cooled in an ice bath. To this solution was added 140 µL NHS-
PEG4-N3 (100 mM stock solution in DMSO, ~ 10 equiv per reactive amine). The tube was 
gently inverted to mix reagents and incubated for 16 h at 4°C. Particles were purified using 
PD-10 prepacked Sephadex columns (GE Healthcare) according to manufacturer’s 
instructions. Particles were further concentrated to 5.2 mg/mL using Amicon Ultra-4 
centrifugal filters with 100 kDa molecular weight cutoff. The degree of acylation was 
quantified by ESI-TOF analysis (600 per particle, 3.3 per subunit).  
Qb-POEGMA13-L: A solution of Qb-(PEG4-N3)600 (25 µL from 7.3 mg/mL stock solution 
in 0.1M KPO4, pH 7.4, 12.9 nmol subunit, 42.5 nmol reactive azide) was diluted with 3.33 
µL 0.1M KPO4. To this solution was added 10 µL of 3 (300 mg/mL in DMSO; 0.2 equiv 
per reactive azide). The tube was gently inverted to create a homogenous solution. 
Subsequently, 2.2 µL of 100 mM CuSO4 (5 equiv to azide) and 22 µL of 100 mM THPTA 
(50 equiv to azide) were added in a single portion, followed by the addition of 6.5 µL of 
200 mM aminoguanidine (30 equiv to azide). The tube was again gently inverted to mix 
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all components and the reaction was initiated by the addition of 2.6 µL of 500 mM sodium 
ascorbate (30 equiv to azide). After mixing, the reaction was incubated at 50°C for 16 h. 
The reaction mixture was purified by centrifugal filtration against 0.1M KPO4 using 
Amicon Ultra-4 centrifugal filters with 100 kDa MWCO and concentrated to 2.5 mg/mL. 
The sample was filtered through a 0.22 µm PTFE sterile syringe filter, and the total protein 
content was quantified by Bradford assay using BSA standards. Recovery of protein was 
approximately 95%. The extent of modification was determined by SEC-MALS analysis 
and NAGE; the final modified particles were composed of >95% intact particles as 
determined by DLS and FPLC analysis. 
Qb-POEGMA13-M: A solution of Qb-(PEG4-N3)600 (25 µL from 7.3 mg/mL stock solution 
in 0.1M KPO4, pH 7.4, 12.9 nmol subunit, 42.5 nmol reactive azide) was diluted with 3.33 
µL 0.1M KPO4. To this solution was added 6.7 mg of 3 dissolved in 10 µL DMSO (2 equiv 
per reactive azide). The tube was gently inverted to create a homogenous solution. 
Subsequently, 2.2 µL of 100 mM CuSO4 (5 equiv to azide) and 22 µL of 100 mM THPTA 
(50 equiv to azide) were added in a single portion, followed by the addition of 6.5 µL of 
200 mM aminoguanidine (30 equiv to azide). The tube was again gently inverted to mix 
all components and the reaction was initiated by the addition of 2.6 µL of 500 mM sodium 
ascorbate (30 equiv to azide). After mixing, the reaction was incubated at 50°C for 16 h. 
The reaction mixture was purified by centrifugal filtration against 0.1M KPO4 using 
Amicon Ultra-4 centrifugal filters with 100 kDa MWCO and concentrated to 2.5 mg/mL. 
The sample was filtered through a 0.22 µm PTFE sterile syringe filter, and the total protein 
content was quantified by Bradford assay using BSA standards. Recovery of protein was 
approximately 95%. The extent of modification was determined by SEC-MALS analysis 
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and NAGE; the final modified particles were composed of >95% intact particles as 
determined by DLS and FPLC analysis. 
Qb-POEGMA13-H: A solution of Qb-(PEG4-N3)600 (192 µL from 5.2 mg/mL stock 
solution in 0.1M KPO4, pH 7.4, 70.3 nmol subunit, 0.232 µmol reactive azide) was diluted 
with 3.33 µL 0.1M KPO4. To this solution was added 13.3 mg of 3 dissolved in 100 µL 
DMSO (4.3 equiv per reactive azide). The tube was gently inverted to create a homogenous 
solution. Subsequently, 11.9 µL of 100 mM CuSO4 (5 equiv to azide) and 59.5 µL of 100 
mM THPTA (25 equiv to azide) were added in a single portion, followed by the addition 
of 33.25 µL of 200 mM aminoguanidine (30 equiv to azide). The tube was again gently 
inverted to mix all components and the reaction was initiated by the addition of 66.5 µL of 
100 mM sodium ascorbate (30 equiv to azide). After mixing, the reaction was incubated at 
50°C for 16 h. The reaction mixture was purified by centrifugal filtration against 0.1M 
KPO4 using Amicon Ultra-4 centrifugal filters with 100 kDa MWCO and concentrated to 
1.3 mg/mL. The sample was filtered through a 0.22 µm PTFE sterile syringe filter, and the 
total protein content was quantified by Bradford assay using BSA standards. Recovery of 
protein was approximately 95%. The extent of modification was determined by SEC-
MALS analysis, and the final modified particles were composed of >95% intact particles 
as determined by DLS and FPLC analysis.  
Qb-POEGMA38: A solution of Qb-(PEG4-N3)600 (192 µL from 5.2 mg/mL stock solution 
in 0.1M KPO4, pH 7.4, 70.3 nmol subunit, 0.232 µmol reactive azide) was diluted with 
36.6 µL 0.1M KPO4. To this solution was added 27.2 mg of 4 dissolved in 100 µL DMSO 
(4.3 equiv per reactive azide). The tube was gently inverted to create a homogenous 
solution. Subsequently, 11.9 µL of 100 mM CuSO4 (5 equiv to azide) and 59.5 µL of 100 
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mM THPTA (25 equiv to azide) were added in a single portion, followed by the addition 
of 33.25 µL of 200 mM aminoguanidine (30 equiv to azide). The tube was again gently 
inverted to mix all components and the reaction was initiated by the addition of 66.5 µL of 
100 mM sodium ascorbate (30 equiv to azide). After mixing, the reaction was incubated at 
50°C for 16 h. The reaction mixture was purified by centrifugal filtration against 0.1M 
KPO4 using Amicon Ultra-4 centrifugal filters with 100 kDa MWCO and concentrated to 
1 mg/mL. The sample was filtered through a 0.22 µm PTFE sterile syringe filter, and the 
total protein content was quantified by Bradford assay using BSA standards. Recovery of 
protein was approximately 95%. The extent of modification was determined by SEC-
MALS analysis, and the final modified particles were composed of >95% intact particles 
as determined by DLS and FPLC analysis. 
Qb-POEGMA57: A solution of Qb-(PEG4-N3)600 (192 µL from 5.2 mg/mL stock solution 
in 0.1M KPO4, pH 7.4, 70.3 nmol subunit, 0.232 µmol reactive azide) was diluted with 
36.6 µL 0.1M KPO4. To this solution was added 40.0 mg of 5 dissolved in 100 µL DMSO 
(4.3 equiv per reactive azide). The tube was gently inverted to create a homogenous 
solution. Subsequently, 11.9 µL of 100 mM CuSO4 (5 equiv to azide) and 59.5 µL of 100 
mM THPTA (25 equiv to azide) were added in a single portion, followed by the addition 
of 33.25 µL of 200 mM aminoguanidine (30 equiv to azide). The tube was again gently 
inverted to mix all components and the reaction was initiated by the addition of 66.5 µL of 
100 mM sodium ascorbate (30 equiv to azide). After mixing, the reaction was incubated at 
50°C for 16 h. The reaction mixture was purified by centrifugal filtration against 0.1M 
KPO4 using Amicon Ultra-4 centrifugal filters with 100 kDa MWCO and concentrated to 
1.2 mg/mL. The sample was filtered through a 0.22 µm PTFE sterile syringe filter, and the 
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total protein content was quantified by Bradford assay using BSA standards. Recovery of 
protein was approximately 95%. The extent of modification was determined by SEC-
MALS analysis, and the final modified particles were composed of >95% intact particles 
as determined by DLS and FPLC analysis. 
Qb-PMAG: A solution of Qb-(PEG4-N3)600 (192 µL from 5.2 mg/mL stock solution in 
0.1M KPO4, pH 7.4, 70.3 nmol subunit, 0.232 µmol reactive azide) was diluted with 36.6 
µL 0.1M KPO4. To this solution was added 13.5 mg of 6 dissolved in 100 µL DMSO (4 
equiv per reactive azide). The tube was gently inverted to create a homogenous solution. 
Subsequently, 11.9 µL of 100 mM CuSO4 (5 equiv to azide) and 59.5 µL of 100 mM 
THPTA (25 equiv to azide) were added in a single portion, followed by the addition of 
33.25 µL of 200 mM aminoguanidine (30 equiv to azide). The tube was again gently 
inverted to mix all components and the reaction was initiated by the addition of 66.5 µL of 
100 mM sodium ascorbate (30 equiv to azide). After mixing, the reaction was incubated at 
50°C for 16 h. The reaction mixture was purified by centrifugal filtration against 0.1M 
KPO4 using Amicon Ultra-4 centrifugal filters with 100 kDa MWCO and concentrated to 
2 mg/mL. The sample was filtered through a 0.22 µm PTFE sterile syringe filter, and the 
total protein content was quantified by Bradford assay using BSA standards. Recovery of 
protein was approximately 95%. The extent of modification was determined by SEC-
MALS analysis, and the final modified particles were composed of >95% intact particles 
as determined by DLS and FPLC analysis. 
Qb-mPEG: A solution of Qb-(PEG4-N3)600 (192 µL from 5.2 mg/mL stock solution in 0.1M 
KPO4, pH 7.4, 70.3 nmol subunit, 0.232 µmol reactive azide) was diluted with 36.6 µL 
0.1M KPO4. To this solution was added 9.1 mg of 7 dissolved in 100 µL DMSO (4 equiv 
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per reactive azide). The tube was gently inverted to create a homogenous solution. 
Subsequently, 11.9 µL of 100 mM CuSO4 (5 equiv to azide) and 59.5 µL of 100 mM 
THPTA (25 equiv to azide) were added in a single portion, followed by the addition of 
33.25 µL of 200 mM aminoguanidine (30 equiv to azide). The tube was again gently 
inverted to mix all components and the reaction was initiated by the addition of 66.5 µL of 
100 mM sodium ascorbate (30 equiv to azide). After mixing, the reaction was incubated at 
50°C for 16 h. The reaction mixture was purified by centrifugal filtration against 0.1M 
KPO4 using Amicon Ultra-4 centrifugal filters with 100 kDa MWCO and concentrated to 
6.8 mg/mL. The sample was filtered through a 0.22 µm PTFE sterile syringe filter, and the 
total protein content was quantified by Bradford assay using BSA standards. Recovery of 
protein was approximately 85%. The extent of modification was determined by SEC-
MALS analysis, and the final modified particles were composed of >95% intact particles 
as determined by DLS and FPLC analysis. 
SEC-MALS analysis 
Samples were diluted to 0.1 mg/mL in 0.1M KPO4 buffer (pH 7.4) and injected 
onto a Superose 6 10/300 GL size exclusion column (GE Healthcare) using an Agilent 
HPLC to maintain a 0.4 mL/min flow rate during analysis. Samples were detected using a 
UV-Vis detector (Agilent), a Viscotek SEC-MALS 20 multi-angle light scattering detector 
(Malvern), and a Viscotek VE3580 refractometer (Malvern). The average molecular 
weight, Mw, was calculated with OmniSEC 5.0 software and plotted across the elution 
peak. The degree of modification for the polymer-labeled samples was related to the 
measured difference in Mw between the sample and starting material divided by the average 
molecular weight of the respective polymer chain. 
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Sandwich ELISA  
Anti-Qb IgY (10 µg/mL) was plated overnight at 4°C. Plate was washed thrice with 
PBS-Tween 20 (0.05% Tween; PBST) and blocked with 3% BSA in PBST for 2 h at RT. 
Plate was aspirated and VLP-polymer conjugates were added in triplicate from 0.01-100 
µg/mL and incubated for 1 h at RT. Plate was washed thrice with PBST and mouse anti-
Qb IgG monoclonal antibody (1:2500, Clone 5D6; Abbiotec, Inc.) incubated for 1 h at RT. 
Plate was washed thrice with PBST and anti-mouse IgG HRP-conjugate reporter antibody 
(1:2500; Pierce) incubated for 1 h at RT, followed by a final washing with PBST and 
development with TMB substrate (1-Stepä Ultra TMB; Thermo Fisher Scientific). 
Development was quenched by the addition of 1M H2SO4 and absorbance measured at 405 
nm on microplate reader (Thermo Fisher Scientific). 
Mice and immunizations 
CD-1 IGS mice (8-12 weeks) were purchased from Charles River Laboratories and 
maintained in the animal facility of the Georgia Institute of Technology. All animal care 
and experimental procedures were approved by the Institutional Care and Use Committee 
of the Georgia Institute of Technology. Mice were administered 10 µg VLP-polymer 
conjugates via subcutaneous injection at days 0, 14, and 28. Blood was collected via 
submandibular bleed on days 7, 21, and 35 for serum analysis. Mice were maintained until 
day 70 for subsequent blood collection prior to sacrifice.    
ELISA analysis 
Qb WT (1 µg/mL) was plated overnight at 4°C. Plate was washed thrice with PBST 
and blocked with 3% BSA in PBST for 2 h at RT. Serum dilutions were prepared in master 
plate using 3% BSA in PBST and added to assay plate to give final dilutions from 1:500-
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1:128000, which were incubated for 1 h at RT. Plate was washed thrice with PBST and 
incubated with anti-mouse IgG HRP-conjugate reporter antibody (1:2500, Abbiotec, Inc.) 
for 1 h at RT. A final washing with PBST was followed by development with TMB 
substrate (1-StepÔ Ultra TMB; Thermo Fisher Scientific) and quenching with 1M H2SO4. 
Absorbance was measured at 405 nm on a microplate reader (Thermo Fisher Scientific).   
Avidity ELISA 
Plates were prepared as described for standard ELISA analysis. After blocking with 
3% BSA in PBST, serum was added to assay plate at a final dilution of 1:8000, which was 
incubated for 1 h at RT. Plate was washed thrice with PBST and incubated with increasing 
concentrations of NaSCN (0-5 M) in PBS for 15 min at RT. Plate was washed thrice and 
analysis continued as described for standard ELISA. 
5.4. Results and Discussion 
5.4.1. Conjugate synthesis and characterization 
To prepare protein-polymer hybrids from the icosahedral Qb VLPs, a series of 
poly(oligo(ethylene glycol) methacrylate (POEGMA) and poly(methacrylamido 
glucopyranose) (PMAG) polymer chains (3-6) was prepared by RAFT polymerization as 
previously described.42 The resulting polymers were found to be rather water-soluble and 
not detrimental to the stability of the protein nanoparticle upon covalent attachment. Each 
polymer was synthesized with a terminal alkyne to allow for conjugation to the VLP by 
the robust copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) reaction using the 
accelerating ligand 8 (THPTA).43 The VLP, which bears a total of 720 amino groups on 
the surface, was acylated with a molar excess of N-hydroxysuccinimide ester 1. After 
purification from the excess small molecule, the azidated VLP was addressed with 
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polymers 3-7 to yield conjugates 9-15, respectively (Scheme 1). Heating of the reaction 
was found to be necessary in order to achieve reasonable levels of attachment to the VLP, 
presumably due to steric hindrance. The resulting conjugates were characterized by size  
exclusion chromatography coupled with multi-angle light scattering (SEC-MALS), which 
allowed for quantification of polymer labeling through calculation of the absolute 
molecular weight of the hybrid species. The Qb conjugates were labeled with ~36, ~59, 
~93, ~38, ~33, ~78, and ~92 chains to yield Qb-POEGMA13-L, Qb-POEGMA13-M, Qb-
POEGMA13-H, Qb-POEGMA38, Qb-POEGMA57, Qb-PMAG, and Qb-mPEG, 
respectively (Table 1). The alphabetic notation following POEGMA13 was used to denote 
conjugates with low, moderate, and high loadings of the same polymer chain. Despite 
variations in loading density, polymer chains were conjugated to VLPs at similar mass 
loadings for conjugates 11-15 (Table 1). The lower loadings observed with the higher 
molecular weight species were attributed to decreased reactivity of the larger polymers due 
to steric crowding, and higher loadings could not be achieved in significant yield. 
Scheme 1: Preparation of Qb-polymer conjugates. 
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The radius of gyration (Rg) for each conjugate was also calculated from SEC-
MALS analysis and related to the conformation adopted by the polymer chains on the 
particle surface. For conjugates 9, 12, and 13, the Rg was measured at 18.9 nm, 22.1 nm,  
 
Table 1: SEC-MALS analysis of Qb-polymer conjugates 
 
and 23.0 nm, respectively; the contribution by the conjugate polymer chains scaled with 
the degree of polymerization (N) as Rg ~ N0.47, indicative of more swollen polymer 
conformations.44 Interestingly, there was a distinct change in Rg with increasing degrees of 
modification for conjugates 9-11, with Rg increasing to 20.1 nm for conjugate 10 and 
contracting to 18.1 nm for conjugate 11. Decreases in Rg were even more pronounced for 
conjugates 14 (17.5 nm) and 15 (18.2 nm), with sizes scaling as Rg ~ N0.31 and Rg ~ N0.28, 
indicative of dense globular conformations. The decrease in Rg observed for the most 
heavily modified VLPs (11, 14, and 15) suggests that the polymer chains may be 
interacting and associating into more tightly packed structures. This observation may 
extend to the free polymer chains in solution, as species with lower Rg would exhibit 




Figure 1. Characterization of Qb-polymer conjugates. (A) DLS histograms of Qb-polymer 
conjugates. Rh = hydrodynamic radius. (B) Comparative SEC traces of Qb-polymer 
conjugates relative to starting material (2; dashed trace). (C) Native agarose gel (0.7 % 
w/v) of intact Qb-polymer conjugates. Unmodified particles (lane 1) migrate into the gel 
because of the endogenous RNA packaged inside of the VLP during assembly; modified 
particles (lanes 2-5) show significantly hindered migration into the gel. Lane 1: Qb-PEG4-
N3; Lane 2: Qb-PMAG; Lane 3: Qb-POEGMA13-H; Lane 4: Qb-POEGMA38; Lane 5: 
Qb-POEGMA57. Gel stained with SYBR Safe Gel Stain.  
 
Size-exclusion chromatography, dynamic light scattering, and gel electrophoretic 
analysis were all characteristic of intact hybrid particles for conjugates 9-15 (Figure 1A-
C). Modified particles displayed significant increases in hydrodynamic radius from ~15 
nm for unmodified Qb VLPs to ~ 25-35 nm, with differences in radii between conjugates  
likely a result of the varying chain lengths and architectures. The hydrodynamic radii 
were noticeably larger than the radii of gyration obtained from SEC-MALS analysis, as 
Rg is inherently dependent upon shape. All hybrid VLP conjugates displayed significant 
decreases in elution volume as measured by size-exclusion chromatography, indicative of 
larger molecular weight species (Figure 1A,B). Native agarose gel electrophoresis 
(NAGE) displayed significant retention of all modified species within the gel wells, while  
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Figure 2. SDS-PAGE analysis of Qb-polymer conjugates. L: ladder; Lanes 1-2: 
unmodified Qb; Lanes 3-4: Qb-POEGMA13-H; Lanes 5-6: Qb-POEGMA38; Lanes 7-8: 
Qb-POEGMA57; Lanes 9-10: Qb-PMAG; Lanes 11-12: Qb-mPEG. Even-numbered lanes 
loaded with 10 µg; odd-numbered lanes loaded with 5 µg. Gel stained with Coomassie 
Blue.    
 
unmodified VLPs migrated farther into the gel as they were unhindered by the bulk of the 
conjugated chains (Figure 1C). Analysis by SDS-PAGE also showed distinct smearing 
of higher molecular weight species for all Qb conjugates, which is typically observed for 
high molecular weight protein-polymer hybrids (Figure 2). To ensure that these  
observations were due to covalent attachment of polymer chains rather than nonspecific 
association with the particle surface, reaction mixtures of Qb VLPs and polymers were 
incubated without the addition of a reducing agent to initiate the CuAAC reaction. 
Particles purified from these mixtures did not show an increase in hydrodynamic radius, 






Figure 3. Analysis of POEGMA control reactions without addition of sodium ascorbate. 
Native agarose gel (0.7%) analysis (left) of POEGMA control reactions. Equivalent 
migration distance into gel indicates a lack of modification by polymer species. Gel stained 
with SYBR Safe Gel Stain. DLS histograms of POEGMA control reactions (right). Rh = 
hydrodynamic radius. Observed radii consistent with azidated VLP size. Sample 1: Qb+ 3; 
Sample 2: Qb+4; Sample 3: Qb+5. 
 
Figure 4. Cartoon representation of the Qb coat protein monomer. The flexible AB loop is 
highlighted, and lysine residues 13 and 16 are shown in green. The side chain of lysine 16 





5.4.2. Assessment of conjugate properties on antibody binding 
We first chose to investigate the ability of the conjugated polymers to block 
recognition of the Qb VLP by monoclonal antibodies generated against two different 
variants of the viral coat protein (wild-type and K13Q/K16Q). Lysine-13 and lysine-16 
both reside in the flexible AB loop of the coat protein structure (Figure 4), which is  
predicted to be the dominant epitope for display and recognition by the immune system on 
major histocompatibility complex class II (MHC-II) molecules.45 Immunization of mice  
with Qb VLPs comprised of the wild-type coat protein allowed for the generation of B-cell 
hybridomas from which mAb 11A1 was identified; immunizations with the K13Q/K16Q  
mutant VLP allowed for selection of mAb 5D6. Interestingly, mAb 5D6 was capable of 
recognizing both the wild-type and mutant VLPs, whereas mAb 11A1 solely recognized 
particles comprised of the wild-type protein. This disparity suggests that the epitope 
recognized by mAb 11A1 lies within the AB loop, whereas the epitope recognized by mAb 
5D6 lies elsewhere on the particle. 
Recognition of Qb-POEGMA conjugates 9, 12, and 13 was assessed by sandwich 
ELISA using mAbs 11A1 and 5D6, with significant differences observed between the 
performance of the two antibodies (Figure 5A,B). Both mAbs showed significant binding 
to unmodified Qb VLPs, with 5D6 displaying significantly stronger binding compared to 
11A1 (Figure 6). VLPs modified with POEGMA polymers 3-5 showed diminished 
binding by 5D6 that correlated with increasing molecular weight of the conjugated polymer 
chain (Figure 5A), consistent with previous observations that increasing the chain length 
of a common polymer architecture diminished the immunogenicity of protein conjugates.27 
Interestingly, mAb 11A1 binding was completely abolished by the attachment of 
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POEGMA chains of any size (Figure 5B). This result further supported the hypothesis that 
mAbs 11A1 and 5D6 recognize discrete epitopes on the particle surface. As the polymer 
chains are conjugated to Qb VLPs at the lysine residues (Scheme 1), the complete 
abrogation of binding by 11A1 further indicates that this mAb recognizes an epitope in the 
exposed AB loop as this would be a site directly blocked by polymer attachment at either 
lysine-13 or lysine-16 (Figure 4).    
We next investigated how the density of polymer loading influenced recognition 
of the Qb VLP by mAb 5D6. Recognition of Qb-POEGMA conjugates 9-11 was 
assessed by sandwich ELISA, and significant inhibition of antibody binding was 
observed with increasing density of polymer chains on the Qb particle surface (Figure 
5C). Qb-POEGMA13-L did not significantly inhibit binding of mAb 5D6 (> 95% 
recognition relative to wild-type VLPs), whereas increasing the POEGMA loading to ~ 
59 (Qb-POEGMA13-M) and ~ 93 (Qb-POEGMA13-H) modifications resulted in 53% 
and 18% relative recognition, respectively. This result correlated with previous 
observations that increasing coverage of polymer chains on a viral particle surface served 
to dampen the immunogenicity of the platform.26 
In addition to investigating the effect of polymer density, we also studied the 
effects of polymer architecture on antibody recognition. A linear mPEG chain (7) was 
compared against the brush-type POEGMA (3) and the linear glycopolymer PMAG (6) 
conjugated at equivalent densities to Qb VLPs, and recognition of the VLPs by mAb 5D6 
was evaluated by sandwich ELISA (Figure 5D). Particles modified with mPEG (15) and 
POEGMA13 (11) displayed significant inhibition of antibody binding compared to 
recognition of wild-type VLPs, with Qb-POEGMA13-H showing equivalent ability to 
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block recognition compared to Qb-mPEG (18% vs. 24% of signal relative to wild-type, 
respectively). Interestingly, Qb-PMAG displayed significantly poorer performance in 
blocking recognition of the VLP (78%), despite similar coverage density and molecular 
weight of the polymer chain. These observations are consistent with previous reports that  
Figure 5. Analysis of Qb-polymer conjugate properties that influence antibody 
recognition in vitro. (A) ELISA response using mAb 5D6 for detection of Qb-POEGMA 
conjugates as a function of increasing polymer molecular weight. (B) ELISA response 
using mAb 11A1 for detection of Qb-POEGMA conjugates. Differential response 
between mAb 5D6 and mAb 11A1 demonstrates the impact of differential epitope 
blocking by polymer attachment. (C) ELISA response using mAb 5D6 for detection of 
Qb-POEGMA conjugates as a function of polymer loading density. (D) ELISA response 
using mAb 5D6 for detection of Qb-polymer conjugates as a function of polymer 
architecture. Results are normalized to recognition of unmodified VLP at 1 µg/mL for all 
assays. Data are mean value from 3 independent replicates +/- standard error. Statistical 
analysis performed using Student’s t-test. p < 0.0001: ****; p < 0.001: ***; p < 0.01: 
**; p < 0.05: *; N.S. = not significant. 
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polymer architecture and conformation on the particle surface influence the ability of 
antibodies to bind to protein conjugates.20,21 Furthermore, our analysis of Rg for the 
conjugate polymers suggested that conjugates 11, 14, and 15 would adopt compact  
 
Figure 6. Comparative binding analysis between mAbs 5D6 and 11A1 against 
unmodified Qb VLPs.  
 
structures on the VLP surface, but there are clearly distinct differences in how these 
structural conformations relate to shielding of the particle surface. 
5.4.3. Evaluation of antibody responses in mice 
To this point, we had investigated various components of polymer structure and 
conjugate composition individually; however, recognition by the immune system is likely 
a complex interplay between features of protein-polymer materials. In order to address 
this, we finally chose to investigate the performance of the protein-polymer conjugates in  
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vivo to determine if attachment of the polymers could effectively dampen the immune 
response to the VLP. For this study, female CD-1 mice (n=4) were immunized with 10 
µg of each VLP conjugate and received two subsequent 10 µg immunizations in weeks 2 
and 4, respectively (Figure 7A). Based on the in vitro performance tests, Qb-
POEGMA13-H was selected from the POEGMA13 conjugates for testing in vivo. Serum  
Figure 7. Analysis of Qb-polymer conjugate immunogenicity in vivo. (A) Schematic of 
immunization schedule. (B) IgG titers against the unmodified Qb particle in mice 
immunized with indicated polymer conjugates. Sera analyzed from weeks 1, 3, and 5 of 
study following immunizations. The data was fit and solved using a Generalized Reduced 
Gradient algorithm, and the titer was calculated as the mid-point of the corresponding 
curve fit. Bars represent mean value for each group +/- standard error (n = 4). (C) 
Endpoint IgG titers against unmodified Qb particle. Sera analyzed from week 5 of study 
following final immunization. Lines represent mean value for each group +/- standard 
error (n = 4). All statistical analysis performed using Student’s t-test. p < 0.0001: ****; p 
< 0.001: ***; p < 0.01: **; p < 0.05: *; N.S. = not significant. 
 
samples were obtained in weeks 1, 3, and 5; and serum IgG antibody titers specific to the 
Qb VLP were measured by ELISA against the unconjugated wild-type particle (Figure  
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7B,C). Antibodies specific to the Qb VLP were generated in all cohorts, but development 
of antibody responses in all groups immunized with polymer conjugates was significantly 
delayed relative to cohorts immunized with the wild-type particle (Figure 7B). Following 
a second immunization, IgG titers remained lower in all mice immunized with polymer 
conjugates but not significantly (Figure 7B). Endpoint titer analysis following a third  
 
Figure 8. IgG subclass distribution for Qb conjugates. Each data set compares IgG 
subclasses from mice immunized with Qb polymer conjugates (black) and mice 
immunized with unmodified Qb particles (white). Bars represent mean value for each 
data set +/- standard error (n = 4). 
 
immunization revealed a significant increase in the IgG titer in cohorts immunized with 
the wild-type particle, whereas titers remained much lower in all groups treated with 
polymer conjugates (Figure 7C). Analysis of the different IgG subclasses revealed that,  
while overall titers were lower, the distribution remained unchanged relative to mice 
immunized with unlabeled VLPs (Figure 8). Despite differing performances in blocking 
antibody recognition in vitro, all Qb polymer conjugates gave rise to similar IgG titers 
 166 
with Qb-mPEG displaying the lowest (6,720). While the series of Qb-POEGMA 
conjugates (11-13) displayed decreasing recognition by mAb 5D6 with increasing length  
of the polymer chain in vitro, IgG titers among these cohorts were statistically equivalent 
(Figure 7C). Interestingly, Qb-PMAG also gave rise to equivalent IgG titers (17,175) 
despite its poor performance in blocking antibody recognition in vitro. 
 
Figure 9. Normalized ELISA response against unmodified Qb particle from mice 
immunized with indicated polymer conjugates. Sera analyzed from week 5 of study at 
1:8000 dilution. Results are normalized to recognition of unmodified VLP by sera from 
mice immunized with unmodified Qb particle. Bars represent mean value for each group 
+/- standard error (n = 4). All statistical analysis performed using Student’s t-test. p < 
0.0001: ****; p < 0.001: ***; p < 0.01: **; p < 0.05: *; N.S. = not significant. 
 
Although the IgG titers among cohorts immunized with VLP-polymer conjugates 
were statistically equivalent, there were distinct differences in antibody performance that 
were consistent with observations from the in vitro assays. Antibody recognition of Qb 
VLPs was assessed at a normalized serum dilution for each cohort, and recognition of the  
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particle was compared to serum from mice immunized with unlabeled VLPs (Figure 9). 
Interestingly, mice immunized with Qb-POEGMA (11-13) displayed significantly lower 
seroreactivity compared to serum from mice immunized with unlabeled VLPs following 
the initial immunization (Figure 9). Reactivity increased with subsequent immunizations 
but remained significantly lower than in mice receiving unmodified particles. Surprisingly,  
following the final immunization, serum from mice immunized with Qb-POEGMA13-H 
displayed equivalent recognition compared to serum from mice immunized with unlabeled  
Figure 10. Avidity analyses of polyclonal sera against unmodified Qb particles. (A) 
Avidity of serum IgG responses assessed by NaSCN-displacement ELISA. (B) EC50 
determined from sigmoidal dose response regression analysis. Lines represent mean value 
for each group +/- standard error (n = 4). All statistical analysis performed using Student’s 
t-test. p < 0.0001: ****; p < 0.001: ***; p < 0.01: **; p < 0.05: *; N.S. = not significant. 
 
VLPs (~ 95% relative to wild-type); serum from mice immunized with Qb-POEGMA38 
and Qb-POEGMA57 showed significantly lower response levels (68% and 58%, 
respectively). Serum from mice immunized with Qb-PMAG and Qb-mPEG showed 
significantly reduced responses to the particle following the initial immunization, although 
not as marked as mice immunized with the Qb-POEGMA conjugates. These responses 
increased following subsequent immunizations but remained significantly lower than the 
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response to unlabeled VLPs (78% and 61% relative to wild-type, respectively). This 
variation in recognition of the Qb VLP despite mice from all cohorts exhibiting similar 
IgG titers seemed to indicate functional differences among the antibody repertoires 
generated, which correlated with weaker responses as the polymer chain length increased 
(Figure 11A, B).  
In order to investigate these differences further, we next analyzed the functional 
affinity (avidity) of the polyclonal sera from each cohort. The chaotropic agent sodium 
thiocyanate (NaSCN) was used to displace serum antibodies in a standard ELISA run at a  
Figure 11. Spearman correlation analysis of polymer loading and chain length with EC50 
values and seroreactivity for Qb conjugates. Correlation of chain length with EC50 (A) 
and seroreactivity (B). Correlation of polymer loading with EC50 (C) and seroreactivity 
(D). Individual points represent the mean value measured for the indicated polymer 
conjugate. 
 
normalized serum dilution, and the EC50 (concentration of NaSCN needed to decrease 
O.D. by 50%) was calculated for each cohort. All cohorts immunized with polymer 
conjugates generated lower avidity antibody responses against the Qb VLP relative to 
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mice immunized with unlabeled particles (Figure 10A,B),with Qb-PMAG and Qb-
mPEG giving rise to antibody responses with significantly lower avidities. Surprisingly, 
Qb-POEGMA conjugates 9-11 showed a trend of increasing avidity with increasing 
chain length of the conjugate POEGMA polymer despite an overall decrease in 
seroreactivity. This observation could be rationalized as a function of polymer loading 
and epitope accessibility, as there was a definitive correlation between the number of 
polymer modifications and avidity (Figure 11C, D). Overall, polymer attachment 
dampened the immunogenicity of the Qb VLPs in vivo, but there were distinctive 
differences in the function of the antibody populations generated. 
5.4.4. Discussion 
Despite the advantages that have been demonstrated by the conjugation of polymers 
to protein-based therapeutics, there have been relatively few advancements of protein-
polymer hybrid materials into the clinic since the advent of PEGylation. While PEG has 
been effective at limiting recognition of conjugate proteins by the immune system and 
prolonging circulation in the bloodstream, more complex polymer architectures have been 
shown to have improved properties in these respects; these represent opportunities for the 
development of novel materials that could expand the application of protein-polymer 
materials in the clinic and possibly supplant PEG as the polymer of choice in biomedical 
applications. Despite this mounting evidence, studies on the influence that protein-polymer 
conjugate structure and composition have on this behavior have remained limited in scope. 
We show in this work a comprehensive assessment of these structural and organizational 
features that play clear roles in governing antigen recognition and the quality of antibody 
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responses, and we further explore direct comparisons to PEGylated conjugates both in vitro 
and in vivo.  
The Qb VLP proved a robust platform for developing hybrid polymer materials in 
a controlled manner that could be systematically evaluated as: 1) its organized periodic 
structure provided for well-defined sites of attachment and 2) its inherently immunogenic 
nature allowed for the shielding capacity of the conjugate polymers to be directly assessed 
in vivo. Synthesis of VLP-polymer conjugates could be readily achieved for all polymers 
tested, although the difficulties of ligating the larger molecular weight POEGMA species 
to the VLP surface were apparent as the loadings of conjugates 12 and 13 were substantially 
lower. Despite the lower polymer loading, the increased chain length of these species 
allowed for the VLP conjugates to possess similar mass loadings to the conjugates prepared 
with the lower molecular weight polymer species.   
As several features of protein-polymer hybrid structure and composition have been 
implicated as factors governing immune recognition, we first set out to collectively 
characterize the impact of polymer loading density, polymer chain length, and polymer 
architecture on the ability of antibodies to recognize the Qb particle. To accomplish this, 
we leveraged the immunogenic nature of Qb VLPs to generate two different mAbs (clones 
5D6 and 11A1) that recognized distinct epitopes on the particle surface. Indeed, these two 
antibodies displayed markedly different recognition capabilities when compared against 
Qb-POEGMA conjugates of increasing chain lengths. Recognition by clone 5D6 was 
progressively inhibited with increasing chain length of the POEGMA conjugates, with a 
maximum of 45% knockdown in binding. Interestingly, binding by clone 11A1 was 
completely abrogated for all three polymer conjugates. Given the striking difference in 
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performance between the two mAbs, we believe the site of polymer conjugation on the 
protein surface to be a key determinant in governing protein-protein interactions and 
epitope accessibility. Our previous observation that clone 5D6 was capable of recognizing 
VLPs derived from both the wild-type coat protein as well as a double mutant 
(K13Q/K16Q), whereas clone 11A1 only recognized the wild-type protein, suggested that 
not only did the antibodies recognize distinct epitopes but that the epitope for 11A1 was 
located on the flexible AB loop. As all of the polymer conjugates were synthesized through 
attachment at the lysine residues on the particle surface, any degree of polymer 
modification at lysine-13 or lysine-16 would directly block epitope accessibility in the 
loop. This observation suggests that the site of polymer conjugation may play a crucial role 
in governing protein-protein interactions and recognition of protein-polymer materials by 
the immune system. 
The density of polymer loading has been previously found to influence the immune 
response against viral capsids, with increased loadings of PEG resulting in diminished 
antibody responses and cellular uptake.27 In this vein, we analyzed Qb-POEGMA 
conjugates with mAb 5D6 in order to assess the impact from density of functionalization 
on subsequent antibody recognition. These Qb-POEGMA conjugates were modified with 
POEGMA 3 at increasing levels of functionalization (36, 59, and 93 modifications, 
respectively), and antibody binding was significantly inhibited with increased polymer 
loading. As clone 5D6 recognizes an epitope distinct from the AB loop, direct blocking of 
antibody binding due to the conjugation site is unlikely; however, these polymer chains 
extend into solution above the VLP surface and increasing the number of modifications 
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likely impedes accessibility of the Qb particle through either steric repulsion or the 
presence of a hydration shell around the surface.   
More recently, studies have shown that the conformation of polymer chains 
conjugated to nanoparticle surfaces also influences protein-protein interactions and 
immune recognition.20,21 The conformation adopted by the conjugate polymer is inherently 
related to the architecture of the polymer chain (i.e., branched vs. linear) as well as 
interactions between the extended polymer chains in solution. Intramolecular association 
of polymer chains was clearly evident in more heavily modified conjugates (11, 14, 15), as 
there was a small but marked decrease in their Rg (17-18 nm) compared to conjugates with 
fewer modifications (22-23 nm). This higher degree of modification would have resulted 
in a denser array of polymer chains on the VLP surface, likely allowing for association 
between these chains into more tightly packed globular domains. This correlated well with 
predictions from Flory’s theory, where the Rg for the polymer chains scaled with exponents 
indicative of densely packed globular conformations.44 Interestingly, these conjugates 
exhibited markedly different performance in blocking antibody recognition despite similar 
polymer loadings and molecular weights. Qb-PMAG only inhibited antibody recognition 
by ~20%, while Qb-POEGMA13-H and Qb-mPEG both abolished binding by ~80%, 
suggesting clear differences in conformation between polymer architectures. It is possible 
that multiple hydrogen-bonding events between the carbohydrate moieties in 14 promote 
association between the polymer chains, whereas POEGMA and PEG adopt less compact 
structures in solution, allowing for greater coverage of the VLP surface. Further studies to 
investigate the conformations adopted by these polymer chains when conjugated to the Qb 
particle are currently ongoing.   
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Our evaluation of these structural features in vitro provided a comprehensive 
analysis of individual components on the same protein platform, but nothing to address the 
simultaneous influence of multiple features on immune recognition. To fully explore the 
impact of structure and composition on recognition by the immune system and relate these 
findings with our in vitro analysis, we finally analyzed the antibody response against the 
Qb VLP in mice administered multiple doses of conjugates 11-15. The administration of 
doses was set to reflect a scenario whereby a patient would be administered several rounds 
of treatment to gauge if recognition by the immune system could be inhibited during this 
time period. Indeed, all protein-polymer conjugates resulted in significantly lower anti-Qb 
IgG antibody titers, but there were only slight differences in titer between conjugates. 
Interestingly, the initial development of an antibody response was significantly delayed 
relative to the response against unmodified particles. Following a second immunization, 
titers began to approach levels generated by unlabeled VLPs; however, titers did not 
increase significantly after a third dose while mice administered unlabeled particles 
experienced a much larger increase. Although class switching does occur, it appears that 
memory recall is significantly reduced as repeated dosing did not result in significant 
increases in titer compared to unlabeled particles. This would seem to indicate that, despite 
differences in conjugate structure and composition, the modifications tested were sufficient 
to limit protein-protein interactions and cellular uptake of particles in vivo, thereby 
mitigating the humoral response against the VLP.   
Despite similar antibody titers among mice immunized with polymer conjugates, 
there were distinct differences in the performance of these antibody populations. All Qb-
POEGMA conjugates (11-13) displayed lower responses than either Qb-PMAG (14) or 
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Qb-mPEG (15) in a normalized test for seroreactivity following a single injection. 
Following secondary immunizations, stronger responses against the particle were 
developed; however, these responses remained significantly lower than those against wild-
type VLPs. Interestingly, responses in mice immunized with both Qb-PMAG and Qb-
mPEG showed only a moderate increase in signal. This would suggest that affinity 
maturation occurs at differential rates between Qb-PMAG, Qb-mPEG, and Qb-POEGMA 
conjugates; and further experiments to investigate this phenomenon are warranted to fully 
understand the onset of immune responses to protein-polymer materials. Although in vitro 
tests suggested that Qb-POEGMA13-H (11) would demonstrate the greatest shielding 
capacity, this conjugate surprisingly gave rise to antibodies with comparable reactivity to 
unlabeled particles following a third immunization. Antibody recognition progressively 
decreased with increasing chain lengths of POEGMA conjugated to the VLP, thus 
indicating that polymer chain length may play a critical role in governing the quality of 
antibody responses against conjugate proteins. However, weaker antibody responses 
observed with Qb-PMAG and Qb-mPEG suggest that the conformation adopted by 
conjugate polymer chains also plays a key role in the immune response. 
To further investigate the quality of antibody responses in immunized mice, we 
investigated the observed avidity of the polyclonal antibody population in sera against Qb 
VLPs. Interestingly, the avidity of the antibodies generated against the particle decreased 
with increasing density of functionalization. It is likely that epitope accessibility is more 
limited in conjugates that are more heavily modified as the polymer chains cover more of 
the particle surface area, which could play a fundamental role in governing the diversity 
and affinity of the antibodies comprising the polyclonal population. Interestingly, when 
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comparing avidity and seroreactivity for Qb-POEGMA conjugates 11-13, opposing trends 
were observed. While the relative recognition of the particle decreased with increasing 
polymer chain length, the avidity increased. This could suggest that the polyclonal 
populations may fundamentally differ in terms of epitope diversity, such that the Qb 
conjugates bearing more POEGMA chains give rise to a less diverse population of 
antibodies with higher affinity; whereas conjugates bearing fewer POEGMA chains give 
rise to a more diverse population of antibodies with lower affinities. However, Qb-mPEG 
gave rise to an antibody population with both low avidity as well as diminished 
seroreactivity, suggesting that the density of polymer loading is not the sole determining 
factor on the quality of the antibody response. Studies to fully identify differences in the 
antibody populations arising after exposure to these conjugates, such as differences in 
antibody affinities or epitope diversity, could provide significant insight into protein-
polymer material design and are currently in progress.  
5.5. Conclusions 
When analyzed collectively, the data from this study suggests a complex interplay 
among the structural features of protein-polymer materials that influence recognition by 
the immune system. Complete abrogation of the immune response against a nanoparticle 
carrier is well beyond our current technology, yet the results from this study provide an 
understanding of the structural features that influence immune recognition and 
subsequent antibody responses. The degree of modification and the chain length of the 
conjugate polymer appear to significantly influence the antibody populations generated 
against the VLP, and further studies will serve to elucidate the mechanisms governing 
these phenomena. While Qb-mPEG produced the weakest overall response, the 
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POEGMA and PMAG conjugates gave rise to similar titers and levels of seroreactivity in 
most cases. This shows that, while our understanding of the structure-function 
relationship for protein-polymer hybrid materials is incomplete, advanced polymer 
architectures can be used to generate novel materials without sacrificing the performance 
gained from PEGylation, and these materials could serve to develop the next generation 
of biomaterials for clinical applications. 
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Chapter 6: Genetic modification of PP7 VLPs to dampen phagocytic uptake 
 
6.1. Abstract 
 Virus-like particles (VLPs) represent useful nanoscale platforms for engineering 
delivery vehicles in biomedicine. Particles derived from the bacteriophage PP7 are 
particular useful in this context as they are incredibly stable and remarkably tolerant of 
genetically encoded peptide extensions from the N-or C-termini of the coat protein 
subunits. Their incredible tolerance towards genetic manipulation allows for quantitative 
display of peptide extensions from each subunit, which can be precisely tuned by 
employment of an assembly-competent single chain dimer of the coat protein to generate 
particles with 50% fewer extensions. Despite their genetic and structural plasticity, VLP 
platforms remain limited in clinical employment due to their immunogenic structural 
properties which can promote adaptive immune responses and rapid clearance from the 
bloodstream. Previously, the display of a minimal peptide (Self) derived from CD47 on 
polystyrene nanoparticles was shown to inhibit phagocytic uptake and increase 
circulation half-lives in the bloodstream. In this work, we chose to explore the utility of 
the Self peptide in mitigating recognition of PP7 VLPs by genetically encoding the Self 
peptide as a C-terminal extension of the single chain coat protein dimer. Particles were 
tolerant of the peptide extension and could be produced in high yields without the need 
for subunit co-expression. Display of the Self peptide significantly inhibited particle 
uptake by RAW 264.7 macrophages in vitro, and immunized mice generated IgG titers 
moderately lower than those treated with unmodified PP7 particles. Overall, the display 
of the Self peptide on PP7 can be precisely tuned and shows promise for inhibiting 
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phagocytic uptake (and presumably clearance) of particles, which would expand their 
utility as platforms for delivery in medicine.   
6.2. Introduction 
 The immune system has evolved to clear invading pathogenic organisms and 
dying cells from the body through a variety of cellular mechanisms; these responses also 
mediate the clearance of foreign materials (i.e., nanoparticles, virus-like particles (VLPs), 
etc.) that are typically employed in drug delivery or other therapeutic applications.1,2 As 
noted in the introductory chapter, the size and periodic organization of VLPs are key 
determinants for interactions at the biological interface and can serve to stimulate 
complement deposition or pattern recognition receptor (PRR) engagement.3–5 Likewise, 
synthetic nanocarriers are often comprised of unnatural materials or chemical linkages 
that the body recognizes as foreign.  
 The field of drug delivery has primarily employed the chemical conjugation of 
polymeric species (namely, PEG) to the surface of nanoparticles and protein therapeutics 
in order to combat phagocytic clearance and recognition by the immune system.6–8 These 
conjugate polymers mimic the glycocalyx of a healthy cell, thereby disrupting protein-
protein interactions and inhibiting immune-mediated clearance of the therapeutic species. 
However, the bulk of the attached polymer chains often reduces the activity of biologics9 
and can also hinder therapeutic uptake by diseased cells.10 Furthermore, as discussed in 
Chapter 5, the properties of the attached polymer species as well as the degree to which 
the therapeutic is modified can directly influence the resulting immune response, making 
predictive design of these materials challenging. As was evidenced in previous chapters 
regarding the modification of VLPs to mediate cellular targeting, the ability to 
 183 
manipulate protein-based therapeutics at the genetic level also offers an alternative 
approach for evading immune-mediated clearance. 
 The glycoprotein CD47 has been identified as a “marker of self” in mice11 and is 
ubiquitously expressed on cell membranes in humans and other mammals.12 Lindberg 
and colleagues were the first to demonstrate the biological role of CD47 in a blood 
transfusion study using CD47-/- mice.13 These mice were found to be completely viable; 
however, if red blood cells (RBCs) from the CD47-/- mice were transfused into wild-type 
(CD47+/+) mice, macrophages cleared them from circulation within hours. The native 
binding partner of CD47 is signal regulatory protein alpha (SIRPa), an inhibitory 
receptor that is abundantly expressed on leukocytes and monocytes.14 Lindberg and 
colleagues demonstrated that the CD47-SIRPa interaction was responsible for inhibiting 
macrophage uptake of RBCs, while inhibition or absence of this interaction promoted 
rapid clearance.11 
 The role and potential application of CD47 in the inhibition of phagocytic 
clearance was further explored by Discher and colleagues, who showed that display of 
human CD47 on microparticles prevented uptake by macrophages.15 They further 
developed the potential for CD47 to be explored in therapeutic delivery applications by 
minimizing the domain to a 21-amino acid peptide (Self) derived from the most 
prominent contacting residues in the hCD47-SIRPa crystal structure.16,17 Polystyrene 
nanoparticles displaying the Self peptide showed delayed clearance from the circulation 
which subsequently enhanced delivery of the particles to tumors.16 This study was the 
first to demonstrate display of a minimal component of CD47 on a nanoparticle for the 
inhibition of immune-mediated clearance in vivo.  
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 In addition to its role in regulating phagocytic uptake and clearance, CD47-SIRPa 
signaling is also a key component that governs immune cell activation. Sarfati and co-
workers identified the CD47-SIRPa signaling axis as a crucial checkpoint in dendritic 
cell and monocyte activation, as ligation of CD47 inhibited both cytokine production and 
maturation of these cell subsets.18 Furthermore, CD47 ligation also inhibited cellular 
responsiveness to IL-12 and the maturation of naïve T-cells.19,20 The results of these 
studies clearly implicate CD47-SIRPa signaling as an important element governing not 
only phagocytic clearance but also recognition and stimulation of adaptive immunity. 
 The engineered display of peptides on the surface of VLPs has been investigated 
previously for applications in the development of vaccines and other biomimetic 
scaffolds. Chackerian and Peabody have extensively explored the development of MS2 
and PP7 platforms for the display of disease-associated peptide epitopes, specifically 
through incorporation of extensions in the AB-loop of the viral coat protein.21–23 Single-
chain dimer variants of both MS2 and PP7 were generated and shown to have increased 
stability relative to analogous particles comprised of coat protein monomers.21 These 
particles were shown to be tolerant to the incorporation of 6-10 amino acid peptides into 
the AB-loop, which has typically been shown to destabilize VLP structures; however, the 
VLP could only tolerate incorporation into a single subunit of the fused dimer.23,24 
Chackerian and colleagues employed these particles for the affinity selection of epitopes 
as well as the display of viral peptides for the development of vaccines. Despite the 
enhanced stability of these constructs and their tolerance of peptide insertions, the display 
of peptides as N-or C-terminal extensions of a fused dimer has not been explored (Figure 
1).  
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Figure 1. Genetic modification of VLP particles to present extensions/insertions. (A) 
Functional peptide extensions fused onto PP7 monomeric coat protein as either N- or C-
terminal extensions, which allows for presentation of 180 copies. (B) Functional peptide 
extensions fused onto PP7 single-chain coat protein dimers as either N- or C-terminal 
extensions, which allows for presentation of 90 copies. (C) Functional peptides fused 
onto PP7 monomeric coat protein via insertion into the AB loop, which allows for 
presentation of 90 copies. Depending on the intrinsic properties of the functional peptide, 
not all peptides can be readily fused using the strategies shown.  
 
 In this work, we sought to investigate the generation of PP7 VLPs comprised of a 
single-chain dimer displaying a C-terminal extension of the Self peptide identified by 
Discher and colleagues. While Douglas and coworkers have previously explored the 
display of the Self peptide on the surface of P22 VLPs, this display was facilitated by 
fusing the peptide to the trimeric decoration protein (Dec) from bacteriophage L,25 which 
binds tightly to the P22 capsid.26 Although display in this fashion did mitigate particle 
uptake by phagocytic cells, our system provides for direct covalent linkage of the 
inhibitory peptide to the VLP surface. PP7 VLPs produced in our system could be 
isolated in high yields with 90 copies of the Self peptide displayed on the surface 
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(although there is mounting evidence that particles formed from single-chain dimer 
extensions adopt T = 4 geometry, equating to 120 displayed peptides). Display of the Self 
peptide significantly inhibited uptake of PP7 VLPs by macrophages in vitro relative to 
unmodified particles, but immunization with these particles gave rise to comparable IgG 
titers in mice. Overall, the results of this study suggest that genetic display of the Self 
peptide could serve to mitigate phagocytic uptake and clearance of VLP delivery 
platforms and extend the range of their applications.  
6.3. Materials and Methods 
Molecular Cloning and Construct Design 
 To construct the expression plasmid for PP7-Self in this work, an existing 
expression vector for the PP7 fused dimer (pET28-PP72) was modified. Briefly, the 
coding sequence for the Self peptide (GNYTSEVTELTREGETIIELK) was codon-
optimized for expression in E. coli with a serine-to-cysteine mutation introduced at the 
fifth position to mitigate aggregation of VLPs during expression and purification. To 
incorporate this sequence as a C-terminal extension of the fused dimer, a Q5 Site-
Directed Mutagenesis Kit (New England Biolabs) was used with forward primer 5’-
GGATCCATGTCGAAAACCAT-3’ and reverse primer 5’-TTATTTTAACTCGATAAT 
AGTTTCTCCTTCGCGGGTTAACTCCGTAACTTCGGAGGTGTAATTGCCGGCGC
CGCTTTCGCTCGCGCCACCGCGGCCCA-3’, where the coding sequence for the Self 
peptide is underlined.  
Protein Production and Characterization 
 PP7 VLPs were expressed and purified following protocols previously established 
for the purification of Qb VLPs. Briefly, chemically competent BL21(DE3) E. coli cells 
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were transformed with a pET28 plasmid harboring the gene for either the PP7 coat 
protein single-chain dimer or the single-chain dimer bearing C-terminal peptide fusions 
as indicated (Self or scrSelf). Cells were plated on selective SOB agar, and, after 18 h, 
selective SOB media (25 mL) was inoculated with a single colony and grown overnight 
at 37°C. After 24 h, this culture was diluted into selective SOB media (500 mL) and 
grown at 37°C until the optical density (O.D.600) reached mid-log phase (~ 0.9). 
Expression was induced by the addition of IPTG (1 mM) and cultures were maintained at 
30°C for 16 h. Cells were harvested by centrifugation at 6,000 rpm for 10 min, and dried 
cells were re-suspended in 1x TBS prior to lysis using a probe sonicator (10 min total, 75 
W, 5 sec intervals) in an ice bath. Lysate was clarified by centrifugation at 14,000 rpm 
for 10 min, and proteins were precipitated from supernatant by the addition of 30% 
(NH4)2SO4 (w/v) at 4°C for 2 h. Precipitate was pelleted by centrifugation at 14,000 rpm 
for 10 min and was re-suspended in 1x TBS prior to extraction with n-BuOH:CHCl3 (1:1, 
v/v) to remove aggregates and lipids. Mixture was separated by centrifugation at 14,000 
rpm for 10 min, and aqueous phase was collected and immediately loaded onto 10-40% 
sucrose density gradient. VLPs were purified by centrifugation at 28,000 rpm for 4 h, and 
bands corresponding to intact particles were extracted via syringe. Particles were pelleted 
by ultracentrifugation at 68,000 rpm for 2 h, and the resulting pellets were dissolved in 
0.1M potassium phosphate buffer. 
 The protein concentration of the VLP samples was determined by Bradford assay 
using BSA standards. Particles were characterized by dynamic light scattering (Wyatt 
Dynapro plate reader), FPLC size-exclusion chromatography (Superose 6 10/300 GL) 
monitoring the absorbance at 280 nm, microfluidic gel electrophoresis (Agilent 2100 
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Bioanalyzer with Series II Protein 80 chips), and mass spectrometry (Agilent 6230B TOF 
LC/MS).  
Cell Culture 
 All cell culture reagents were purchased from Invitrogen. RAW 264.7 
macrophage cells (ATCC) were cultured in phenol red-free Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 5% fetal bovine serum (FBS), GlutaMAX (2 mM), 
sodium pyruvate (1 mM), penicillin (100 U/mL), and streptomycin (100 µg/mL). Cells 
were maintained in a humidified incubator at 37°C with 5% CO2 atmosphere.  
Live-Cell Microscopy and Fluorescence Imaging 
 RAW 264.7 macrophages were cultured to 80% confluence and seeded onto 
chambered microscope slides (ibidi) at 1:10 dilution. After 24 h, cells were treated with 
PP7 VLPs (10 or 20 nM) labeled with Alexa Fluor 488 and incubated for 6 h, 12 h, and 
24 h at 37°C in a humidified incubator with 5% CO2. At each respective time point, cells 
were rinsed twice with 1x PBS and imaged on an Eclipse Ti-U fluorescence microscope 
(Nikon) equipped with a 60x oil immersion objective. Images were subsequently 
analyzed with ImageJ software. To calculate the corrected fluorescence per cell (CFPC), 
cells were manually selected by freeform drawing, and the area integrated density was 
calculated. Background fluorescence was calculated in the same manner as an average of 
three points were no cells were present. Calculations of the CFPC were made using the 
following equation: 




Mice and Immunizations 
 Female CD-1 IGS mice (8-12 weeks) were obtained from Charles River 
Laboratories and maintained in the animal facility of the Georgia Institute of Technology. 
All animal care and experimental procedures were approved by the Institutional Animal 
Care and Use Committee of the Georgia Institute of Technology. Mice were administered 
10 µg VLP by subcutaneous injection at days 0, 14, and 28. Blood was collected via 
submandibular bleed at days 7, 21, and 35 for serum antibody analysis. Mice were 
maintained until day 50 for continued analysis prior to sacrifice.  
ELISA 
 Wild-type PP7 (single-chain dimer; 1 µg/mL) VLPs were plated overnight at 4°C. 
Plate was washed thrice with PBST and blocked with 3% BSA in PBST for 2 h at room 
temperature. Serum dilutions were prepared in a master plate using 3% BSA in PBST as 
diluent and transferred to the assay plate to give final dilutions of 1:500-1:128000, which 
were incubated for 1 h at room temperature. Plate was washed thrice with PBST and 
incubated with anti-mouse IgG HRP-conjugate reporter antibody (1:2500, Abbiotec, Inc.) 
for 1 h at room temperature. A final washing with PBST was followed by development 
with TMB substrate (1-StepÔ Ultra TMB; Thermo Fisher Scientific) and quenching with 








Figure 2. Characterization of PP7-Self and PP7wt particles. (A) Dynamic light scattering 
measurements of PP7wt particles (left) and PP7-Self particles (right). Particles displaying 
the peptide extension have a slightly larger radius than unmodified VLPs. (B) FPLC 
elution profile for PP7wt (blue) and PP7-Self (orange) showing particles are intact and 
greater than 95% pure. PP7-Self VLPs display shorter retention times indicative of larger 
molecular species. (C) Denaturing electrophoretic analysis of PP7wt and PP7-Self VLPs 
showing single distinct protein species comprising both samples, respectively. (D) High-
resolution mass spectrometry analysis of PP7-Self, revealing a single protein species with 
the predicted mass. 
 
6.4. Results and Discussion 
6.4.1. Particle design and characterization 
 To prepare VLP constructs bearing the Self peptide, a codon-optimized sequence 
for the Self peptide was appended to the 3’-end of the gene encoding for the single chain 
PP7 coat protein dimer. This strategy allowed for every dimeric unit to display exactly 
one copy of the peptide extension, equating to 90 copies on the entire particle surface. 
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Expression of this construct in E. coli generated monodisperse particles that could be 
isolated in high yields (30 mg/L). Size-exclusion chromatography, dynamic light 
scattering, and gel electrophoretic analysis were all characteristic of intact, monodisperse 
particles for preparations of PP7wt and PP7-Self (Figure 2A-C). Particles displaying the 
peptide extension showed an increase in their hydrodynamic radius relative to PP7wt 
particles (~ 21 versus ~ 18 nm), indicative of the uniform display of the Self peptide on 
the particle surface (Figure 2A). In addition, PP7-Self particles displayed a slight but 
distinct decrease in elution volume relative to PP7wt as measured by size-exclusion 
chromatography, which is also indicative of larger particles (Figure 2B). Electrophoretic 
analysis of PP7wt and PP7-Self showed a single band at the corresponding molecular 
weight for each respective species (~ 13 kDa for PP7wt versus ~ 31 kDa for PP7-Self), 
demonstrating that the fused-dimer bearing the Self peptide extension was the sole 
component mediating particle assembly (Figure 2C). Analysis by mass spectrometry 
further confirmed that PP7-Self particles were comprised of solely the fused-dimer 
bearing the Self peptide extension (Figure 2D). This stands in contrast to our previous 
work with the Qb VLP, which requires co-expression of the subunit bearing the peptide 
extension together with the unmodified coat protein for assembly of hybrid particles. The 
disadvantage of the Qb platform with this respect is a lack of control over the number of 
extensions incorporated, whereas the PP7 fused-dimer constructs bearing terminal 
extensions allow for precise control based on the geometry of particle assembly.  
6.4.2. Assessment of macrophage uptake  
 Following successful assembly and characterization of the PP7-Self VLPs, we 
sought to test if display of the Self peptide was sufficient to inhibit particle uptake by  
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Figure 3. Uptake of PP7wt and PP7-Self VLPs in RAW 264.7 macrophages. (Upper 
panels) Representative microscopy images of macrophages after incubation with PP7wt 
or PP7-Self VLPs (10 nM and 20 nM) for 24 h. (Lower panel) Quantification of VLP 
uptake as measured by the corrected fluorescence per cell. Bars represent the average +/- 
standard error (n = 15). 
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phagocytic cells as first reported by Discher. VLPs were first labeled with Alexa Fluor 
488 in order to visualize particle uptake by fluorescence microscopy, and RAW 264.7 
macrophages were subsequently incubated with either PP7wt or PP7-Self (10 nM and 20 
nM) for 24 hours. Significant uptake by macrophages was observed in a dose-dependent 
manner for PP7wt, with punctate staining indicative of phagocytic uptake and 
localization of particles into endosomal compartments (Figure 3). In contrast, uptake of 
PP7-Self was significantly inhibited at both concentrations tested, indicating that display 
of the Self peptide on the surface of the VLP was able to inhibit phagocytic uptake 
(Figure 3). PP7-Self particles that were phagocytosed also exhibited punctate staining,  
further supporting that particle uptake was mediated by the same process but inhibited by 
signaling through the CD47-SIRPa axis. 
6.4.3. Evaluation of humoral immune response 
 To further explore the ability of the Self peptide to mitigate cellular recognition of 
particles, we next tested the humoral immune response generated against PP7-Self 
relative to PP7wt VLPs. Female CD-1 mice (n = 4) were initially immunized 
subcutaneously with 10 µg of either PP7-Self or PP7wt particles, followed by two 
subsequent immunizations at the same dose. Following the initial immunization, mice 
immunized with PP7-Self displayed lower titers than mice immunized with PP7wt, but 
the difference in titers was not significant (Figure 4). Interestingly, IgG titers against the 
coat protein increased but remained significantly lower in mice administered PP7-Self 
relative to PP7wt following a second immunization (Figure 4).  
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Figure 4. Total IgG titers against PP7wt and PP7-Self. (A) Average titer curves for anti-
PP7 total IgG in sera collected 7 days post-immunization with either PP7wt or PP7-Self 
(n = 4). (B) Individual titers from mice immunized with PP7wt or PP7-Self. The data was 
fit and solved using four parameter logistic regression analysis, and the titer was 
calculated as the mid-point of the corresponding curve fit. Lines represent mean value for 
each group; symbols represent individual mice (n = 4).   
 
6.5. Conclusions 
 The PP7 particle represents a very robust platform for engineering drug delivery 
vehicles as it can more readily accommodate genetic manipulation and display of large 
peptide domains from the N- or C-termini. Expression of monomeric PP7 fusions is 
capable of generating particles displaying a peptide from each subunit (180), while the 
fused dimer construct can be used to finely tune display in a more controlled fashion than 
co-expression of hybrid subunits, which was employed in previous chapters with the Qb 
platform. Display of the Self peptide was capable of mitigating the uptake of VLPs by 
macrophages in vitro and had a moderate effect on the generation of a humoral immune 
response against PP7, as measured by total IgG antibody titers. While the Self peptide 
may not be capable of completely shielding particles from the immune system, it does 
appear to have potent efficacy at inhibiting phagocytosis, which could translate into 
useful applications for prolonged systemic delivery. Phagocytic clearance is one of the 
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primary mechanisms by which nanoscale particles are removed from circulation, so if 
these results translate to clearance studies in vivo, it will provide a useful platform for 
applications in drug delivery.  
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Chapter 7: Conclusion 
 
7.1. Comprehensive Discussion 
 The overarching theme of the work presented in this thesis was the chemical and 
genetic engineering of virus-like particle platforms for vaccine design and drug delivery. 
In this final chapter, the key findings of this thesis will be summarized and a discussion 
on future directions of study will follow.  
 Chapter 2 focused on the genetically-encoded display of peptide epitopes on Qb 
VLPs for applications in vaccine development. For this study, our efforts were focused 
on the treatment of complement-mediated autoimmune disorders, such as paroxysmal 
nocturnal hemoglobinuria (PNH),1 in an effort to leverage the inherent immunogenicity 
of the Qb platform to break tolerance against a self-antigen. Furthermore, patients 
suffering from PNH and other hemolytic pathologies have limited therapeutic options, so 
a more effective (and cheaper) alternative would be a tremendous benefit in the clinic.2 
Our efforts found that immunization with a homologous xenoprotein of complement 
component 5 (C5) generated high IgG titers in mice, but these antibodies failed to cross-
react with the native C5 protein. After failing to generate a cross-reactive immune 
response with this vaccine, we next identified 12 potential immunogenic peptides in the 
native mouse C5 protein and prepared a mosaic protein comprised of these epitopes 
interspersed with a known tolerance-breaking peptide (PADRE).3 Immunization with this 
construct gave rise to cross-reactive antibody responses that mapped to a dominant 
peptide epitope on the surface of the C5 protein. Finally, we designed Qb VLPs to 
display this peptide epitope as a C-terminal extension of the coat protein and assembled 
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hybrid particles for immunization. Complement activity was significantly diminished, but 
not abolished, in mice receiving the Qb vaccine, and clinical indicators of disease in a 
PNH mouse model were undetectable following immunization. These studies build on 
previous efforts employing the Qb VLP as a vaccine platform against self-antigens4–7 but 
is the first such study to engineer the display of the antigen as a genetic fusion rather than 
through chemical conjugation. Furthermore, the vaccine was well-tolerated in mice, and 
the results of this study show great promise at progressing forward into clinical 
applications. 
 Chapter 3 described the production and application of Qb VLPs displaying 
genetically-encoded protein extensions for applications in cellular targeting and 
therapeutic delivery. Incorporation of the Fc-binding Z-domain8 as a C-terminal 
extension of the coat protein allowed for the production of particles that could be targeted 
against specific cell surface markers by virtue of antibodies arrayed on the particle 
surface. As a proof-of-concept, we first chose to focus our efforts in this area on the 
selective elimination of human pluripotent stem cells (hPSCs) in vitro. Residual hPSCs in 
transplantation cultures are one of the primary hindrances towards advancing stem cell 
therapies forward into the clinic, as the immortal nature of these cells can lead to the 
formation of teratomas in vivo.9–11 Leveraging the specificity of antibodies as targeting 
moieties, we first labeled VLPs with antibodies against a glycan target (SSEA-5) that is 
specifically expressed on the surface of undifferentiated hPSCs.12 Particles bearing this 
antibody were capable of selectively targeting hPSC colonies co-cultured with dermal 
fibroblasts even at low nanomolar concentrations; given the high selectivity of this 
system, we next encapsulated cytosine deaminase within the VLP to mediate targeted 
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prodrug therapy.13 Administration of these particles followed by treatment with the 
prodrug 5-fluorocytosine (5-FC) induced cell death only in the hPSCs, with no detectable 
cell death in the surrounding fibroblasts. Finally, to test this system as it would be applied 
in a clinical setting, hPSCs were differentiated into cardiomyocytes, and the 
differentiation culture was treated with the VLP/prodrug in the same manner. No residual 
stem cells were detected following treatment, and differentiated cardiomyocytes 
exhibited no negative side effects from exposure to the treatment.  
 This platform proved to be incredibly modular, allowing for simple exchange of 
packaged proteins and/or displayed antibodies to mediate different functions or delivery 
to different cell types. Another avenue that was explored using this technology was the 
selective targeting of cancer cells expressing HER2, a common cancer marker that has 
been well-validated with antibody-based therapeutics.14–16 Display of antibodies against 
HER2 allowed for the selective delivery of Qb VLPs to these cells; furthermore, delivery 
of cytosine deaminase in vitro also mediated prodrug-induced cytotoxicity in a selective 
manner. The modularity of this platform shows great promise at translating into several 
realms of clinically relevant applications.  
 The first two chapters of this work focused on the power of genetic manipulation 
to mediate display of peptide and protein domains on the surface of Qb VLPs for 
different applications in medicine; Chapter 4 detailed the chemical modification of VLPs 
with small molecules to modulate cellular uptake and trafficking. Macrolide antibiotics 
have been well-documented to accumulate in phagocytic cells, which has directed their 
distribution into tissues from the bloodstream.17,18 In this work, we developed a series of 
Qb macrolide conjugates in order to enhance uptake in macrophages and direct particles 
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to the lungs as a proof-of-concept for pulmonary drug delivery. VLP-macrolide 
conjugates showed enhanced uptake by macrophages in vitro, with particles displaying 
azithromycin exhibiting the greatest effect. Macrophages treated with these conjugates 
exhibited activations towards an M2b phenotype,19 indicating that these materials may 
have some therapeutic potential in altering macrophage activation states; this stands in 
contrast to previous reports with macrolide-modified gold nanorods, which were shown 
to stimulate activation towards a cytotoxic phenotype in macrophages.20 More 
importantly, azithromycin-modified VLPs accumulated in the lungs within 2 hours of 
systemic administration, demonstrating these materials could potentially be employed as 
agents for pulmonary drug delivery through a route other than inhalation. 
 While the development of targeted therapeutics is an admirable goal, one must not 
overlook the innate defenses of the body that work to clear foreign materials, including 
drug delivery vehicles, from systemic circulation. The attachment of hydrophilic polymer 
chains to the surface of protein-based therapeutics has been commonly employed to 
mitigate recognition by the immune system and prolong circulation lifetimes,21–23 but 
there have been no comprehensive studies investigating the performance of these 
materials in relation to (polyethylene)glycol (PEG). Chapter 5 details efforts to fully 
characterize the immune response to protein-polymer hybrid materials using Qb VLPs 
modified with different polymer architectures (POEGMA, PMAG, PEG) at different 
chain lengths and densities. Initial screenings with monoclonal antibodies against the coat 
protein in vitro showed decreased recognition with increasing chain length as well as 
polymer loading. The humoral immune response in vivo is much more complex, yet still 
bears distinct correlations with polymer chain length as well as degree of modification. 
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Mice immunized with these conjugates developed significantly lower titers than mice 
immunized with unmodified VLPs; however, the apparent seroreactivity (or observed 
strength of binding) decreased with increasing polymer chain length. Furthermore, VLPs 
bearing more polymer chains gave rise to antibodies with weaker avidities, suggesting 
that the epitope repertoire may be influenced by surface accessibility in these constructs. 
The results from this survey will help inform on the design of polymer-modified 
materials, as well as the overall factors governing antibody responses to protein-polymer 
materials. 
 Finally, Chapter 6 returned to the use of genetically-encoded peptide domains in 
order to accomplish shielding of PP7 VLPs from phagocytic uptake. The body is capable 
of discriminating foreign materials by recognition of CD47 on the surface of its own 
cells,24 and this interaction have been exploited to prolong the circulation of 
microparticles in vivo using a minimal peptide (Self) from the CD47 binding interface.25 
Building on this study, we sought to genetically display the Self peptide on the surface of 
PP7 VLPs in a controllable fashion, as PP7 offers a greater tolerance to the incorporation 
of genetic extensions and can display peptides on every subunit if needed.26 Particles 
displaying the Self peptide exhibited decreased uptake by macrophages in vitro, but these 
constructs failed to significantly diminish antibody responses generated against PP7 in 
immunized mice. Overall, it appears that display of the Self peptide may be useful for 
mitigating phagocytic clearance but does not have an effect on the generation of an 




7.2. Future Directions 
 Collectively, the body of work detailed in this thesis presents many interesting 
and exciting opportunities for further exploration. The vaccines developed in Chapter 2 
proved to be very effective at giving rise to C5-specific antibody responses that were 
capable of ameliorating C5 activity and hemoglobinuria. In order to fully establish the 
safety of this vaccine, a challenge study with a non-lethal dose of bacteria should be 
conducted to definitively ensure that innate immunity has not been compromised due to 
knockdown of C5 activity. Pursuant to translating this technology into the clinic, particles 
displaying human homologs of the same peptide epitopes identified in this study could 
also be designed and screened through in vitro immunization of human peripheral 
mononuclear cells before eventually translating into clinical studies.27 Finally, the ability 
of Qb VLPs to serve as an effective vaccine platform against genetically encoded self-
antigens presents many opportunities to apply this design strategy in treating other 
autoimmune disorders. 
 The platform developed in Chapter 3 for the targeted delivery of prodrug-
converting enzymes offers a number of different avenues for exploration. As a direct 
supplement to the work conducted in these initial studies, an assessment of teratoma 
formation in vivo could be conducted by transplanting differentiated cardiomyocytes into 
mice following treatment of the differentiation culture with SSEA-5-targeted VLPs and 
subsequent dosing with 5-FC. With respect to targeting HER2-positive cancers, 
validation of specific killing in co-culture can be screened, followed by application of 
targeted killing in established mouse tumor models. As previously mentioned, the 
modularity of this system lends itself to numerous applications in targeting disease – the 
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ability to exchange the targeting antibody on the particle surface and the enzyme 
packaged on the interior allows for the generation of particles with a wide range of 
biological activities that can be delivered to various cell types.  
 The Qb-macrolide conjugates developed in Chapter 4 offer an interesting 
platform for applications in pulmonary drug delivery. Confirmation of delivery to 
pulmonary macrophages via histological studies should be undertaken, but more 
importantly, loading of these particles with a drug and screening for the treatment of 
respiratory infections could prove to be incredibly useful for clinical applications. Most 
drug delivery routes for addressing the lung involve inhalation,28 with very few reports of 
systemic administration for delivery to the lung. Further study on the activation state of 
treated macrophages in vivo would be highly beneficial, as this data would inform on the 
potential of these conjugates to modulate the immunological fate of these cells.  
 In addition to having the ability to specifically deliver particles to tissues or cells 
as desired, shielding these constructs from recognition and clearance by the immune 
system is another important goal. The efficacy of drug delivery vehicles depends largely 
on their ability to circulate for prolonged periods of time, in addition to directing delivery 
to a specific subset of cells. Our survey of different polymer architectures covalently 
conjugated to the Qb VLP could be greatly supplemented through structural analysis of 
the attached polymer chains and determination of their conformation in solution. 
Furthermore, the distinct differences in the antibody responses generated in vivo warrant 
a more in-depth study of the antibody repertoires and how they correlate with the 
physical properties of the protein-polymer conjugates. Isolation of individual B-cells and 
determination of epitope diversity and affinities in the population will help further 
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elucidate the influence of polymer chain length and loading density on the humoral 
response against protein conjugates.  
 Our exploratory studies displaying the Self peptide on PP7 VLPs to mitigate 
phagocytosis showed promising results that can be readily explored for applications in 
drug delivery. The tolerance for PP7 for peptide extensions will allow the correlation 
between peptide display density and phagocytosis to be explored in vitro, and it will be 
extremely interesting to see if these particles display extended circulation half-lives in 
vivo due to their inhibition of phagocytic uptake.  
 Finally, it will be incredibly interesting to combine multiple facets of these studies 
into the development of Qb VLPs with novel properties. It will be paramount to combine 
the targeting moieties discussed in Chapters 3 and 4 with polymer modifications (Chapter 
5) to reduce particle clearance and immunogenicity while imparting targeting 
capabilities. It is worth noting that the chemical attachment of targeting molecules (such 
as macrolides) can be accomplished on the pendant ends of polymer chains equipped 
with the proper functionalities, so that polymer modification does not impede the 
targeting moiety. Furthermore, the ability to genetically display Self peptides on the 
surface of the VLP in order to mitigate clearance (Chapter 6) leaves reactive functional 
groups on the coat protein fully addressable for modification with therapeutics or other 
molecular cargo.  
 Overall, the work detailed in each chapter of this thesis is focused in a unique area 
that can address individual problems in medicine, but when brought together, the results 
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Complete list of primers 
Note: All sequences listed in 5’ to 3’ directionality 






















































Coding regions for protein production 
 The sequences listed in this section were inserted into plasmid backbones for 
expression (as indicated in the main text) using restriction enzymes and standard 
molecular cloning techniques. Coding sequences for extensions are underlined. 



















































































































































FACS buffer: 5% fetal bovine serum, 2 mM EDTA in 1x PBS 
10x potassium phosphate buffer (1M): 107.5 g dibasic potassium phosphate 
(anhydrous) and 52 g monobasic potassium phosphate (anhydrous) in 1 L of H2O 
1x TBS: 50 mM Tris-HCl, 150 mM NaCl, pH 7.6 
1x PBS: 137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.47 mM KH2PO4, pH 7.4 
PBST: 1x PBS + 0.1% Tween 20 
